

A Method to Determine the Optimal Intensity of Oral A

Thrombosis and Haemostasis

69, 236-239

DOI: [10.1055/s-0038-1651587](https://doi.org/10.1055/s-0038-1651587)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Bleeding Complications in Oral Anticoagulant Therapy. Archives of Internal Medicine, 1993, 153, 1557.	4.3	394
2	Laboratory Monitoring of New Antithrombotic Drugs. Clinics in Laboratory Medicine, 1994, 14, 825-846.	0.7	7
3	Quality of oral anticoagulant control and treatment in Sweden. Journal of Internal Medicine, 1994, 236, 143-152.	2.7	21
4	Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses.. Circulation, 1994, 89, 635-641.	1.6	932
5	Anticoagulation: how low can one go?. Lancet, The, 1994, 343, 867-868.	6.3	9
6	Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart Valves. New England Journal of Medicine, 1995, 333, 11-17.	13.9	846
7	Long-term Patient Self-management of Oral Anticoagulation. Archives of Internal Medicine, 1995, 155, 2185.	4.3	124
8	Optimal Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Recent Cerebral Ischemia. New England Journal of Medicine, 1995, 333, 5-10.	13.9	449
9	Optimal intensity of oral anticoagulant therapy after myocardial infarction. Journal of the American College of Cardiology, 1996, 27, 1349-1355.	1.2	65
10	Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet, The, 1996, 348, 423-428.	6.3	1,270
11	Risk of stroke during long-term anticosgulant therapy in patients after myocardial infarction. Annals of Neurology, 1996, 39, 301-307.	2.8	31
12	Management of anticoagulant therapy: The dutch experience. Journal of Thrombosis and Thrombolysis, 1996, 2, 265-269.	1.0	5
13	Audit of anticoagulant therapy.. Journal of Clinical Pathology, 1996, 49, 5-9.	1.0	48
14	The Scylla and Charybdis of Oral Anticoagulant Treatment. New England Journal of Medicine, 1996, 335, 587-589.	13.9	59
15	Atrial Fibrillation and Stroke Prevention With Warfarin in the Long-term Care Setting. Archives of Internal Medicine, 1997, 157, 978.	4.3	140
16	Progression of the Culprit Lesion in Unstable Coronary Artery Disease With Warfarin and Aspirin Versus Aspirin Alone: Preliminary Study. Journal of the American College of Cardiology, 1997, 30, 364-369.	1.2	60
17	Comparison of oral anticoagulant control by a nurse-practitioner using a computer decision-support system with that by clinicians. International Journal of Laboratory Hematology, 1997, 19, 203-207.	0.2	37
18	A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Annals of Neurology, 1997, 42, 857-865.	2.8	509

#	ARTICLE	IF	CITATIONS
19	Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation—The investigators and institutions participating in the study are listed in the Appendix.. American Journal of Cardiology, 1998, 82, 433-437.	0.7	111
20	Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. , 1998, 59, 22-27.		62
21	A new regimen for starting warfarin therapy in outpatients. British Journal of Clinical Pharmacology, 1998, 46, 157-161.	1.1	55
22	Multicentre randomised study of computerised anticoagulant dosage. Lancet, The, 1998, 352, 1505-1509.	6.3	203
23	Modern Management of Prosthetic Valve Anticoagulation. Mayo Clinic Proceedings, 1998, 73, 665-680.	1.4	71
24	Comparison of an Anticoagulation Clinic With Usual Medical Care. Archives of Internal Medicine, 1998, 158, 1641.	4.3	510
25	European Concerted Action on Anticoagulation (ECAA): Clinical and Laboratory Studies. Hematology, 1998, 3, 321-332.	0.7	2
26	A Guide to Oral Anticoagulant Therapy. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1998, 28, 1-46.	0.5	9
27	Secondary stroke prevention in atrial fibrillation: indications, risks, and benefits. , 1999, 7, 61-65.		3
28	Oral Anticoagulation Management in Primary Care With the Use of Computerized Decision Support and Near-Patient Testing. Archives of Internal Medicine, 2000, 160, 2343.	4.3	152
29	A Multicomponent Intervention To Prevent Major Bleeding Complications in Older Patients Receiving Warfarin. Annals of Internal Medicine, 2000, 133, 687.	2.0	303
30	Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis. Journal of Clinical Oncology, 2000, 18, 3078-3083.	0.8	691
31	Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. , 2000, 63, 192-196.		43
32	Randomized, Placebo-Controlled Trial of Oral Phytonadione for Excessive Anticoagulation. Pharmacotherapy, 2000, 20, 1159-1166.	1.2	71
33	Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. Journal of Thrombosis and Thrombolysis, 2000, 9, 283-292.	1.0	133
35	Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, 2000, 96, 1816-1819.	0.6	380
36	A Comparison of the Safety and Efficacy of Oral Anticoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy. Thrombosis and Haemostasis, 2000, 84, 805-810.	1.8	208
37	Minimum Effective Intensity of Oral Anticoagulant Therapy in Primary Prevention of Coronary Heart Disease. Archives of Internal Medicine, 2000, 160, 2462.	4.3	13

#	ARTICLE	IF	CITATIONS
38	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology American Society of Hematology Education Program, 2000, 2000, 266-284.	0.9	18
39	Quality of Anticoagulation Management Among Patients With Atrial Fibrillation. Archives of Internal Medicine, 2000, 160, 967.	4.3	268
40	Low-Dose Warfarin in Patients with Carbomedics Heart Valve Prostheses. Asian Cardiovascular and Thoracic Annals, 2000, 8, 11-14.	0.2	9
41	Effect of Coumarins Started Before Coronary Angioplasty on Acute Complications and Long-Term Follow-Up. Circulation, 2000, 102, 386-391.	1.6	59
42	A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke. New England Journal of Medicine, 2001, 345, 1444-1451.	13.9	1,117
43	Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Journal of Vascular Surgery, 2001, 33, 522-527.	0.6	43
44	Better delivery of standard antithrombotic care. American Heart Journal, 2001, 141, 1038-1042.	1.2	4
45	Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. Annals of Thoracic Surgery, 2001, 72, 1523-1527.	0.7	76
46	Recommendations for patients undertaking self management of oral anticoagulation. BMJ: British Medical Journal, 2001, 323, 985-989.	2.4	69
47	A Benefit/Risk Analysis of the Prevention of Brain Ischaemia with Anticoagulant Drugs: When, How and Whom to Treat?. Cerebrovascular Diseases, 2001, 11, 100-104.	0.8	0
48	Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Risk of Bleeding. Thrombosis and Haemostasis, 2001, 85, 418-422.	1.8	138
49	Disagreement between bedside and laboratory activated partial thromboplastin time and international normalized ratio for various novel anticoagulants. Blood Coagulation and Fibrinolysis, 2001, 12, 583-591.	0.5	17
50	Venous thrombosis and anticoagulant therapy. British Journal of Haematology, 2001, 114, 258-270.	1.2	31
51	Warfarin toxicity in the emergency department: Recommendations for management. Emergency Medicine (Fremantle, W A), 2001, 13, 91-97.	0.0	18
52	Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting. Archives of Internal Medicine, 2001, 161, 2458-2463.	4.3	166
53	Oral Anticoagulant Therapy During and After Coronary Angioplasty. Circulation, 2001, 103, 2042-2047.	1.6	30
54	Oral anticoagulation for cerebral ischemia of arterial origin. Neurology, 2001, 57, 1993-1999.	1.5	43
55	State-of-the-Art Review: The Oral Anticoagulant Saga: Past, Present, and Future. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 269-275.	0.7	48

#	ARTICLE	IF	CITATIONS
56	Management of haemorrhagic complications associated with oral anticoagulant treatment. Expert Opinion on Drug Safety, 2002, 1, 129-136.	1.0	9
57	Warfarin Therapy for Atrial Fibrillation in the Elderly. Annals of Pharmacotherapy, 2002, 36, 200-204.	0.9	27
58	Need of more frequent International Normalized Ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. Blood Coagulation and Fibrinolysis, 2002, 13, 297-300.	0.5	23
59	Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. American Journal of Medicine, 2002, 113, 42-51.	0.6	131
60	Substitution of Generic Warfarin for Coumadin in an HMO Setting. Annals of Pharmacotherapy, 2002, 36, 764-768.	0.9	31
61	The safety and effectiveness of a nurse-led anticoagulant service. Journal of Advanced Nursing, 2002, 38, 407-415.	1.5	18
62	Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. British Journal of Haematology, 2002, 117, 940-946.	1.2	64
63	Reliability of point-of-care prothrombin time testing in a community clinic: a randomized crossover comparison with hospital laboratory testing. British Journal of Haematology, 2002, 119, 370-375.	1.2	53
64	Age and First INR After Initiation of Oral Anticoagulant Therapy with Acenocoumarol Predict the Maintenance Dosage. Journal of Thrombosis and Thrombolysis, 2003, 15, 197-203.	1.0	6
65	Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range. Journal of Thrombosis and Thrombolysis, 2003, 15, 213-216.	1.0	159
66	ESPRIT: The European/Australian stroke prevention in reversible ischaemia trial. Seminars in Cerebrovascular Diseases and Stroke, 2003, 3, 18-24.	0.1	0
67	Evaluation of the Clinical and Economic Impact of a Brand Name to-Generic Warfarin Sodium Conversion Program. Pharmacotherapy, 2003, 23, 360-368.	1.2	19
69	Early and late stroke after mitral valve replacement with a mechanical prosthesis: risk factor analysis of a 24-year experience. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 358-363.	0.4	130
70	SMART: Self-Management of Anticoagulation, a Randomised Trial [ISRCTN19313375]. BMC Family Practice, 2003, 4, 11.	2.9	15
71	Asymptomatic excessive coumarin anticoagulation is a risk factor for thrombotic and bleeding complications of oral anticoagulant therapy. Journal of Thrombosis and Haemostasis, 2003, 1, 1840-1841.	1.9	11
72	Patient self-management of oral anticoagulation and external quality assessment procedures. British Journal of Haematology, 2003, 122, 825-828.	1.2	18
73	Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. New England Journal of Medicine, 2003, 349, 1019-1026.	13.9	1,136
74	A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation. Journal of Clinical Pathology, 2003, 56, 48-51.	1.0	21

#	ARTICLE	IF	CITATIONS
75	External quality assessment for warfarin dosing using computerised decision support software. <i>Journal of Clinical Pathology</i> , 2003, 56, 605-607.	1.0	7
76	A Comparison Between Six- and Four-Week Intervals in Surveillance of Oral Anticoagulant Treatment. <i>American Journal of Clinical Pathology</i> , 2003, 120, 944-947.	0.4	21
77	Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2685.	3.8	635
78	Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia. <i>Circulation</i> , 2003, 108, 313-318.	1.6	268
79	Comparison of the Quality of Oral Anticoagulant Therapy Through Patient Self-management and Management by Specialized Anticoagulation Clinics in the Netherlands. <i>Archives of Internal Medicine</i> , 2003, 163, 2639.	4.3	103
80	ESPRIT: Safety and Efficacy of Oral Anticoagulation—a Rebuttal. <i>Stroke</i> , 2003, 34, e184.	1.0	1
81	Title is missing!. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 269-275.	0.5	8
82	Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 269-275.	0.5	18
83	Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. <i>Thrombosis and Haemostasis</i> , 2003, 89, 458-467.	1.8	74
84	Oral Anticoagulation in Patients After Cerebral Ischemia of Arterial Origin and Risk of Intracranial Hemorrhage. <i>Stroke</i> , 2003, 34, e45-6.	1.0	25
85	Systematic review of studies of self-management of oral anticoagulation. <i>Thrombosis and Haemostasis</i> , 2004, 91, 225-232.	1.8	54
87	Lowering the Intensity of Oral Anticoagulant Therapy. <i>Archives of Internal Medicine</i> , 2004, 164, 668.	4.3	41
88	Significance of consecutive international normalized ratio (INR) outcomes using statistical control rules in long-term anticoagulated patients. Optimization of laboratory monitoring and interpretation of borderline measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 294-9.	1.4	6
89	International Normalized Ratios (INR): the first 20 years. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 849-860.	1.9	132
90	The relationship between adherence and quality of treatment with vitamin K antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 362-363.	1.9	2
91	A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]. <i>BMC Cardiovascular Disorders</i> , 2004, 4, 5.	0.7	11
92	Personalized versus non-personalized computerized decision support system to increase therapeutic quality control of oral anticoagulant therapy: an alternating time series analysis. <i>BMC Health Services Research</i> , 2004, 4, 27.	0.9	12
93	Self-Management of Oral Anticoagulant Therapy: A Review. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 18, 127-143.	1.0	30

#	ARTICLE	IF	CITATIONS
94	Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. <i>British Journal of Haematology</i> , 2004, 124, 348-354.	1.2	86
95	CV4 EVALUATION OF SURVIVAL AND ISCHAEMIC AND THROMBOEMBOLIC EVENT RATES IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN THE GENERAL POPULATION WHEN TREATED AND UNTREATED WITH WARFARIN. <i>Value in Health</i> , 2004, 7, 638.	0.1	0
96	Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. <i>Clinical Therapeutics</i> , 2004, 26, 1470-1478.	1.1	49
97	Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. <i>Clinical Therapeutics</i> , 2004, 26, 1149-1159.	1.1	72
98	Literacy and Numeracy Skills and Anticoagulation Control. <i>American Journal of the Medical Sciences</i> , 2004, 328, 88-93.	0.4	187
99	Mechanical heart valve prostheses and persistent lupus anticoagulant: is the thrombotic risk increased?. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 183-185.	0.5	1
100	Monitoring oral anticoagulant therapy by telephone communication. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 227-230.	0.5	9
101	Comparing Self-Management of Oral Anticoagulant Therapy with Clinic Management. <i>Annals of Internal Medicine</i> , 2005, 142, 1.	2.0	178
102	Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 955-961.	1.9	88
103	Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 939-942.	1.9	273
104	Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 582-587.	1.1	123
105	Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. <i>British Journal of Haematology</i> , 2005, 128, 242-247.	1.2	101
106	Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. a retrospective study of 2300 consecutive patients with venous thromboembolism. <i>British Journal of Haematology</i> , 2005, 128, 513-519.	1.2	187
107	Risks factors for highly unstable response to oral anticoagulation: a case-control study. <i>British Journal of Haematology</i> , 2005, 129, 72-78.	1.2	86
108	Audit of correction of high INR in an anticoagulation clinic. <i>International Journal of Laboratory Hematology</i> , 2005, 27, 172-176.	0.2	0
109	The Impact of Patient Self-Testing of Prothrombin Time for Managing Anticoagulation: Rationale and Design of VA Cooperative Study #481â€”The Home INR Study (THINRS). <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 163-172.	1.0	25
110	An Examination of the Association Between Therapeutic Anticoagulation Control and Glycemic Control for Patients with Diabetes on Oral Anticoagulation Therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 209-212.	1.0	6
111	Patient Self-Management of Anticoagulation: An Idea Whose Time Has Come. <i>Annals of Internal Medicine</i> , 2005, 142, 73.	2.0	1

#	ARTICLE	IF	CITATIONS
112	Self management of oral anticoagulation: randomised trial. <i>BMJ: British Medical Journal</i> , 2005, 331, 1057.	2.4	101
113	Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. <i>Cmaj</i> , 2005, 173, 496-501.	0.9	80
114	Preanalytical Variables and Off-Site Blood Collection: Influences on the Results of the Prothrombin Time/International Normalized Ratio Test and Implications for Monitoring of Oral Anticoagulant Therapy. <i>Clinical Chemistry</i> , 2005, 51, 561-568.	1.5	64
115	Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. <i>Heart</i> , 2005, 91, 472-477.	1.2	287
116	Risks of Oral Anticoagulant Therapy With Increasing Age. <i>Archives of Internal Medicine</i> , 2005, 165, 1527.	4.3	200
117	The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial. <i>European Heart Journal</i> , 2005, 26, 2159-2165.	1.0	44
118	Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation. <i>Circulation</i> , 2005, 112, 1687-1691.	1.6	413
119	Anticoagulation in Ischemic Stroke: Opportunities in Arterial Disease. <i>Cerebrovascular Diseases</i> , 2005, 20, 101-108.	0.8	3
120	Culprit Factors for the Failure of Well-Conducted Warfarin Therapy to Prevent Ischemic Events in Patients With Atrial Fibrillation. <i>Stroke</i> , 2005, 36, 2159-2163.	1.0	65
121	Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis. <i>New England Journal of Medicine</i> , 2005, 352, 1305-1316.	13.9	1,620
122	Quality of Anticoagulation Control and Costs of Monitoring Warfarin Therapy among Patients with Atrial Fibrillation in Clinic Settings: A Multi-Site Managed-Care Study. <i>Annals of Pharmacotherapy</i> , 2005, 39, 446-451.	0.9	71
123	Cognitive Impairment as Determinant for Sub-Optimal Control of Oral Anticoagulation Treatment in Elderly Patients with Atrial Fibrillation. <i>Drugs and Aging</i> , 2005, 22, 353-360.	1.3	38
125	Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. <i>Thrombosis Research</i> , 2006, 117, 493-499.	0.8	145
126	Influenza vaccination in patients on long-term anticoagulant therapy. <i>Vaccine</i> , 2006, 24, 6624-6628.	1.7	16
127	Patients who take uneven doses of acenocoumarol exhibit significant fluctuating levels of anticoagulation. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 509-512.	0.5	2
128	Estimation of optimal dynamic anticoagulation regimes from observational data: a regret-based approach. <i>Statistics in Medicine</i> , 2006, 25, 4197-4215.	0.8	35
129	Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. <i>International Journal of Clinical Practice</i> , 2006, 60, 258-264.	0.8	81
130	Early detection of patients with a poor response to vitamin K antagonists: the clinical impact of individual time within target range in patients with heart disease. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1625-1627.	1.9	15

#	ARTICLE	IF	CITATIONS
131	Health literacy and anticoagulation-related outcomes among patients taking warfarin. <i>Journal of General Internal Medicine</i> , 2006, 21, 841-846.	1.3	154
132	ANTICOAGULATION OF ATRIAL FIBRILLATION IN OLDER PEOPLE: A CLINICAL PRACTICE OBSERVATIONAL STUDY. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 176-177.	1.3	0
133	Age and the Risk of Warfarin-Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation Study. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1231-1236.	1.3	214
134	Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. <i>British Journal of Haematology</i> , 2006, 132, 277-285.	1.2	351
135	A randomised control trial of patient self-management of oral anticoagulation compared with patient self-testing. <i>British Journal of Haematology</i> , 2006, 132, 598-603.	1.2	43
136	Gains and losses of warfarin therapy as performed in an anticoagulation clinic. <i>Journal of Internal Medicine</i> , 2006, 259, 296-304.	2.7	26
137	Management of Chinese patients on warfarin therapy in two models of anticoagulation service ? a prospective randomized trial. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 601-609.	1.1	55
138	Monitoring anticoagulation in atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 191-198.	1.0	33
139	Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 73-77.	1.0	111
140	A "two-step" educational approach for patients taking oral anticoagulants does not improve therapy control. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 185-190.	1.0	12
141	Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. <i>Cmaj</i> , 2006, 174, 1847-1852.	0.9	68
142	Comparison of Outcomes Using 2 Delivery Models of Anticoagulation Care. <i>Archives of Internal Medicine</i> , 2006, 166, 997.	4.3	38
143	Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. <i>Heart</i> , 2006, 92, 196-200.	1.2	39
144	A Pharmacotherapy Clinic in a Neurologic Practice. <i>Journal of Pharmacy Technology</i> , 2006, 22, 254-260.	0.5	0
145	Management of oral anticoagulation in a population of children with cardiac disease using a computerised system to support decision-making. <i>Cardiology in the Young</i> , 2006, 16, 256-260.	0.4	10
146	Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation. <i>Circulation</i> , 2007, 116, 2563-2570.	1.6	660
147	What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2007, 6, 390-396.	0.5	10
148	Patient self management of oral anticoagulation in routine care in the UK. <i>Journal of Clinical Pathology</i> , 2007, 60, 1263-1267.	1.0	16

#	ARTICLE	IF	CITATIONS
149	Newly Detected Atrial Fibrillation and Compliance With Antithrombotic Guidelines. Archives of Internal Medicine, 2007, 167, 246.	4.3	149
150	Burden of Potentially Avoidable Anticoagulant-Associated Hemorrhagic and Thromboembolic Events in the Elderly. Chest, 2007, 131, 1508-1515.	0.4	72
151	Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. New England Journal of Medicine, 2007, 357, 217-227.	13.9	383
152	Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics, 2007, 8, 851-861.	0.6	58
153	Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control. Archives of Internal Medicine, 2007, 167, 239.	4.3	527
154	Quality of Clinical Documentation and Anticoagulation Control in Patients With Chronic Nonvalvular Atrial Fibrillation in Routine Medical Care. American Journal of Medical Quality, 2007, 22, 327-333.	0.2	14
155	Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation. Circulation, 2007, 115, 2689-2696.	1.6	962
156	A Visual Medication Schedule to Improve Anticoagulation Control: A Randomized, Controlled Trial. Joint Commission Journal on Quality and Patient Safety, 2007, 33, 625-635.	0.4	42
157	The effect of hospitalization on oral anticoagulation control: A population-based study. Thrombosis Research, 2007, 119, 705-714.	0.8	34
158	Risk of bleeding in very old atrial fibrillation patients on warfarin: Relationship with ageing and CHADS2 score. Thrombosis Research, 2007, 121, 347-352.	0.8	82
159	The Safety of Warfarin Therapy in the Nursing Home Setting. American Journal of Medicine, 2007, 120, 539-544.	0.6	93
160	Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet, The, 2007, 370, 493-503.	6.3	1,466
161	The Influence of NSAIDs on Coumarin Sensitivity in Patients with CYP2C9 Polymorphism After Total Hip Replacement Surgery. Molecular Diagnosis and Therapy, 2007, 11, 123-128.	1.6	15
162	Low-Intensity Oral Anticoagulant Plus Low-Dose Aspirin During the First Six Months Versus Standard-Intensity Oral Anticoagulant Therapy After Mechanical Heart Valve Replacement: A Pilot Study of Low-Intensity Warfarin and Aspirin in Cardiac Prostheses (LIWACAP). Clinical and Applied Thrombosis/Hemostasis, 2007, 13, 241-248.	0.7	30
163	The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: Consequences for the assessment of the dose. Thrombosis and Haemostasis, 2007, 98, 738-746.	1.8	18
164	Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. British Journal of Haematology, 2007, 136, 26-29.	1.2	71
165	The quality of oral anticoagulant therapy and recurrent venous thrombotic events in the Leiden Thrombophilia Study. Journal of Thrombosis and Haemostasis, 2007, 5, 931-936.	1.9	7
166	A comparison of anticoagulation results of patients managed with narrow vs. standard international normalized ratio target ranges. Journal of Thrombosis and Haemostasis, 2007, 5, 1332-1333.	1.9	7

#	ARTICLE	IF	CITATIONS
167	Improved control of oral anticoagulant dosing: a randomized controlled trial comparing two computer algorithms. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1644-1649.	1.9	17
168	Daily vitamin K supplementation improves anticoagulant stability. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2043-2048.	1.9	74
169	Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. <i>Lancet Neurology</i> , The, 2007, 6, 115-124.	4.9	211
170	Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 335-343.	0.8	23
171	Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 24, 65-72.	1.0	42
172	Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 83-91.	1.0	131
173	Paper-based dosing algorithms for maintenance of warfarin anticoagulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 23, 195-198.	1.0	13
174	Anticoagulation Control in the Peri-Hospitalization Period. <i>Journal of General Internal Medicine</i> , 2007, 22, 727-735.	1.3	10
175	Effectiveness of Warfarin among Patients with Cancer. <i>Journal of General Internal Medicine</i> , 2007, 22, 997-1002.	1.3	53
176	Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 14-21.	1.0	31
177	Determinants and measures of quality in oral anticoagulation therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 61-66.	1.0	55
178	Quality of anticoagulation and use of warfarin-interacting medications in long-term care: A chart review. <i>BMC Geriatrics</i> , 2008, 8, 13.	1.1	41
179	CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 460-470.	2.3	338
180	Warfarin anticoagulation intensity in specialist-based and in computer-assisted dosing practice. <i>International Journal of Laboratory Hematology</i> , 2008, 30, 382-389.	0.7	7
181	Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 451-456.	1.9	51
182	An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 935-943.	1.9	98
183	Warfarin for atrial fibrillation in community-based practise. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1647-1654.	1.9	108
184	Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1655-1662.	1.9	81

#	ARTICLE	IF	CITATIONS
185	A multicentre randomised clinical endpoint study of <scp>parma</scp> 5 computer-assisted oral anticoagulant dosage. British Journal of Haematology, 2008, 143, 274-283.	1.2	23
186	Quality of Anticoagulation Care in Patients Discharged from a Pharmacist-Managed Anticoagulation Clinic After Stabilization of Warfarin Therapy. Pharmacotherapy, 2008, 28, 20-26.	1.2	35
187	Warfarin Pharmacogenetics. Pharmacotherapy, 2008, 28, 1084-1097.	1.2	120
188	Comparison of INR stability between self-monitoring and standard laboratory method: Preliminary results of a prospective study in 67 mechanical heart valve patients. Archives of Cardiovascular Diseases, 2008, 101, 753-761.	0.7	26
189	Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. American Heart Journal, 2008, 156, 148-154.	1.2	54
190	Genetic Determinants of Response to Warfarin during Initial Anticoagulation. New England Journal of Medicine, 2008, 358, 999-1008.	13.9	516
191	Quality of Anticoagulation Monitoring in Nonvalvular Atrial Fibrillation Patients: Comparison of Anticoagulation Clinic versus Usual Care. Annals of Pharmacotherapy, 2008, 42, 62-70.	0.9	48
192	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. Circulation, 2008, 118, 2029-2037.	1.6	789
193	Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation. Stroke, 2008, 39, 3009-3014.	1.0	32
194	Couma-Gen: implications for future randomized trials of pharmacogenetic-based warfarin therapy. Personalized Medicine, 2008, 5, 163-168.	0.8	3
195	Effects of <i>CYP2C9</i> and <i>VKORC1</i> on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics, 2008, 9, 1237-1250.	0.6	38
196	Anticoagulation Control in Hospitalised Patients on Warfarin. Journal of Pharmacy Practice and Research, 2008, 38, 292-295.	0.5	0
197	Quality of Anticoagulation Control: Do Race and Language Matter?. Journal of Health Care for the Poor and Underserved, 2008, 19, 41-55.	0.4	31
198	Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thrombosis and Haemostasis, 2009, 101, 938-942.	1.8	91
199	A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. Thrombosis and Haemostasis, 2009, 101, 487-494.	1.8	45
200	How Well Does the Target INR Level Maintain in Warfarin-Treated Patients with Non-Valvular Atrial Fibrillation?. Yonsei Medical Journal, 2009, 50, 83.	0.9	14
201	Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics, 2009, 10, 1687-1695.	0.6	131
202	Effect of an interactive voice response system on oral anticoagulant management. Cmaj, 2009, 180, 927-933.	0.9	24

#	ARTICLE	IF	CITATIONS
203	Self-monitoring of oral anticoagulation: does it work outside trial conditions?. <i>Journal of Clinical Pathology</i> , 2009, 62, 168-171.	1.0	18
204	The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation. <i>Circulation</i> , 2009, 120, 1029-1035.	1.6	79
205	Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 297-304.	0.9	96
206	Anticoagulation: Effect of a Warfarin Adherence Aid on Anticoagulation Control in an Inner-City Anticoagulation Clinic Population. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1165-1172.	0.9	19
207	Epidemiology of Subtherapeutic Anticoagulation in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 591-597.	0.9	53
208	Genetic Testing Before Anticoagulation? A Systematic Review of Pharmacogenetic Dosing of Warfarin. <i>Journal of General Internal Medicine</i> , 2009, 24, 656-664.	1.3	105
209	Warfarin dose management affects INR control. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 94-101.	1.9	44
210	Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1284-1290.	1.9	74
211	Screening computer-assisted dosage programs for anticoagulation with warfarin and other vitamin K antagonists: minimum safety requirements for individual programs. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1736-1736.	1.9	6
212	INR variability in atrial fibrillation: A risk model for cerebrovascular events. <i>European Journal of Internal Medicine</i> , 2009, 20, 63-69.	1.0	28
213	Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. <i>Thrombosis Research</i> , 2009, 124, 37-41.	0.8	263
215	The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients. <i>International Journal of Cardiology</i> , 2009, 132, 109-113.	0.8	15
216	Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. <i>American Heart Journal</i> , 2009, 157, 805-810.e2.	1.2	298
217	Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: A single-center, retrospective, observational study. <i>American Journal of Geriatric Pharmacotherapy</i> , 2009, 7, 159-166.	3.0	62
218	Bleeding Risk During Oral Anticoagulation in Atrial Fibrillation Patients Older Than 80 Years. <i>Journal of the American College of Cardiology</i> , 2009, 54, 999-1002.	1.2	115
219	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	13.9	9,839
220	Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. <i>Lancet</i> , The, 2009, 374, 534-542.	6.3	1,876
221	Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 965-971.	0.7	6

#	ARTICLE	IF	CITATIONS
222	Optimal Level of Oral Anticoagulant Therapy for the Prevention of Arterial Thrombosis in Patients With Mechanical Heart Valve Prostheses, Atrial Fibrillation, or Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2009, 169, 1203.	4.3	39
223	Achieved Anticoagulation vs Prosthesis Selection for Mitral Mechanical Valve Replacement. <i>Chest</i> , 2009, 136, 1503-1513.	0.4	23
224	Measuring Quality of Oral Anticoagulation Care: Extending Quality Measurement to a New Field. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2009, 35, 146-155.	0.4	46
225	The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2009, 151, 297.	2.0	585
226	Influenza Vaccination and Vitamin K Antagonist Treatment. <i>Archives of Internal Medicine</i> , 2010, 170, 609-16.	4.3	16
228	Quality of Warfarin Control Affects the Incidence of Stroke in Elderly Patients with Atrial Fibrillation. <i>Internal Medicine</i> , 2010, 49, 1711-1716.	0.3	13
229	Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2010, 104, 633-641.	1.8	311
230	Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2010, 103, 442-449.	1.8	41
231	Comparison of Two Different Models of Anticoagulation Management Services with Usual Medical Care. <i>Pharmacotherapy</i> , 2010, 30, 330-338.	1.2	94
232	A team-based approach to warfarin management in long term care: A feasibility study of the MEDeINR electronic decision support system. <i>BMC Geriatrics</i> , 2010, 10, 38.	1.1	19
233	Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial. <i>Trials</i> , 2010, 11, 108.	0.7	79
234	Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 101-106.	1.9	77
235	Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 95-100.	1.9	65
236	Patient characteristics associated with oral anticoagulation control: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2182-2191.	1.9	201
237	Improving Anticoagulation Control in Hospitalized Elderly Patients on Warfarin. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 242-247.	1.3	31
238	Risks and Benefits of Combined Use of Bivalirudin and Warfarin in Anticoagulation Therapy. <i>International Heart Journal</i> , 2010, 51, 399-403.	0.5	3
239	Anticoagulation for valvular heart disease in community-based practice. <i>Thrombosis and Haemostasis</i> , 2010, 103, 329-337.	1.8	4
240	Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 624-631.	0.9	174

#	ARTICLE	IF	CITATIONS
241	Dabigatran and Warfarin in Vitamin K Antagonistâ€“Naive and â€“Experienced Cohorts With Atrial Fibrillation. <i>Circulation</i> , 2010, 122, 2246-2253.	1.6	158
242	Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial. <i>Clinical Trials</i> , 2010, 7, 597-604.	0.7	19
243	Effect of Home Testing of International Normalized Ratio on Clinical Events. <i>New England Journal of Medicine</i> , 2010, 363, 1608-1620.	13.9	235
244	Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 277-283.	0.9	96
245	Patient Education: The Missing Link in Improving Quality of Oral Anticoagulation. <i>Cardiology</i> , 2010, 116, 59-60.	0.6	3
246	The Evolving Field of Stroke Prevention in Patients With Atrial Fibrillation. <i>Stroke</i> , 2010, 41, S17-S20.	1.0	15
247	Decreasing warfarin sensitivity during the first three months after heart valve surgery: Implications for dosing. <i>Thrombosis Research</i> , 2010, 125, 224-229.	0.8	25
248	Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. <i>Thrombosis Research</i> , 2010, 125, e128-e131.	0.8	11
249	The â€“carry-overâ€™ effects of patient self-testing: Positive effects on usual care management by an anticoagulation management service. <i>Thrombosis Research</i> , 2010, 126, e345-e348.	0.8	6
250	Out of hospital anticoagulant therapy in patients with acute pulmonary embolism is frequently practised but not perfect. <i>Thrombosis Research</i> , 2010, 126, 481-485.	0.8	7
251	Primary care practices and determinants of optimal anticoagulation management in a collaborative care model. <i>American Heart Journal</i> , 2010, 159, 183-189.	1.2	12
252	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoagulation with factor xA next GEneration in Atrial Fibrillationâ€“Thrombolysis In Myocardial Infarction study 48 (ENGAGE AFâ€“TIMI 48). <i>American Heart Journal</i> , 2010, 160, 635-641.e2.	1.2	439
253	The Effect and Safety of the Antithrombotic Therapies in Patients with Atrial Fibrillation and CHADS₂ Score 1. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 501-507.	0.8	44
254	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet, The</i> , 2010, 376, 975-983.	6.3	913
255	A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing. <i>Pharmacoeconomics</i> , 2010, 28, 61-74.	1.7	86
256	Warfarin prophylaxis in patients after total knee or hip arthroplasty â€“ international normalized ratio patterns and venous thromboembolism. <i>Current Medical Research and Opinion</i> , 2011, 27, 1973-1985.	0.9	12
257	Home Management of Oral Anticoagulation via Telemedicine Versus Conventional Hospital-Based Treatment. <i>Telemedicine Journal and E-Health</i> , 2011, 17, 169-176.	1.6	37
258	New Options in Anticoagulation for Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 952-953.	13.9	28

#	ARTICLE	IF	CITATIONS
259	Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment. <i>Circulation</i> , 2011, 124, 824-829.	1.6	188
260	Failure of Pharmacogenetic-based Dosing Algorithms to Identify Older Patients Requiring Low Daily Doses of Warfarin. <i>Journal of the American Medical Directors Association</i> , 2011, 12, 633-638.	1.2	20
261	Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 968-977.	1.8	320
262	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	13.9	8,006
263	Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. <i>Blood</i> , 2011, 118, 3163-3171.	0.6	81
264	Randomized Trial of a Warfarin Communication Protocol for Nursing Homes: an SBAR-based Approach. <i>American Journal of Medicine</i> , 2011, 124, 179.e1-179.e7.	0.6	46
265	Dabigatran Etexilate: A Novel Oral Thrombin Inhibitor for Thromboembolic Disease. <i>Annals of Pharmacotherapy</i> , 2011, 45, 603-614.	0.9	13
266	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	13.9	7,537
267	High platelet reactivity and clinical outcome – Fact and fiction. <i>Thrombosis and Haemostasis</i> , 2011, 106, 191-202.	1.8	63
268	“Zeus” a new oral anticoagulant therapy dosing algorithm : A cohort study. <i>Thrombosis Research</i> , 2011, 128, 325-330.	0.8	15
269	Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. <i>Lancet, The</i> , 2011, 378, 41-48.	6.3	508
270	Stroke prevention in non-valvular atrial fibrillation: Can warfarin do better?. <i>Thrombosis and Haemostasis</i> , 2011, 106, 753-754.	1.8	7
271	Effect of Chronic Kidney Disease on Warfarin Management in a Pharmacist-Managed Anticoagulation Clinic. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 523-530.	2.2	55
272	Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. <i>Thrombosis and Haemostasis</i> , 2011, 105, 169-180.	1.8	29
273	INR Goal Attainment and Oral Anticoagulation Knowledge of Patients Enrolled in an Anticoagulation Clinic in a Veterans Affairs Medical Center. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 133-142.	2.2	38
274	Effect of Herbal Consumption on Time in Therapeutic Range of Warfarin Therapy in Patients With Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 87-90.	0.8	31
275	Bleeding and Stroke Risk in a Real-world Prospective Primary Prevention Cohort of Patients With Atrial Fibrillation. <i>Chest</i> , 2011, 140, 918-924.	0.4	29
276	Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. <i>Blood</i> , 2011, 118, 4992-4999.	0.6	67

#	ARTICLE	IF	CITATIONS
277	Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios. <i>Annals of Internal Medicine</i> , 2011, 155, 653.	2.0	79
278	Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. <i>Haematologica</i> , 2011, 96, 583-589.	1.7	23
279	Effects of Combination Therapy With Warfarin and Bucolome for Anticoagulation in Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2011, 75, 201-203.	0.7	5
280	Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2011, 75, 1852-1859.	0.7	130
281	Time in the Therapeutic Range During Warfarin Therapy in Japanese Patients With Non-Valvular Atrial Fibrillation - A Multicenter Study of Its Status and Influential Factors -. <i>Circulation Journal</i> , 2011, 75, 2087-2094.	0.7	52
282	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS ₂ Score: A Subgroup Analysis of the RE-LY Trial. <i>Annals of Internal Medicine</i> , 2011, 155, 660.	2.0	181
283	Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2011, 105, 535-545.	1.8	103
284	Improved anticoagulant control in patients using home international normalized ratio testing and decision support provided through the internet. <i>Internal Medicine Journal</i> , 2011, 41, 332-337.	0.5	17
285	Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists. <i>British Journal of Haematology</i> , 2011, 153, 508-514.	1.2	11
286	Effect of provision of the NHS NPSA oral anticoagulant therapy patient information pack upon patients' knowledge and anticoagulant control. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 231-233.	1.9	7
287	Comparison of time within therapeutic INR range with percentage INR within therapeutic range for assessing long-term anticoagulation control in children. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1090-1092.	1.9	10
288	Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2215-2220.	1.9	38
289	Using the laboratory to predict recurrent venous thrombosis. <i>International Journal of Laboratory Hematology</i> , 2011, 33, 333-342.	0.7	25
290	Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation - The J-RHYTHM Registry study design. <i>Journal of Cardiology</i> , 2011, 57, 95-99.	0.8	69
291	Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: A pilot study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, e1-e2.	0.4	69
292	Health Care Expenditures and Therapeutic Outcomes of a Pharmacist-Managed Anticoagulation Service versus Usual Medical Care. <i>Pharmacotherapy</i> , 2011, 31, 686-694.	1.2	41
293	Quality measures and benchmarking for warfarin therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 242-248.	1.0	6
294	Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. <i>Clinical Research in Cardiology</i> , 2011, 100, 955-971.	1.5	3

#	ARTICLE	IF	CITATIONS
295	The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 581-590.	0.8	11
296	Practice nurse-based, individual and video-assisted patient education in oral anticoagulation - Protocol of a cluster-randomized controlled trial. <i>BMC Family Practice</i> , 2011, 12, 17.	2.9	16
297	Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. <i>BMC Family Practice</i> , 2011, 12, 88.	2.9	61
298	Using highly variable warfarin dosing to identify patients at risk for adverse events. <i>Thrombosis Journal</i> , 2011, 9, 14.	0.9	1
299	A randomized controlled trial of genotype-based Coumadin initiation. <i>Genetics in Medicine</i> , 2011, 13, 509-518.	1.1	112
300	Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. <i>European Heart Journal</i> , 2011, 32, 2282-2289.	1.0	218
301	Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral Anticoagulation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 22-29.	0.9	134
302	Evaluation of Anticoagulation Management and Chronic Disease State Control in a Pharmacist-Run Pharmacotherapy/Anticoagulation Clinic. <i>Journal of Pharmacy Technology</i> , 2011, 27, 3-8.	0.5	1
303	The Business Case for Quality Improvement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 416-424.	0.9	45
304	Reexamining the Recommended Follow-up Interval After Obtaining an In-Range International Normalized Ratio Value. <i>Chest</i> , 2011, 140, 359-365.	0.4	22
305	Prompt Repeat Testing After Out-of-Range INR Values. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 276-282.	0.9	42
306	Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. <i>Journal of Human Hypertension</i> , 2011, 25, 304-310.	1.0	30
307	Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. <i>Future Cardiology</i> , 2011, 7, 459-470.	0.5	16
308	Quality of management of oral anticoagulation as assessed by time in therapeutic INR range in elderly and younger patients with low mean years of formal education: a prospective cohort study. <i>Age and Ageing</i> , 2011, 40, 375-381.	0.7	16
309	Impact of i-STAT Point of Care Implementation in a Pharmacist-Managed Anticoagulation Clinic: A Retrospective Analysis. <i>Hospital Pharmacy</i> , 2011, 46, 105-109.	0.4	2
310	Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. <i>Circulation</i> , 2012, 126, 2309-2316.	1.6	133
311	Quality of INR Control and Outcomes Following Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 370-378.	0.7	16
312	Prediction of warfarin dose: why, when and how?. <i>Pharmacogenomics</i> , 2012, 13, 429-440.	0.6	66

#	ARTICLE	IF	CITATIONS
313	A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 88-95.	2.5	423
314	A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II). <i>Circulation</i> , 2012, 125, 1997-2005.	1.6	217
315	Prescribing anticoagulation medication for the elderly. <i>Aging Health</i> , 2012, 8, 205-216.	0.3	1
316	Implementation and Impact of a Hybrid Pharmacist-Assisted Anticoagulation Clinic Model on the Quality of Anticoagulation Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 334-337.	0.7	3
317	Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. <i>Pharmacogenomics Journal</i> , 2012, 12, 417-424.	0.9	62
318	New Oral Anticoagulants for Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 133-137.	1.6	23
319	Application of the UK NHS Improvement Anticoagulation Commissioning Support Document for "safety indicators"™ in atrial fibrillation. Results of the European Action on Anticoagulation study. <i>Journal of Clinical Pathology</i> , 2012, 65, 452-456.	1.0	4
320	Incidence rates in dynamic populations. <i>International Journal of Epidemiology</i> , 2012, 41, 1472-1479.	0.9	84
321	Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2012, 107, 1100-1106.	1.8	30
322	Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. <i>Blood</i> , 2012, 119, 861-867.	0.6	66
323	Anticoagulation Control Quality Affects the D-Dimer Levels of Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2012, 76, 317-321.	0.7	21
324	Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2012, 76, 2104-2111.	0.7	589
325	Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2012, 76, 1840-1847.	0.7	105
326	Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. <i>Lancet, The</i> , 2012, 379, 322-334.	6.3	334
327	Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2039-2044.	1.9	110
328	Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 239.	0.7	15
329	Pilot Study of a Novel Patient Self-Management Program for Warfarin Therapy Using Venipuncture- <i>Acquired International Normalized Ratio Monitoring</i> . <i>Pharmacotherapy</i> , 2012, 32, 1078-1084.	1.2	8
332	Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 776-783.	2.4	407

#	ARTICLE	IF	CITATIONS
333	Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. <i>Thrombosis Research</i> , 2012, 129, 32-35.	0.8	65
334	Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. <i>Thrombosis Research</i> , 2012, 129, 715-719.	0.8	37
335	Risk of bleeding in low-risk atrial fibrillation patients on warfarin waiting for elective cardioversion. <i>Thrombosis Research</i> , 2012, 129, 588-590.	0.8	1
336	Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: A single-center observational study. <i>Thrombosis Research</i> , 2012, 130, 21-26.	0.8	29
337	The effect of subclinical hypothyroidism on vitamin K antagonist treatment. <i>Thrombosis Research</i> , 2012, 129, 520-522.	0.8	3
338	Organizational Characteristics of High- and Low-Performing Anticoagulation Clinics in the Veterans Health Administration. <i>Health Services Research</i> , 2012, 47, 1541-1560.	1.0	32
339	Perceived stress predicts the stability of vitamin K-antagonist treatment of anticoagulant clinic patients. <i>Thrombosis and Haemostasis</i> , 2012, 108, 581-582.	1.8	9
340	Bleeding Risk and Major Adverse Events in Patients With Previous Ulcer on Oral Anticoagulation Therapy. <i>American Journal of Cardiology</i> , 2012, 110, 373-377.	0.7	12
341	Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients. <i>Journal of Vascular Surgery</i> , 2012, 56, 96-105.	0.6	35
342	New drugs for thromboprophylaxis in atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2012, 23, 1-5.	1.0	17
343	Most Important Outcomes Research Papers on Anticoagulation for Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, e65-74.	0.9	14
344	Impact of a Pharmacist-Led Warfarin Self-Management Program on Quality of Life and Anticoagulation Control: A Randomized Trial. <i>Pharmacotherapy</i> , 2012, 32, 871-879.	1.2	63
345	A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 49.	0.7	17
346	Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial. <i>Implementation Science</i> , 2012, 7, 79.	2.5	11
347	Relation of Gender-Specific Risk of Ischemic Stroke in Patients With Atrial Fibrillation to Differences in Warfarin Anticoagulation Control (from AFFIRM). <i>American Journal of Cardiology</i> , 2012, 110, 1799-1802.	0.7	85
348	Dementia and Risk of Adverse Warfarin-Related Events in the Nursing Home Setting. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 323-330.	3.0	13
349	Computerised assistance for warfarin dosage – Effects on treatment quality. <i>European Journal of Internal Medicine</i> , 2012, 23, 742-744.	1.0	17
350	Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time. <i>Thrombosis Research</i> , 2012, 130, 674-681.	0.8	19

#	ARTICLE	IF	CITATIONS
351	The Effect of Cognitive Impairment in the Elderly on the Initial and Long-Term Stability of Warfarin Therapy. <i>Drugs and Aging</i> , 2012, 29, 307-317.	1.3	9
352	Benchmark for Time in Therapeutic Range in Venous Thromboembolism: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e42269.	1.1	71
353	The Creating an Optimal Warfarin Nomogram (CROWN) Study. <i>Thrombosis and Haemostasis</i> , 2012, 107, 59-68.	1.8	14
354	Evaluation of a Pharmacist-Managed Anticoagulation Clinic. <i>Hospital Pharmacy</i> , 2012, 47, 848-854.	0.4	0
355	Home point-of-care international normalised ratio monitoring sustained by a non-selective educational program in children. <i>Thrombosis and Haemostasis</i> , 2012, 108, 710-718.	1.8	13
356	Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices. <i>Vascular Health and Risk Management</i> , 2012, 8, 587.	1.0	22
357	Phenprocoumon and acenocoumarol treatment in paediatric patients. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1238-1241.	1.8	5
358	Sustained Impact of Anticoagulant Control Achieved in an Anticoagulation Management Service After Transfer of Management to the Primary Care Physician. <i>Pharmacotherapy</i> , 2012, 32, 112-119.	1.2	10
359	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. <i>New England Journal of Medicine</i> , 2012, 366, 1859-1869.	13.9	511
360	Oral Anticoagulant Therapy. <i>Chest</i> , 2012, 141, e44S-e88S.	0.4	1,323
361	Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. <i>Thrombosis and Haemostasis</i> , 2012, 108, 561-569.	1.8	35
362	Identifying Potential Predictors of High-Quality Oral Anticoagulation Assessed by Time in Therapeutic International Normalized Ratio Range: A Prospective, Long-Term, Single-Center, Observational Study. <i>Clinical Therapeutics</i> , 2012, 34, 1511-1520.	1.1	23
363	INR targets and site-level anticoagulation control: results from the Veterans Affairs Study to Improve Anticoagulation (VARIA). <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 590-595.	1.9	22
364	Oral anticoagulant therapy in Italian patients 80 years of age or older with atrial fibrillation: a pilot study of low vs. standard PT/INR targets. <i>European Journal of Haematology</i> , 2012, 89, 81-86.	1.1	6
365	Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 105-112.	1.0	43
366	Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 736-743.	1.0	22
367	Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. <i>BMC Health Services Research</i> , 2013, 13, 85.	0.9	13
368	Identifying the Risks of Anticoagulation in Patients with Substance Abuse. <i>Journal of General Internal Medicine</i> , 2013, 28, 1333-1339.	1.3	11

#	ARTICLE	IF	CITATIONS
369	Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 1406-1415.	13.9	1,607
370	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. <i>New England Journal of Medicine</i> , 2013, 369, 1206-1214.	13.9	1,201
371	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2013, 67, 516-526.	0.8	20
372	Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin. <i>Thrombosis Research</i> , 2013, 131, 481-486.	0.8	22
373	Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. <i>Pharmacogenomics</i> , 2013, 14, 1593-1603.	0.6	47
374	Assessment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013, 29, S34-S44.	0.8	40
375	Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 491-502.	1.9	20
376	A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. <i>New England Journal of Medicine</i> , 2013, 369, 2283-2293.	13.9	660
377	A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. <i>New England Journal of Medicine</i> , 2013, 369, 2304-2312.	13.9	210
378	A Randomized Trial of Genotype-Guided Dosing of Warfarin. <i>New England Journal of Medicine</i> , 2013, 369, 2294-2303.	13.9	735
379	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	13.9	4,215
381	Monitoring of anticoagulant therapy applying a dynamic statistical model. <i>Computer Methods and Programs in Biomedicine</i> , 2013, 110, 380-388.	2.6	4
382	Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. <i>American Heart Journal</i> , 2013, 166, 435-441.e2.	1.2	15
383	Nonadherence with INR Monitoring and Anticoagulant Complications. <i>Thrombosis Research</i> , 2013, 132, e124-e130.	0.8	29
384	Describing the Profile of Patients on Concurrent Rifampin and Warfarin Therapy in Western Kenya: A Case Series. <i>Drugs in R and D</i> , 2013, 13, 191-197.	1.1	15
385	Use of Vitamin K Antagonist Therapy in Geriatrics: A French National Survey from the French Society of Geriatrics and Gerontology (SFGG). <i>Drugs and Aging</i> , 2013, 30, 1019-1028.	1.3	15
386	The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1053-1058.	1.9	43
387	A Bayesian Dose-Individualization Method for Warfarin. <i>Clinical Pharmacokinetics</i> , 2013, 52, 59-68.	1.6	41

#	ARTICLE	IF	CITATIONS
388	Presenting D-dimer and early symptom severity are independent predictors for post-thrombotic syndrome following a first deep vein thrombosis. <i>British Journal of Haematology</i> , 2013, 160, 817-824.	1.2	28
389	The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. <i>Thrombosis Research</i> , 2013, 131, 125-129.	0.8	20
390	Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 10-14.	1.0	13
391	Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 720-729.	1.6	594
392	Effect of 200µg/day of vitamin k1 on the variability of anticoagulation control in patients on warfarin: A randomized controlled trial. <i>Thrombosis Research</i> , 2013, 132, 329-335.	0.8	9
393	Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. <i>Thrombosis Research</i> , 2013, 132, 770-775.	0.8	37
394	Impact of Co-morbidities and Patient Characteristics on International Normalized Ratio Control Over Time in Patients With Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2013, 112, 509-512.	0.7	49
395	Anticoagulation in real world patients with atrial fibrillation in Italy: Results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. <i>International Journal of Cardiology</i> , 2013, 168, 4729-4733.	0.8	10
396	Computer aided warfarin dosing in the Swedish national quality registry Auricula – Algorithmic suggestions are performing better than manually changed doses. <i>Thrombosis Research</i> , 2013, 131, 130-134.	0.8	26
397	HeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 675-683.	0.3	330
398	Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2013, 166, 549-558.	1.2	42
399	Patient Factors against Stable Control of Warfarin Therapy for Japanese Non-valvular Atrial Fibrillation Patients. <i>Thrombosis Research</i> , 2013, 132, 537-542.	0.8	16
400	Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. <i>Journal of Electrocardiology</i> , 2013, 46, 45-50.	0.4	23
401	Dose-adjusted warfarin: writing the prescription is only the beginning. <i>Journal of Electrocardiology</i> , 2013, 46, 51-53.	0.4	0
402	Clinical validation of a new algorithm for computerized dosing of vitamin K antagonist therapy: a retrospective simulation study. <i>Internal and Emergency Medicine</i> , 2013, 8, 55-63.	1.0	0
403	New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2013, 145, 105-112.e15.	0.6	347
404	The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 107-115.	1.9	39
405	The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013, 109, 431-439.	1.8	32

#	ARTICLE	IF	CITATIONS
406	Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 435-443.	1.9	75
407	Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 333-335.	1.0	45
408	Major bleeding risk in anticoagulated patients receiving concomitant antiplatelet therapy: A prospective study. <i>Thrombosis Research</i> , 2013, 131, 502-507.	0.8	3
409	Bleeding risks associated with vitamin K antagonists. <i>Blood Reviews</i> , 2013, 27, 111-118.	2.8	17
410	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 799-808.	13.9	1,915
411	Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 2166-2176.	1.6	196
412	Gender differences of bleeding and stroke risk in very Old atrial fibrillation patients on VKA treatment. <i>Thrombosis Research</i> , 2013, 131, 12-16.	0.8	36
413	Thromboembolic and bleeding outcomes of low-intensity warfarin thromboprophylaxis following elective total hip arthroplasty. <i>Thrombosis Research</i> , 2013, 131, 390-395.	0.8	8
414	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. <i>European Heart Journal</i> , 2013, 34, 2464-2471.	1.0	154
415	Limited English Proficient Patients and Time Spent in Therapeutic Range in a Warfarin Anticoagulation Clinic. <i>Journal of the American Heart Association</i> , 2013, 2, e000170.	1.6	27
416	Bleeding Risk Assessment in Patients With Atrial Fibrillation Who Are Taking Oral Anticoagulants. <i>Hospital Practice (1995)</i> , 2013, 41, 71-78.	0.5	5
417	Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial. <i>Journal of the American Heart Association</i> , 2013, 2, e000067.	1.6	179
418	Novel Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. <i>Hospital Practice (1995)</i> , 2013, 41, 37-48.	0.5	3
419	Triple Antithrombotic Therapy Is the Independent Predictor for the Occurrence of Major Bleeding Complications. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 444-451.	1.4	17
420	Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2013, 6, 740-747.	1.6	102
421	Age as a Determinant of Instability of Serum Lithium Concentrations. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 643-648.	1.0	8
422	Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 611-618.	0.7	12
423	Vitamin E Serum Levels and Bleeding Risk in Patients Receiving Oral Anticoagulant Therapy: a Retrospective Cohort Study. <i>Journal of the American Heart Association</i> , 2013, 2, e000364.	1.6	36

#	ARTICLE	IF	CITATIONS
424	Comparing clinicians'™ use of an anticoagulation management service and usual care in ambulatory oncology. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 237-245.	0.5	2
425	New oral therapies for the prevention and treatment of venous thromboembolism. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 113-125.	0.5	7
426	Applying the Triple Aim to the Quality Agenda for Anticoagulation Care. <i>Journal of the American Heart Association</i> , 2013, 2, e000377.	1.6	1
427	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). <i>European Heart Journal</i> , 2013, 34, 1498-1505.	1.0	109
428	Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. <i>Pharmacogenomics</i> , 2013, 14, 869-883.	0.6	17
429	Effects of Depressive and Other Psychiatric Disorders on Anticoagulation Control in a Pharmacist-Managed Anticoagulation Clinic. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1292-1300.	0.9	5
430	A Pharmacist-Led Point-of-Care INR Clinic: Optimizing Care in a Family Health Team Setting. <i>International Journal of Family Medicine</i> , 2013, 2013, 1-4.	1.2	16
431	The use of vitamin K supplementation to achieve INR stability: A systematic review and meta-analysis. <i>Journal of the American Association of Nurse Practitioners</i> , 2013, 25, n/a-n/a.	0.5	5
432	The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1540-1546.	1.9	30
433	Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 474-480.	1.9	86
434	Assessment of Warfarin Dosing Requirements After Bariatric Surgery in Patients Requiring Long-Term Warfarin Therapy. <i>Pharmacotherapy</i> , 2013, 33, 1175-1183.	1.2	29
435	Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study " methodological implications for clinical trials. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1287-1294.	1.9	72
436	Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home. <i>Journal of Telemedicine and Telecare</i> , 2013, 19, 298-301.	1.4	16
437	Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2013, 2, e000535.	1.6	92
438	Target International Normalized Ratio Values for Preventing Thromboembolic and Hemorrhagic Events in Japanese Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2013, 77, 2264-2270.	0.7	118
439	Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1189-1198.	1.8	182
440	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	1.8	347
441	Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin. <i>Chest</i> , 2013, 144, 1555-1563.	0.4	440

#	ARTICLE	IF	CITATIONS
442	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. , 2013, , CD008600.		35
443	Gaps in Monitoring During Oral Anticoagulation. Chest, 2013, 143, 751-757.	0.4	44
444	Vitamin K antagonists in patients with nonvalvular atrial fibrillation. Journal of Cardiovascular Medicine, 2013, 14, 534-540.	0.6	7
445	Dietary vitamin K intake and anticoagulation control during the initiation phase of warfarin therapy: A prospective cohort study. Thrombosis and Haemostasis, 2013, 109, 195-196.	1.8	6
446	Management of Stroke Prevention in Canadian Patients with Atrial Fibrillation at Moderate to High Risk of Stroke. Canadian Journal of Hospital Pharmacy, 2013, 66, 296-303.	0.1	1
447	Pharmacological treatments for stroke prevention in AF. British Journal of Cardiac Nursing, 2013, 8, 580-587.	0.0	1
450	Simultaneous Use of Amiodarone Influences Warfarin Maintenance Dose but Is Not Associated with Adverse Events. Journal of Managed Care Pharmacy, 2014, 20, 376-381.	2.2	12
451	Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. Thrombosis and Haemostasis, 2014, 112, 511-521.	1.8	69
452	Patient Self-Management of Oral Anticoagulation with Vitamin K Antagonists in Everyday Practice: Efficacy and Safety in a Nationwide Long-Term Prospective Cohort Study. PLoS ONE, 2014, 9, e95761.	1.1	25
453	Educating Orally Anticoagulated Patients in Drug Safety. Deutsches Ärztblatt International, 2014, 111, 607-14.	0.6	18
454	Eficacia y seguridad del tratamiento anticoagulante oral con antagonistas de vitamina K en pacientes con prÃ³tesis valvulares cardÃ¡acas. Revista Chilena De CardiologÃ­a, 2014, 33, 27-32.	0.0	2
455	International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation. Current Medical Research and Opinion, 2014, 30, 2437-2442.	0.9	14
456	Eligibility and Preference of New Oral Anticoagulants in Patients With Atrial Fibrillation. Stroke, 2014, 45, 2983-2988.	1.0	26
457	Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Research Notes, 2014, 7, 891.	0.6	39
458	Seguir el protocolo: enseÃ±ar a los pacientes a autoevaluarse. Nursing (Ed EspaÃ±ola), 2014, 31, 10-12.	0.0	0
459	A suite of inpatient and outpatient clinical measures for pharmacy accountability: Recommendations from the Pharmacy Accountability Measures Work Group. American Journal of Health-System Pharmacy, 2014, 71, 1669-1678.	0.5	8
460	The influence of coagulation factors on the in-treatment biological variation of international normalized ratio for patients on warfarin. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 470-476.	0.6	7
461	Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open, 2014, 4, e005379-e005379.	0.8	2

#	ARTICLE	IF	CITATIONS
462	An audit of anticoagulant management to assess anticoagulant control using decision support software. <i>BMJ Open</i> , 2014, 4, e005864-e005864.	0.8	9
463	Relationship of the SAME-TT 2 R 2 Score to Poor-Quality Anticoagulation, Stroke, Clinically Relevant Bleeding, and Mortality in Patients With Atrial Fibrillation. <i>Chest</i> , 2014, 146, 719-726.	0.4	108
464	Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data. <i>BMJ Open</i> , 2014, 4, e004071.	0.8	21
465	Pathways to poor anticoagulation control. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 628-634.	1.9	27
466	Oral anticoagulants for Asian patients with atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2014, 11, 290-303.	6.1	36
467	Relevance of depression for anticoagulation management in a routine medical care setting: results from the ThrombEVAL study program. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 2024-2033.	1.9	16
468	Risk of falls and bleeding in elderly patients with acute venous thromboembolism. <i>Journal of Internal Medicine</i> , 2014, 276, 378-386.	2.7	17
469	Warfarin dosing after bariatric surgery: a retrospective study of 10 patients previously stable on chronic warfarin therapy. <i>Clinical Obesity</i> , 2014, 4, 108-115.	1.1	17
470	The effects of fasting in Muslim patients taking warfarin. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 349-354.	1.9	18
471	Association between ABCG2 and ABCB1 genes and warfarin stability: A case-control study. <i>Thrombosis Research</i> , 2014, 134, 1359-1362.	0.8	4
472	Bleeding Rates in Veterans Affairs Patients with Atrial Fibrillation Who Switch from Warfarin to Dabigatran. <i>American Journal of Medicine</i> , 2014, 127, 1179-1185.	0.6	49
473	Recurrence of ICH after resumption of anticoagulation with VK antagonists. <i>Neurology</i> , 2014, 82, 1020-1026.	1.5	66
475	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. <i>Thrombosis Journal</i> , 2014, 12, 24.	0.9	45
476	Oral anticoagulant therapy and clinical outcomes in patients with atrial fibrillation. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 688-694.	0.5	1
477	Pharmacist-Managed International Normalized Ratio Patient Self-Testing Is Associated with Increased Time in Therapeutic Range in Patients with Left Ventricular Assist Devices at an Academic Medical Center. <i>ASAIO Journal</i> , 2014, 60, 193-198.	0.9	46
478	Improving Quality Measurement for Anticoagulation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 664-669.	0.9	50
479	The Association of Health Literacy With Time in Therapeutic Range for Patients on Warfarin Therapy. <i>Journal of Health Communication</i> , 2014, 19, 19-28.	1.2	24
480	Stratifying the Risks of Oral Anticoagulation in Patients With Liver Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 461-467.	0.9	48

#	ARTICLE	IF	CITATIONS
481	Sex Differences in Treatment Quality of Self-Managed Oral Anticoagulant Therapy: 6,900 Patient-Years of Follow-Up. PLoS ONE, 2014, 9, e113627.	1.1	22
482	Integrating Real-Time Clinical Information to Provide Estimates of Net Clinical Benefit of Antithrombotic Therapy for Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 680-686.	0.9	27
483	Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2014, 312, 1988.	3.8	765
484	Vitamin K Antagonist Treatment in Patients With Atrial Fibrillation and Time in Therapeutic Range in Four European Countries. Clinical Therapeutics, 2014, 36, 1160-1168.	1.1	54
485	Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial. Journal of the American Heart Association, 2014, 3, e000521.	1.6	94
486	Follow the protocol. Nursing, 2014, 44, 20-22.	0.2	0
487	A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants. Blood Coagulation and Fibrinolysis, 2014, 25, 812-815.	0.5	6
488	Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 114, 70-78.	0.7	56
489	Comparing patient-level and site-level anticoagulation control as predictors of adverse events. Thrombosis Research, 2014, 133, 652-656.	0.8	30
490	Higher vitamin K intake is associated with better INR control and a decreased need for INR tests in long-term warfarin therapy. Thrombosis Research, 2014, 134, 210-212.	0.8	10
491	The quality of oral anticoagulation in general practice in patients with atrial fibrillation. European Journal of Internal Medicine, 2014, 25, 247-254.	1.0	30
492	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. Journal of Thrombosis and Thrombolysis, 2014, 37, 435-442.	1.0	10
493	Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. Cardiovascular Intervention and Therapeutics, 2014, 29, 193-199.	1.2	13
494	Optimal Dynamic Treatment Strategies with Protection Against Missed Decision Points. Statistics in Biosciences, 2014, 6, 261-289.	0.6	1
495	Improvement of anticoagulant treatment using a dynamic decision support algorithm. Thrombosis Research, 2014, 133, 375-379.	0.8	9
496	Outcomes of Anticoagulation Therapy in Patients with Mental Health Conditions. Journal of General Internal Medicine, 2014, 29, 855-861.	1.3	31
497	Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation. BMC Health Services Research, 2014, 14, 46.	0.9	10
498	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal, 2014, 167, 735-742.e2.	1.2	120

#	ARTICLE	IF	CITATIONS
499	Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: A special reference to low-intensity warfarin therapy. <i>Journal of Cardiology</i> , 2014, 64, 127-132.	0.8	15
500	Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 199-207.	2.3	64
501	Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. <i>European Heart Journal</i> , 2014, 35, 1881-1887.	1.0	96
502	Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 98-104.	1.0	16
503	Association of quality of life with anticoagulant control in patients with heart failure: The Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. <i>International Journal of Cardiology</i> , 2014, 177, 715-717.	0.8	4
504	Improving the management of warfarin in aged-care facilities utilising innovative technology: a proof-of-concept study. <i>International Journal of Pharmacy Practice</i> , 2014, 22, 84-91.	0.3	6
505	Renal function, attributes and coagulation treatment in atrial fibrillation (R-FACT Study): Retrospective, observational, longitudinal cohort study of renal function and antithrombotic treatment patterns in atrial fibrillation patients with documented eGFR. <i>International Journal of Clinical Practice</i> , 2014, 68, 714-724.	0.8	3
506	Clinical Outcomes in Patients With Isolated Left Ventricular Noncompaction and Heart Failure. <i>Journal of Cardiac Failure</i> , 2014, 20, 709-715.	0.7	15
507	Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. <i>Pharmacogenomics Journal</i> , 2014, 14, 542-548.	0.9	17
508	Beyond warfarin: A patient-centered approach to selecting novel oral anticoagulants for stroke prevention in atrial fibrillation. <i>Journal of Hospital Medicine</i> , 2014, 9, 400-406.	0.7	9
509	Thromboembolism, major bleeding and mortality in patients with mechanical heart valves- a population-based cohort study. <i>Thrombosis Research</i> , 2014, 134, 354-359.	0.8	26
510	The management of atrial fibrillation: summary of updated NICE guidance. <i>BMJ, The</i> , 2014, 348, g3655-g3655.	3.0	66
511	Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation. <i>Thrombosis Research</i> , 2014, 134, 717-722.	0.8	14
512	Adherence to warfarin treatment among patients with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2014, 103, 998-1005.	1.5	47
513	Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 226-234.	1.0	6
514	Anticoagulation in atrial fibrillation. <i>BMJ, The</i> , 2014, 348, g2116-g2116.	3.0	68
515	Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England. <i>Age and Ageing</i> , 2014, 43, 708-711.	0.7	7
516	Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques. <i>Stroke</i> , 2014, 45, 1248-1257.	1.0	178

#	ARTICLE	IF	CITATIONS
517	Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. <i>Stroke</i> , 2014, 45, 1739-1747.	1.0	142
518	A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. <i>Internal and Emergency Medicine</i> , 2014, 9, 443-447.	1.0	62
519	The Clinical Impact of Different Coagulometers on Patient Outcomes. <i>Advances in Therapy</i> , 2014, 31, 639-656.	1.3	7
520	National Assessment of Warfarin Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 1407-1414.	1.6	133
521	Defining time in therapeutic range for busy clinicians: Frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin. <i>Thrombosis Research</i> , 2014, 134, 584-586.	0.8	3
522	Impact of Gender on the Prognosis of Patients With Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2014, 113, 957-962.	0.7	57
523	Mechanical heart valve prosthesis and warfarin – Treatment quality and prognosis. <i>Thrombosis Research</i> , 2014, 133, 795-798.	0.8	25
524	A descriptive evaluation of warfarin use in patients with pulmonary arterial hypertension. <i>Thrombosis Research</i> , 2014, 133, 790-794.	0.8	3
525	Improvement of HAS-BLED bleeding score predictive capability by changing the definition of renal dysfunction in Japanese atrial fibrillation patients on anticoagulation therapy. <i>Journal of Cardiology</i> , 2014, 64, 482-487.	0.8	14
526	Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the Prospective Randomized On-X Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 1202-1211.e2.	0.4	220
527	An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 23-34.	0.3	421
529	Evaluation of a mobile electronic assistant to aid in fluindione prescription: The INRPlus cluster randomized trial. <i>Thrombosis Research</i> , 2014, 133, 756-761.	0.8	1
530	The Predictive Ability of the CHADS2 and CHA2DS2-VASc Scores for Bleeding Risk in Atrial Fibrillation: The MAQI2 Experience. <i>Thrombosis Research</i> , 2014, 134, 294-299.	0.8	35
532	Impact of short periods with worsened or improved INR control on life expectancy and QALYs in patients with atrial fibrillation. <i>Thrombosis Research</i> , 2014, 133, 1061-1067.	0.8	3
533	Pharmacogenetics role in the safety of acenocoumarol therapy. <i>Thrombosis and Haemostasis</i> , 2014, 112, 522-536.	1.8	20
534	Prolonged International Normalized Ratio During the First Year of Warfarin Treatment. <i>American Journal of the Medical Sciences</i> , 2014, 348, 71-74.	0.4	1
535	Introduction of Point-of-Care Testing in Japanese Outpatient Clinics Is Associated With Improvement in Time in Therapeutic Range in Anticoagulant-Treated Patients. <i>Circulation Journal</i> , 2014, 78, 1342-1348.	0.7	20
536	Thromboembolic Events in Paroxysmal vs. Permanent Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2014, 78, 2388-2393.	0.7	42

#	ARTICLE	IF	CITATIONS
537	Inappropriate Use of Oral Anticoagulants for Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2014, 78, 2166-2172.	0.7	123
538	Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). <i>Circulation Journal</i> , 2014, 78, 1997-2021.	0.7	385
539	Thrombin and FXa plasma concentration levels in patients with atrial fibrillation on long term warfarin therapy. <i>ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology</i> , 2014, 22, .	0.0	0
540	Anticoagulation Management of Atrial Fibrillation. <i>Health Services Research and Managerial Epidemiology</i> , 2014, 1, 233339281455252.	0.5	0
541	Quality control of oral anticoagulant therapy in Primary Care in Madrid City, Spain: CHRONOS-TAO study. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 192-197.	0.1	11
542	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	1.4	59
544	Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1606-1614.	1.9	44
545	Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism. <i>Haematologica</i> , 2015, 100, 188-193.	1.7	16
546	Target Intensity of Anticoagulation With Warfarin in Japanese Patients With Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2015, 79, 325-330.	0.7	29
547	Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J) Tj ETQq1 1 0.784314 rgBT /Over 0.7	0.7	62
548	Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin—Insights From the ENGAGE AF-TIMI 48 Trial. <i>Circulation Journal</i> , 2015, 79, 2560-2567.	0.7	35
549	Use of Warfarin in Elderly Patients With Non-Valvular Atrial Fibrillation—Subanalysis of the J-RHYTHM Registry. <i>Circulation Journal</i> , 2015, 79, 2345-2352.	0.7	31
550	Percent Time in Range with Warfarin as a Performance Measure: How Long a Sampling Frame Is Needed?. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2015, 41, 561-568.	0.4	6
551	Cohort study of Anticoagulation Self-Monitoring (CASM): a prospective study of its effectiveness in the community. <i>British Journal of General Practice</i> , 2015, 65, e428-e437.	0.7	12
552	Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study. <i>Journal of Arrhythmia</i> , 2015, 31, 339-344.	0.5	45
553	Warfarin treatment complications do not correlate to cTTR when above 70%. <i>Thrombosis Research</i> , 2015, 136, 1185-1189.	0.8	8
554	Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial. <i>Lancet Haematology</i> , 2015, 2, e231-e240.	2.2	23
555	Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 972-976.	0.5	12

#	ARTICLE	IF	CITATIONS
556	Safety and efficacy of well managed warfarin. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1370-1377.	1.8	127
557	Renal, endothelial function, warfarin management, and the CHADS2, CHA2DS2VASc and HAS-BLED scores in predicting MACE in AF. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1155-1157.	1.8	8
558	Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2015, 114, 695-701.	1.8	45
559	Pharmacogenetics-based Warfarin Dosing Algorithm Decreases Time to Stable Anticoagulation and the Risk of Major Hemorrhage. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 364-370.	0.8	15
560	A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1405-1413.	1.9	11
561	Comparison of the Abilities of Summary Measures of International Normalized Ratio Control to Predict Clinically Relevant Bleeding. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 524-531.	0.9	11
562	Predictors of Thromboembolic Events in Patients with Ventricular Assist Device. <i>ASAIO Journal</i> , 2015, 61, 640-647.	0.9	19
563	Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. <i>Coronary Artery Disease</i> , 2015, 26, 372-380.	0.3	19
564	Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice. <i>Medicine (United States)</i> , 2015, 94, e1915.	0.4	8
565	Association Between Usual Vitamin K Intake and Anticoagulation in Patients Under Warfarin Therapy. <i>Clinical Nutrition Research</i> , 2015, 4, 235.	0.5	9
566	Factors Associated with Ischemic Stroke on Therapeutic Anticoagulation in Patients with Nonvalvular Atrial Fibrillation. <i>Yonsei Medical Journal</i> , 2015, 56, 410.	0.9	9
567	Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients. <i>Thrombosis and Haemostasis</i> , 2015, 113, 881-890.	1.8	11
568	Association between Oral Anticoagulation Knowledge, Anticoagulation Control, and Demographic Characteristics of Patients Attending an Anticoagulation Clinic in Saudi Arabia: A Cross-Sectional Prospective Evaluation. <i>Tropical Journal of Pharmaceutical Research</i> , 2015, 14, 1285.	0.2	9
569	Point-of-care testing and INR within-subject variation in patients receiving a constant dose of vitamin K antagonist. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1260-1267.	1.8	0
570	Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centre. <i>Kardiochirurgia i Torakochirurgia Polska</i> , 2015, 4, 334-340.	0.1	14
571	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. <i>PLoS ONE</i> , 2015, 10, e0124719.	1.1	50
572	Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation. <i>PLoS ONE</i> , 2015, 10, e0144314.	1.1	16
573	Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1136-1143.	1.8	11

#	ARTICLE	IF	CITATIONS
574	Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 768-777.	1.8	33
575	New educational approach for patients on warfarin improves knowledge and therapy control. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 472-476.	1.0	5
576	Stroke Prevention in Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1950.	3.8	258
577	The Impact of Inpatient Versus Outpatient Initiation on Early Warfarin Dosing. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 267-274.	1.0	1
578	Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 257-264.	1.3	3
579	To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort. <i>Internal and Emergency Medicine</i> , 2015, 10, 795-804.	1.0	17
580	Point-of-care monitoring of warfarin treatment in community dwelling elderly – A randomised controlled study. <i>Journal of Telemedicine and Telecare</i> , 2015, 21, 298-301.	1.4	1
581	Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists. <i>Europace</i> , 2015, 17, 1223-1228.	0.7	13
582	Quality of Anticoagulation With Vitamin K Antagonists. <i>Clinical Cardiology</i> , 2015, 38, 357-364.	0.7	67
583	Control de la anticoagulación en pacientes con fibrilación auricular no valvular asistidos en atención primaria en España. Estudio PAULA. <i>Revista Española De Cardiología</i> , 2015, 68, 769-776.	0.6	118
584	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e001349.	1.6	12
585	Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	12
586	The changing characteristics of atrial fibrillation patients treated with warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 488-493.	1.0	4
587	INR variability and outcomes in patients with mechanical heart valve prosthesis. <i>Thrombosis Research</i> , 2015, 136, 1211-1215.	0.8	13
588	Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response. <i>Thrombosis Research</i> , 2015, 136, 1174-1178.	0.8	28
589	Tratamiento anticoagulante en la fibrilación auricular no valvular: hay margen de mejora. <i>Revista Clínica Española</i> , 2015, 215, 98-99.	0.2	0
590	Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. <i>European Heart Journal</i> , 2015, 36, 297-306.	1.0	140
591	Thromboembolic and Bleeding Outcomes of Extended Duration Low-Intensity Warfarin Following Elective Total Knee Arthroplasty. <i>Thrombosis Research</i> , 2015, 135, 267-271.	0.8	6

#	ARTICLE	IF	CITATIONS
592	Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients) Tj ETQq0 0 OrgBT /Overlock 10 T		
594	Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands. <i>Pharmacogenomics</i> , 2015, 16, 101-114.	0.6	9
595	Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 488-494.	1.6	224
596	Venous thromboembolism among HIV-positive patients and anticoagulation clinic outcomes integrated within the HIV primary care setting. <i>International Journal of STD and AIDS</i> , 2015, 26, 870-878.	0.5	3
597	Effectiveness and Safety of Therapy with Vitamin K Antagonists in Italian Patients Aged 80 Years or Older: a Multicentre Retrospective Study Comparing the Zeus Algorithm with the PARMIA Algorithm or Manual Therapy. <i>Drugs and Aging</i> , 2015, 32, 235-241.	1.3	2
598	The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist. <i>Internal and Emergency Medicine</i> , 2015, 10, 157-163.	1.0	12
599	Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 53-59.	1.0	32
600	Utility of a Dedicated Pediatric Cardiac Anticoagulation Program: The Boston Children's Hospital Experience. <i>Pediatric Cardiology</i> , 2015, 36, 842-850.	0.6	21
601	A new biomarker quantifies differences in clot microstructure in patients with venous thromboembolism. <i>British Journal of Haematology</i> , 2015, 168, 571-575.	1.2	23
602	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. <i>Lancet, The</i> , 2015, 385, 2280-2287.	6.3	153
603	Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. <i>Thrombosis Research</i> , 2015, 136, 94-100.	0.8	2
604	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). <i>American Heart Journal</i> , 2015, 170, 675-682.e8.	1.2	128
605	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2015, 8, 504-509.	1.6	21
606	Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. <i>European Heart Journal</i> , 2015, 36, 1660-1668.	1.0	329
607	Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 31.	3.8	195
608	Intensity and Quality of Warfarin Anticoagulation in Chinese Patients. <i>Stroke</i> , 2015, 46, 5-6.	1.0	6
609	Determinants and consequences of differences in quality of anticoagulation therapy with vitamin K antagonists. <i>Thrombosis Research</i> , 2015, 136, 183-184.	0.8	1
610	Computerized Clinical Decision Support Improves Warfarin Management and Decreases Recurrent Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 197-203.	0.7	13

#	ARTICLE	IF	CITATIONS
611	The SAME-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective "Real-world" Inception Cohort Study. <i>American Journal of Medicine</i> , 2015, 128, 1237-1243.	0.6	51
612	Quality of Vitamin K Antagonist Anticoagulation in Spain: Prevalence of Poor Control and Associated Factors. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 761-768.	0.4	12
613	Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden. <i>Thrombosis Research</i> , 2015, 136, 216-220.	0.8	37
614	Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink. <i>Thrombosis Research</i> , 2015, 136, 250-260.	0.8	47
615	Comparison of warfarin time in the therapeutic range at a pharmacist-run anticoagulation clinic and the RE-LY trial. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 557-562.	0.5	4
616	Evaluation of oral anticoagulation therapy: Rationale and design of the thrombEVAL study programme. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 622-628.	0.8	16
617	Symptoms of depression and anxiety predict mortality in patients undergoing oral anticoagulation: Results from the thrombEVAL study program. <i>International Journal of Cardiology</i> , 2015, 187, 614-619.	0.8	25
618	Effect of a Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs Anticoagulation Alone on Risk of Recurrent Pulmonary Embolism. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1627.	3.8	404
619	Impact of rivaroxaban compared with warfarin on the coagulation status in Japanese patients with non-valvular atrial fibrillation: A preliminary analysis of the prothrombin fragment 1+2 levels. <i>Journal of Cardiology</i> , 2015, 65, 191-196.	0.8	19
620	Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. <i>Thrombosis Research</i> , 2015, 135, 621-629.	0.8	28
621	Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service " results from the prospective, multi-center, observational cohort study thrombEVAL. <i>BMC Medicine</i> , 2015, 13, 14.	2.3	47
622	Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. <i>Chest</i> , 2015, 148, 701-710.	0.4	26
623	International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 205-211.	1.0	34
624	Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF study. <i>Revista Clínica Española</i> , 2015, 215, 73-82.	0.3	5
625	Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin. <i>Current Medical Research and Opinion</i> , 2015, 31, 439-447.	0.9	21
626	Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non-Valvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2015, 4, e001486.	1.6	171
627	Clinical Outcomes and Adherence to Guideline Recommendations During the Initial Treatment of Acute Venous Thromboembolism. <i>Annals of Pharmacotherapy</i> , 2015, 49, 869-875.	0.9	6
628	Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. <i>Lupus</i> , 2015, 24, 1087-1094.	0.8	70

#	ARTICLE	IF	CITATIONS
629	Effectiveness of Protocol Guided Heparin Anticoagulation in Patients with the TandemHeart Percutaneous Ventricular Assist Device. <i>ASAIO Journal</i> , 2015, 61, 207-208.	0.9	6
630	Practical Management of Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1340-1360.	1.2	92
631	Evaluation of Time in Therapeutic Range on Warfarin Therapy Between Face-to-Face and Telephone Follow-Up in a VA Medical Center. <i>Journal of Pharmacy Technology</i> , 2015, 31, 78-83.	0.5	13
632	Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. <i>American Heart Journal</i> , 2015, 170, 141-148.e1.	1.2	211
633	Relationship between time spent at extreme International Normalized Ratios and time in therapeutic range with bleeding and thrombosis in warfarin-treated patients. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1188-1194.	0.5	9
634	Gender differences in the risk of stroke during support with continuous-flow left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1570-1577.	0.3	47
635	Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 769-776.	0.4	26
636	Effect of distance to health facility on the maintenance of INR therapeutic ranges in rheumatic heart disease patients from Cape Town: no evidence for an association. <i>BMC Health Services Research</i> , 2015, 15, 219.	0.9	10
637	Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. <i>Thrombosis Research</i> , 2015, 136, 1040-1044.	0.8	29
638	Explaining Racial Disparities in Anticoagulation Control. <i>American Journal of Medical Quality</i> , 2015, 30, 214-222.	0.2	19
639	Economic evaluation of a randomized controlled trial of pharmacist-supervised patient self-testing of warfarin therapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 14-19.	0.7	17
640	Anticoagulant management of atrial fibrillation: the influence of dosing algorithm and recall schedule on time in therapeutic range. <i>Family Practice</i> , 2015, 32, 514-519.	0.8	1
641	Physical activity and risk of bleeding in elderly patients taking anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 197-205.	1.9	28
642	The HVAD Left Ventricular Assist Device. <i>JACC: Heart Failure</i> , 2015, 3, 818-828.	1.9	167
643	Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina. <i>Health Economics Review</i> , 2015, 5, 52.	0.8	11
644	Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis. <i>American Heart Journal</i> , 2015, 170, 559-565.	1.2	8
645	International Normalized Ratio Variability: A Measure of Anticoagulation Quality or a Powerful Mortality Predictor. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 2223-2228.	0.7	12
646	Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 677.	3.8	530

#	ARTICLE	IF	CITATIONS
647	A before and after study of warfarin monitoring in a single region as part of the Scottish patient safety programme in primary care. <i>Scottish Medical Journal</i> , 2015, 60, 196-201.	0.7	3
648	Gastrointestinal haemorrhage in atrial fibrillation patients: impact of quality of anticoagulation control. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 265-272.	1.4	12
649	Tratamiento anticoagulante en pacientes con fibrilaci3n auricular no valvular en un centro de salud. Grado de control del INR e incidencia de episodios cardioemb3licos. <i>Medicina General Y De Familia</i> , 2015, 4, 37-42.	0.1	0
650	Improving Anticoagulation Measurement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 600-607.	0.9	10
651	Assessment of Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Primary Health Care in Galicia, Spain: ANFAGAL Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 753-760.	0.4	8
652	Evaluaci3n del grado de anticoagulaci3n de pacientes con fibrilaci3n auricular en el ambito de atenci3n primaria de Galicia. Estudio ANFAGAL. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 753-760.	0.6	49
654	Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 201, 513-516.	0.8	57
655	Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. <i>Pharmacogenomics</i> , 2015, 16, 865-876.	0.6	36
656	Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients. <i>Clinical Nutrition</i> , 2015, 34, 899-903.	2.3	25
657	Features of Electronic Health Records Necessary for the Delivery of Optimized Anticoagulant Therapy. <i>Annals of Pharmacotherapy</i> , 2015, 49, 113-124.	0.9	12
658	Implementation and outcomes of a pharmacist-managed clinical video telehealth anticoagulation clinic. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 70-73.	0.5	34
659	Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin. <i>Stroke</i> , 2015, 46, 23-30.	1.0	90
660	The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. <i>International Journal of Cardiology</i> , 2015, 180, 185-191.	0.8	37
661	The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 17-25.	1.0	17
662	Anticoagulation management by community pharmacists in New Zealand: an evaluation of a collaborative model in primary care. <i>International Journal of Pharmacy Practice</i> , 2015, 23, 173-181.	0.3	38
663	Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 180, 1-5.	0.8	33
664	Evaluation of Differences in Percentage of International Normalized Ratios in Range Between Pharmacist-Led and Physician-Led Anticoagulation Management Services. <i>Journal of Pharmacy Practice</i> , 2015, 28, 249-255.	0.5	14
665	Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 491-498.	0.4	96

#	ARTICLE	IF	CITATIONS
666	Situaci3n del tratamiento anticoagulante oral en pacientes con fibrilaci3n auricular no valvular en EspaA±a. Estudio REACT-AF. Revista Clinica Espanola, 2015, 215, 73-82.	0.2	20
667	Polypharmacy is Associated with an Increased Risk of Bleeding in Elderly Patients with Venous Thromboembolism. Journal of General Internal Medicine, 2015, 30, 17-24.	1.3	64
668	Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Pharmacology and Phase III Clinical Trials. , 0, , .		0
669	Advantages of a Warfarin Protocol for Long-term Care Pharmacists: a Retrospective Cohort Study. Canadian Geriatrics Journal, 2016, 19, 40-49.	0.7	6
670	Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 676-684.	0.5	8
671	Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. Circulation: Heart Failure, 2016, 9, .	1.6	86
672	Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation. Thrombosis and Haemostasis, 2016, 116, 578-580.	1.8	10
673	Renal Function and Treatment Persistence with Non-Vitamin K Antagonist Oral Anticoagulants in Japanese Patients with Atrial Fibrillation: A Single-Center Experience. Japanese Journal of Clinical Pharmacology and Therapeutics, 2016, 47, 115-122.	0.1	1
674	Thromboprophylaxis in patients with atrial fibrillation: a real practice analysis. Global & Regional Health Technology Assessment, 2016, 3, 16-22.	0.2	1
675	Developing a Complex Educational"Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation. Healthcare (Switzerland), 2016, 4, 10.	1.0	6
676	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. Thrombosis and Haemostasis, 2016, 115, 809-816.	1.8	16
677	Economic evaluation of the new oral anticoagulants for the prevention of thromboembolic events: a cost-minimization analysis. Sao Paulo Medical Journal, 2016, 134, 322-329.	0.4	13
678	The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study. Nutrients, 2016, 8, 578.	1.7	14
679	The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. Thrombosis and Haemostasis, 2016, 116, 480-485.	1.8	7
680	Control of anticoagulation with vitamin K antagonists: overestimation of median time in therapeutic range when assessed by linear interpolation. Thrombosis and Haemostasis, 2016, 116, 679-686.	1.8	6
681	The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. Thrombosis and Haemostasis, 2016, 115, 1101-1108.	1.8	24
682	Educational Level, Anticoagulation Quality, and Clinical Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. PLoS ONE, 2016, 11, e0162108.	1.1	4
683	Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists. PLoS ONE, 2016, 11, e0164485.	1.1	16

#	ARTICLE	IF	CITATIONS
684	Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1076-1083.	1.1	12
685	Liberal Versus Conventional Glucose Targets in Critically Ill Diabetic Patients: An Exploratory Safety Cohort Assessment. <i>Critical Care Medicine</i> , 2016, 44, 1683-1691.	0.4	42
686	Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1715-1724.	1.9	16
687	Designing Personalized Treatment: An Application to Anticoagulation Therapy. <i>Production and Operations Management</i> , 2016, 25, 902-918.	2.1	22
688	The effect of the amiodarone-warfarin interaction on anticoagulation quality in a single, high-quality anticoagulation center. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 147-150.	0.5	4
689	Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 899-906.	0.5	2
690	Risk of Bleeding and Thrombosis in Patients 70 Years or Older Using Vitamin K Antagonists. <i>JAMA Internal Medicine</i> , 2016, 176, 1176.	2.6	36
691	The effect of carbamazepine on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 765-771.	1.9	26
692	Increased microbleeds after infective endocarditis in a patient with valvular replacement. <i>Geriatrics and Gerontology International</i> , 2016, 16, 651-652.	0.7	1
693	Clinical and Operational Benefits of International Normalized Ratio Point-of-Care Testing in Remote Indigenous Communities in Australia's Northern Territory. <i>Point of Care</i> , 2016, 15, 30-34.	0.5	5
694	Home medicines reviews in Australian war veterans taking warfarin do not influence international normalised ratio control. <i>Internal Medicine Journal</i> , 2016, 46, 288-294.	0.5	2
695	Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 479-484.	1.9	1
697	Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	19
698	Optimal decision support rules improve personalize warfarin treatment outcomes. , 2016, 2016, 2594-2597.		1
699	Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 224.	0.7	6
700	Assessment of psychometric properties of the Brazilian version of the oral anticoagulation knowledge test. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 96.	1.0	7
701	Effect of medication timing on anticoagulation stability in users of warfarin (the INRange RCT): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 391.	0.7	2
702	Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J-RHYTHM Registry. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	49

#	ARTICLE	IF	CITATIONS
703	Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. <i>Implementation Science</i> , 2016, 11, 159.	2.5	11
705	Antithrombotic stewardship: a multidisciplinary team approach towards improving antithrombotic therapy outcomes during and after hospitalisation: a study protocol. <i>BMJ Open</i> , 2016, 6, e011537.	0.8	7
706	Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study. <i>Heart Rhythm</i> , 2016, 13, 1581-1588.	0.3	41
707	A New, Simplified Measure of Anticoagulation Control With Warfarin: Potential Role in the Direct Oral Anticoagulant Era. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1203.e5-1203.e7.	0.8	0
708	A multidisciplinary team-based process improves outpatient anticoagulation quality with continuous-flow left-ventricular assist devices. <i>International Journal of Cardiology</i> , 2016, 218, 118-119.	0.8	14
709	Relation of the SAME-TT 2 R 2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2016, 216, 168-172.	0.8	21
710	Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials. <i>American Journal of Medicine</i> , 2016, 129, 1110-1116.	0.6	21
711	Net Clinical Benefit of Dabigatran Over Warfarin in Patients With Atrial Fibrillation Stratified by CHA2DS2-VASc and Time in Therapeutic Range. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1247.e15-1247.e21.	0.8	16
712	Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation. <i>Journal of Cardiology</i> , 2016, 68, 517-522.	0.8	6
713	Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2016, 25, 585-599.	0.7	23
714	A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 399-404.	1.0	15
715	Plasma Vitamin K1 Levels in Italian Patients Receiving Oral Anticoagulant Therapy for Mechanical Heart Prosthesis: A Case-Control Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 267-274.	1.0	2
716	Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016, 1, 172.	3.0	119
717	Impact of Body Mass Index on the Prognosis of Japanese Patients With Non-Valvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2016, 118, 215-221.	0.7	40
718	Anticoagulation management in non-valvular atrial fibrillation in rural and remote Crete. A single-center study from the region of Sitia. <i>Hellenic Journal of Cardiology</i> , 2016, 57, 279-281.	0.4	8
719	Estudo HIPOGAIA: monitorizaçãõ da hipocoagulaçãõ oral com dicumarÃnicos no concelho de Gaia. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 459-465.	0.2	4
720	The HIPOGAIA study: Monitoring of oral anticoagulation with vitamin K antagonists in the municipality of Gaia. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 459-465.	0.2	3
721	The impact of new-onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism. <i>Thrombosis Research</i> , 2016, 144, 21-26.	0.8	17

#	ARTICLE	IF	CITATIONS
722	Risk stratifying emergency department patients with acute pulmonary embolism: Does the simplified Pulmonary Embolism Severity Index perform as well as the original?. <i>Thrombosis Research</i> , 2016, 148, 1-8.	0.8	40
723	Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of) Tj ETQq1 1 0,784314 rgBT /Over 18	0.7	18
724	Comparing the effectiveness of pharmacist-managed warfarin anticoagulation with other models: a systematic review and meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 602-611.	0.7	32
725	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2033-2047.	0.9	4
726	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. <i>Lancet Haematology</i> , 2016, 3, e379-e387.	2.2	136
727	Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2124-2131.	1.9	26
728	Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand. <i>International Journal of Cardiology</i> , 2016, 222, 615-619.	0.8	5
729	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from <sc>ENGAGE AF</sc> TIMI 48. <i>European Journal of Heart Failure</i> , 2016, 18, 1153-1161.	2.9	73
730	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. <i>Pharmacogenomics</i> , 2016, 17, 1425-1439.	0.6	21
731	Effectiveness of a computerized decision support system for anticoagulation management in hemodialysis patients: A before-after study. <i>Hemodialysis International</i> , 2016, 20, 530-536.	0.4	4
732	Design and Rationale of the <sc>RECORDIAL PCI</sc> Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016, 39, 555-564.	0.7	65
733	Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. <i>Heart Rhythm</i> , 2016, 13, 1794-1802.	0.3	33
734	A new scoring system (DAIGA) for predicting bleeding complications in atrial fibrillation patients after drug-eluting stent implantation with triple antithrombotic therapy. <i>International Journal of Cardiology</i> , 2016, 223, 985-991.	0.8	6
735	Oral anticoagulation in octogenarians with atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 223, 87-90.	0.8	9
736	Echocardiography does not predict mortality in hemodynamically stable elderly patients with acute pulmonary embolism. <i>Thrombosis Research</i> , 2016, 145, 67-71.	0.8	11
737	Nine-Year Trend of Anticoagulation Use, Thromboembolic Events, and Major Bleeding in Patients With Non-Valvular Atrial Fibrillation - Shinken Database Analysis. <i>Circulation Journal</i> , 2016, 80, 639-649.	0.7	45
738	Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation - Results of the J-RHYTHM Registry 2. <i>Circulation Journal</i> , 2016, 80, 843-851.	0.7	42
739	Regional Differences in Frequency of Warfarin Therapy and Thromboembolism in Japanese Patients With Non-Valvular Atrial Fibrillation - Analysis of the J-RHYTHM Registry. <i>Circulation Journal</i> , 2016, 80, 1548-1555.	0.7	7

#	ARTICLE	IF	CITATIONS
740	Association between Renal Function and Bleeding Risk for Dabigatran after Switching from Warfarin. <i>American Journal of Nephrology</i> , 2016, 44, 11-18.	1.4	9
741	Predictors of anticoagulation quality in 15,834 patients performing patient self-management of oral anticoagulation with vitamin K antagonists in real-life practice: a survey of the International Self-Monitoring Association of Orally Anticoagulated Patients. <i>British Journal of Haematology</i> , 2016, 175, 677-685.	1.2	13
742	Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists. <i>European Journal of Medical Research</i> , 2016, 21, 41.	0.9	11
743	The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2083-2084.	1.9	0
744	A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 241-250.	1.8	9
745	Study of TTR in Patients Receiving Warfarin Therapy. <i>Journal of the Japanese Association of Rural Medicine</i> , 2016, 64, 827-832.	0.0	0
746	Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. <i>BMJ, The</i> , 2016, 353, i2868.	3.0	123
747	Platelet-Monocyte Aggregates and C-Reactive Protein are Associated with VTE in Older Surgical Patients. <i>Scientific Reports</i> , 2016, 6, 27478.	1.6	22
748	Genetic determinants of variability in warfarin response after the dose-titration phase. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 510-516.	0.7	4
749	Cost of vitamin K antagonist anticoagulant treatment in patients with metallic prosthetic valve in mitral position. <i>SAGE Open Medicine</i> , 2016, 4, 205031211666312.	0.7	2
750	Anticoagulated patient's perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy "study protocol for The Switching Study: a prospective cohort study. <i>BMC Hematology</i> , 2016, 16, 22.	2.6	5
751	The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding. <i>Medicine (United States)</i> , 2016, 95, e5467.	0.4	10
752	Quality of warfarin control in atrial fibrillation patients in South East Queensland, Australia. <i>Internal Medicine Journal</i> , 2016, 46, 925-931.	0.5	14
753	Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2016, 2, 2.	0.4	6
754	How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?. <i>American Journal of Cardiology</i> , 2016, 118, 697-699.	0.7	9
755	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. <i>EBioMedicine</i> , 2016, 8, 309-316.	2.7	31
756	Quality of anticoagulation control among patients with atrial fibrillation: An experience of a tertiary care center in Saudi Arabia. <i>Journal of the Saudi Heart Association</i> , 2016, 28, 239-243.	0.2	11
757	Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation. <i>American Heart Journal</i> , 2016, 176, 17-27.	1.2	42

#	ARTICLE	IF	CITATIONS
758	Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin. American Journal of Cardiology, 2016, 118, 232-236.	0.7	6
760	Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thrombosis Journal, 2016, 14, 14.	0.9	43
761	Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. Pharmacogenomics Journal, 2016, 16, 478-484.	0.9	27
762	Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR. Journal of Thrombosis and Thrombolysis, 2016, 42, 146-153.	1.0	6
763	Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients. Journal of Thrombosis and Thrombolysis, 2016, 42, 283-287.	1.0	5
764	Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Journal of the American Heart Association, 2016, 5, .	1.6	334
765	Race-specific Influence of <i>CYP2C9</i> on Dose and Risk of Hemorrhage Among Warfarin Users. Pharmacotherapy, 2016, 36, 263-272.	1.2	22
766	Evaluation of pharmacist-based compared to doctor-based anticoagulation management in <i>Qatar</i> . Journal of Evaluation in Clinical Practice, 2016, 22, 433-438.	0.9	20
767	Impact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study. Journal of Thrombosis and Haemostasis, 2016, 14, 695-703.	1.9	8
768	Free fatty acid as an outcome predictor of atrial fibrillation-associated stroke. Annals of Neurology, 2016, 79, 317-325.	2.8	23
769	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	1.2	13
770	Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2016, 32, 1247.e23-1247.e28.	0.8	23
771	Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. Revista Espanola De Cardiologia (English Ed), 2016, 69, 134-140.	0.4	4
772	Bleeding complications in venous thrombosis patients on well-managed warfarin. Journal of Thrombosis and Thrombolysis, 2016, 41, 351-358.	1.0	14
773	Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. International Journal of Cardiology, 2016, 203, 372-378.	0.8	36
774	Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematology, the, 2016, 3, e12-e21.	2.2	215
775	Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF) Tj ETQq0 0 0 rgBT/Overlock, 10 Tf 50 1	0.7	29
776	Evaluation of SAME-TT ₂ score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain. Current Medical Research and Opinion, 2016, 32, 1201-1207.	0.9	24

#	ARTICLE	IF	CITATIONS
778	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e228-e236.	2.2	55
779	Patient adherence to warfarin therapy and its impact on anticoagulation control. <i>Saudi Pharmaceutical Journal</i> , 2016, 24, 29-34.	1.2	38
780	The SAME-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 177-187.	0.6	18
781	Effect of a Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs Anticoagulation Alone on Risk of Recurrent Pulmonary Embolism: A Randomized Clinical Trial. <i>Journal of Vascular Surgery</i> , 2016, 63, 280.	0.6	2
782	Repercusiones en la posología de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la función renal de los pacientes con fibrilación auricular e insuficiencia cardiaca aguda reciente. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 134-140.	0.6	9
783	Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea. <i>International Journal of Cardiology</i> , 2016, 204, 200-205.	0.8	10
784	Effectiveness and safety of dabigatran versus acenocoumarol in "real-world" patients with atrial fibrillation. <i>Europace</i> , 2016, 18, 1319-1327.	0.7	32
785	Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016, 1, 65.	3.0	37
787	Warfarin Dosing Algorithms and the Need for Human Intervention. <i>American Journal of Medicine</i> , 2016, 129, 431-437.	0.6	7
788	Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. <i>Atherosclerosis</i> , 2016, 244, 48-50.	0.4	14
789	Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. <i>Heart Rhythm</i> , 2016, 13, 366-373.	0.3	32
790	Assessing the utility of an online registry for patients monitoring their own warfarin therapy. <i>Journal of Clinical Pathology</i> , 2016, 69, 331-336.	1.0	3
791	Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2016, 32, 87-94.	0.9	9
792	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. <i>Canadian Journal of Cardiology</i> , 2016, 32, 336-343.	0.8	14
793	Real-World Impact of Setting a Narrow International Normalized Ratio Target Range in the Management of Older Adult Patients on Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 528-534.	0.7	2
794	Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 150-156.	1.0	18
796	Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 445-453.	0.7	9
798	A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS 2 score in Japan. <i>Journal of Cardiology</i> , 2017, 69, 89-97.	0.8	8

#	ARTICLE	IF	CITATIONS
799	Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 685-695.	0.7	1
800	Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy: findings from a "real-world" study. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 540-549.	1.0	15
801	The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 446-453.	1.9	20
802	Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 465-472.	1.9	8
803	Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial. <i>Pharmacogenomics</i> , 2017, 18, 245-253.	0.6	32
804	SAME-TT ₂ R ₂ predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI ² experience. <i>Vascular Medicine</i> , 2017, 22, 197-203.	0.8	13
805	Safety and Efficacy of Warfarin Therapy in Remote Communities of the Top End of Northern Australia. <i>Heart Lung and Circulation</i> , 2017, 26, 1291-1296.	0.2	6
806	Atrial fibrillation incrementally increases dementia risk across all CHADS 2 and CHA 2 DS 2 VASc strata in patients receiving long-term warfarin. <i>American Heart Journal</i> , 2017, 188, 93-98.	1.2	41
807	Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>Clinical Research in Cardiology</i> , 2017, 106, 420-427.	1.5	4
808	Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 657-667.	1.0	17
809	Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	57
810	Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis. <i>Heart</i> , 2017, 103, 198-203.	1.2	33
811	Health literacy and warfarin therapy at two anticoagulation clinics in Brazil. <i>Heart</i> , 2017, 103, 1089-1095.	1.2	23
812	Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation. <i>Heart Rhythm</i> , 2017, 14, 645-651.	0.3	35
813	A hemodialysis cohort study of protocol-based anticoagulation management. <i>BMC Research Notes</i> , 2017, 10, 66.	0.6	3
814	Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. <i>Heart</i> , 2017, 103, 818-826.	1.2	78
815	Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 550-561.	1.0	7
816	Patient-Specific Tailored Intervention Improves INR Time in Therapeutic Range and INR Variability in Heart Failure Patients. <i>American Journal of Medicine</i> , 2017, 130, 982-989.	0.6	4

#	ARTICLE	IF	CITATIONS
817	Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 38-47.	1.0	23
818	Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 1383-1390.	0.7	13
819	Time in the Therapeutic Range for Patients Taking Warfarin in Clinical Trials. <i>Circulation</i> , 2017, 135, 1475-1477.	1.6	46
820	Association Between Patient-Reported Medication Adherence and Anticoagulation Control. <i>American Journal of Medicine</i> , 2017, 130, 1092-1098.e2.	0.6	15
821	Integrating genotypes in the SAME-TT 2 R 2 score for the prediction of anticoagulation control in Chinese patients with atrial fibrillation on warfarin. <i>International Journal of Cardiology</i> , 2017, 241, 358-363.	0.8	7
822	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. <i>Internal and Emergency Medicine</i> , 2017, 12, 1109-1119.	1.0	30
823	Genotype-guided dosing of warfarin through modeling and simulation. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S9-S14.	1.9	10
824	Efficacy of protocol-based pharmacotherapy management on anticoagulation with warfarin for patients with cardiovascular surgery. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 591-597.	0.7	11
825	Safety and efficacy of warfarin in patients with moderate thrombocytopenia. <i>Thrombosis Research</i> , 2017, 155, 53-57.	0.8	6
826	Venous Thromboembolism Requiring Extended Anticoagulation Among HIV-Infected Patients in a Rural, Resource-Constrained Setting in Western Kenya. <i>Annals of Pharmacotherapy</i> , 2017, 51, 380-387.	0.9	9
827	Improvement of time in therapeutic range with warfarin by pharmaceutical intervention. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 41-44.	1.0	6
828	Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?. <i>American Journal of Medicine</i> , 2017, 130, 1220.e17-1220.e22.	0.6	11
829	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
830	Anticoagulation Control in Patients With Ventricular Assist Devices. <i>ASAIO Journal</i> , 2017, 63, 759-765.	0.9	22
831	C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. <i>Scientific Reports</i> , 2017, 7, 3797.	1.6	8
832	Statin Adherence Is Associated With Reduced Recurrent Stroke Risk in Patients With or Without Atrial Fibrillation. <i>Stroke</i> , 2017, 48, 1788-1794.	1.0	43
833	Real-practice thromboprophylaxis in atrial fibrillation. <i>Acta Pharmaceutica</i> , 2017, 67, 227-236.	0.9	3
834	Safety and Efficacy of Warfarin Therapy in Kawasaki Disease. <i>Journal of Pediatrics</i> , 2017, 189, 61-65.	0.9	18

#	ARTICLE	IF	CITATIONS
836	eHealth-based management of patients receiving oral anticoagulation therapy: results from the observational thromb EVAL study. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1375-1385.	1.9	14
837	Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 2102-2110.	0.7	12
838	Effectiveness and safety of dabigatran versus warfarin in "real-world" Japanese patients with atrial fibrillation: A single-center observational study. <i>Journal of Arrhythmia</i> , 2017, 33, 107-110.	0.5	8
839	Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. <i>American Heart Journal</i> , 2017, 190, 86-93.	1.2	19
840	Transition of stable patients from traditional anticoagulation clinic services to telephonic management. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 569-572.	1.0	14
841	Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 303-312.	0.6	28
842	Left atrial appendage exclusion: An alternative to anticoagulation in nonvalvular atrial fibrillation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 1097-1105.	0.4	11
843	The miniaturized pediatric continuous-flow device: Preclinical assessment in the chronic sheep model. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 291-300.	0.4	29
844	Results of a Regional Effort to Improve Warfarin Management. <i>Annals of Pharmacotherapy</i> , 2017, 51, 373-379.	0.9	9
845	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <i>The Cochrane Library</i> , 2017, 2017, CD008600.	1.5	66
846	Blood pressure control in anticoagulated patients with hypertension and atrial fibrillation. <i>Blood Pressure</i> , 2017, 26, 279-283.	0.7	3
847	Geographical differences in thromboembolic and bleeding risks in patients with non-valvular atrial fibrillation: An ancillary analysis from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2017, 236, 244-248.	0.8	1
848	Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 376, 1627-1636.	13.9	348
849	Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 657-665.	0.9	19
850	PORTALS: design of an innovative approach to anticoagulation management through eHealth. <i>BMC Health Services Research</i> , 2017, 17, 213.	0.9	4
851	Latin American Clinical Epidemiology Network Series " Paper 2: Apixaban was cost-effective vs. acenocoumarol in patients with nonvalvular atrial fibrillation with moderate to severe risk of embolism in Chile. <i>Journal of Clinical Epidemiology</i> , 2017, 86, 75-83.	2.4	7
852	Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 249-256.	1.3	38
853	Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 341.	3.0	1

#	ARTICLE	IF	CITATIONS
854	Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 454-464.	1.9	4
855	Using a personalized decision support algorithm for dosing in warfarin treatment: A randomised controlled trial. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2017, 25, 1-6.	1.0	5
856	Effect of a combined education and eHealth programme on the control of oral anticoagulation patients (PORTALS study): a parallel cohort design in Dutch primary care. <i>BMJ Open</i> , 2017, 7, e017909.	0.8	14
857	Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation. <i>Hypertension</i> , 2017, 70, 949-958.	1.3	28
858	Assessment of oral anticoagulation control at two pharmacist-managed clinics in Brazil. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 1157-1161.	1.0	19
859	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1115.	3.8	198
860	Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. <i>Pharmacotherapy</i> , 2017, 37, 1366-1373.	1.2	5
861	Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	15
862	Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2165-2175.	1.9	6
863	Cost-effectiveness of the pharmacist-assisted warfarin monitoring program at a Medical Center in Taiwan. <i>International Journal for Quality in Health Care</i> , 2017, 29, 817-825.	0.9	14
864	Atrial fibrillation decision support tool: Population perspective. <i>American Heart Journal</i> , 2017, 194, 49-60.	1.2	9
865	Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 347-355.	0.7	21
866	A randomized trial of restarting warfarin at maintenance versus loading doses following an elective procedure. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 507-515.	1.0	5
867	Patterns of botulinum toxin treatment for spasticity and bleeding complications in patients with thrombotic risk. <i>Toxicon</i> , 2017, 138, 188-190.	0.8	6
868	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. <i>Scientific Reports</i> , 2017, 7, 12066.	1.6	16
869	Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. <i>International Journal of Clinical Practice</i> , 2017, 71, e12974.	0.8	6
870	Risks Versus Benefits of Anticoagulation for Atrial Fibrillation in Cirrhotic Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2017, 70, 255-262.	0.8	25
871	Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics. <i>Pharmacotherapy</i> , 2017, 37, 1284-1297.	1.2	20

#	ARTICLE	IF	CITATIONS
872	Factors influencing warfarin control in Australia and Singapore. <i>Thrombosis Research</i> , 2017, 157, 120-125.	0.8	8
873	Anticoagulation Control in Warfarin -Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin " Warfarin in Patients Undergoing Cardioversion) Tj ETQq1 1 0.784314 rgBT /Ove	0.8	11
874	Designing and Implementing an Electronic Patient Registry to Improve Warfarin Monitoring in the Ambulatory Setting. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2017, 43, 353-360.	0.4	5
875	Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1923-1933.	1.9	15
876	Assessment of Oral Anticoagulant Use in Residents of Long-Term Care Homes: Evidence for Contemporary Suboptimal Use. <i>Annals of Pharmacotherapy</i> , 2017, 51, 1053-1062.	0.9	4
877	Outcomes of an online pharmacist-managed anticoagulation clinic for individuals on warfarin therapy living in rural communities. <i>Thrombosis Research</i> , 2017, 157, 136-138.	0.8	11
878	Time in Therapeutic Range for Left Ventricular Assist Device Patients Anticoagulated With Warfarin: A Correlation to Clinical Outcomes. <i>ASAIO Journal</i> , 2017, 63, 37-40.	0.9	34
879	Vitamin K antagonists in the era of direct oral anticoagulants: is there still a room for their use?. <i>Internal and Emergency Medicine</i> , 2017, 12, 1087-1089.	1.0	1
880	Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. <i>European Journal of Internal Medicine</i> , 2017, 46, 6-10.	1.0	16
881	Personalized Anticoagulation. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	8
884	Flying Blind: Don't Manage Warfarin Without a Registry. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2017, 43, 351-352.	0.4	1
885	Improving Warfarin Management Within the Medical Home: A Health-System Approach. <i>American Journal of Medicine</i> , 2017, 130, 365.e7-365.e12.	0.6	15
886	Anticoagulation Endpoints With Clinical Implementation of Warfarin Pharmacogenetic Dosing in a Real-World Setting: A Proposal for a New Pharmacogenetic Dosing Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 675-683.	2.3	24
887	Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 283-288.	1.0	22
888	Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study. <i>Journal of Nephrology</i> , 2017, 30, 573-581.	0.9	23
889	Point-of-care testing INR: an overview. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 800-805.	1.4	35
890	Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study). <i>American Journal of Cardiology</i> , 2017, 119, 268-274.	0.7	12
891	Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV) Tj ETQq1 1 0.784314 rgBT /Ove 103-109.	0.8	37

#	ARTICLE	IF	CITATIONS
892	Right Ventricular Dysfunction Complicates Time in Therapeutic Range in Heart Failure Patients Receiving Warfarin. <i>Pharmacology</i> , 2017, 99, 19-26.	0.9	2
893	The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAME TT2R2) Score Predicts Warfarin Control in a Singaporean Population. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 64-69.	0.7	31
894	Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients. <i>Biological Research for Nursing</i> , 2017, 19, 198-205.	1.0	1
896	Antiphospholipid Syndrome On Cloud (APSONCloud): web-based monitoring of oral anticoagulation. <i>Lupus</i> , 2017, 26, 179-185.	0.8	1
897	Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2163-2167.	1.8	3
898	Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR. <i>Thrombosis and Haemostasis</i> , 2017, 117, 27-32.	1.8	21
899	Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2291-2299.	1.8	21
900	Anticoagulation Stability Depends on CHADS ₂ Score and Hepatorenal Function in Warfarin-treated Patients, Including Those with Atrial Fibrillation. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 68-76.	0.9	5
901	Efficacy and Safety of Triple Therapy and Dual Therapy With Direct Oral Anticoagulants Compared to Warfarin. <i>International Heart Journal</i> , 2017, 58, 570-576.	0.5	5
902	The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. <i>Balkan Medical Journal</i> , 2017, 34, 349-355.	0.3	8
903	Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. <i>Blood Advances</i> , 2017, 1, 2536-2540.	2.5	7
904	Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017, Volume 10, 135-143.	0.8	90
905	Effect of Standardized Warfarin Treatment Protocol on Anticoagulant Effect: Comparison of a Warfarin Medication Therapy Adherence Clinic with Usual Medical Care. <i>Frontiers in Pharmacology</i> , 2017, 8, 637.	1.6	24
906	SAME-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 108, 290-296.	0.3	9
907	Predictors of oral cavity bleeding and clinical outcome after dental procedures in patients on vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1432-1439.	1.8	7
908	Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 700-712.	0.5	12
909	Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior		

#	ARTICLE	IF	CITATIONS
911	Obesity is not associated with recurrent venous thromboembolism in elderly patients: Results from the prospective SWITCO65+ cohort study. PLoS ONE, 2017, 12, e0184868.	1.1	8
912	Hospital pharmacist intervention improves the quality indicator of warfarin control: A retrospective cohort study. Journal of Medical Investigation, 2017, 64, 266-271.	0.2	5
913	Time to Revisit the Time in the Therapeutic Range. Journal of Atrial Fibrillation, 2017, 9, 1569.	0.5	6
914	Control of anticoagulation with VKAs: overestimation of median TTR when assessed by linear extrapolation: A comment. Thrombosis and Haemostasis, 2017, 117, 819.	1.8	3
915	Consequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillation. Thrombosis and Haemostasis, 2017, 117, 1828-1830.	1.8	10
916	Evaluation of the Community Pharmacist-led Anticoagulation Management Service (CPAMS) Pilot Program in New Zealand. , 2017, , 159-181.		1
917	Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin. Postgraduate Medical Journal, 2018, 94, 207-211.	0.9	4
918	A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation. Medicine (United States), 2018, 97, e9578.	0.4	6
919	The quality of warfarin therapy and CHA2DS2-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation: data from the nationwide FinWAF Registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 211-219.	1.4	10
920	Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. American Journal of Transplantation, 2018, 18, 1527-1533.	2.6	37
921	Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump—the MAGENTUM 1 study. Journal of Heart and Lung Transplantation, 2018, 37, 579-586.	0.3	128
922	Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. European Journal of Internal Medicine, 2018, 54, 34-39.	1.0	18
923	Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study. Journal of the American Heart Association, 2018, 7, .	1.6	29
924	Interactions between Atrial Fibrillation, Cardiovascular Risk Factors, and ApoE Genotype in Promoting Cognitive Decline in Patients with Alzheimer's Disease: A Prospective Cohort Study. Journal of Alzheimer's Disease, 2018, 62, 713-725.	1.2	25
925	Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. Journal of Thrombosis and Haemostasis, 2018, 16, 1069-1077.	1.9	27
926	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. European Journal of Clinical Investigation, 2018, 48, e12929.	1.7	5
927	Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis. Thrombosis and Haemostasis, 2018, 118, 806-807.	1.8	1
928	Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 596-601.	0.7	28

#	ARTICLE	IF	CITATIONS
929	Use of neutrophilâ€­lymphocyte ratio for risk stratification and relationship with time in therapeutic range in patients with nonvalvular atrial fibrillation: A pilot study. <i>Clinical Cardiology</i> , 2018, 41, 339-342.	0.7	8
930	Treatment Satisfaction Questionnaire for Medication: Validation of the Translated Arabic Version among Patients Undergoing Warfarin Therapy in Saudi Arabia. <i>Value in Health Regional Issues</i> , 2018, 16, 14-21.	0.5	6
931	Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. <i>Clinical Cardiology</i> , 2018, 41, 576-585.	0.7	19
932	Cerebrovascular Accidents During Mechanical Circulatory Support. <i>Stroke</i> , 2018, 49, 1197-1203.	1.0	21
934	Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. <i>Pharmacotherapy</i> , 2018, 38, 588-596.	1.2	33
935	Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 571-582.	0.8	3
936	Effect of increased time in the therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service. <i>Thrombosis Research</i> , 2018, 163, 54-59.	0.8	11
937	Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms. <i>Vascular Pharmacology</i> , 2018, 106, 22-27.	1.0	7
938	Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from <scp>FANTASIIA</scp> Registry. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12910.	1.7	5
939	Quality of oral anticoagulation with vitamin K antagonists in â€­real-worldâ€­™ patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. <i>Europace</i> , 2018, 20, 1435-1441.	0.7	39
940	Re: Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 243-243.	0.9	0
941	Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada. <i>BMJ Open</i> , 2018, 8, e016980.	0.8	27
942	Association between satisfaction with and adherence to warfarin therapy on the control of international normalized ratio: A hospital-based study in Saudi Arabia. <i>Saudi Pharmaceutical Journal</i> , 2018, 26, 145-149.	1.2	16
943	Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2018, 93, 145-154.	1.4	53
944	Outpatient Management of Emergency Department Patients With Acute Pulmonary Embolism: Variation, Patient Characteristics, and Outcomes. <i>Annals of Emergency Medicine</i> , 2018, 72, 62-72.e3.	0.3	41
945	Antiplatelet therapy, vitamin K antagonist and low time in therapeutic range in patients with atrial fibrillation: Highway to bleed. <i>International Journal of Cardiology</i> , 2018, 252, 110-111.	0.8	0
946	Shared decision-making tool for thromboprophylaxis in atrial fibrillation â€­ A feasibility study. <i>American Heart Journal</i> , 2018, 199, 13-21.	1.2	19
947	Predictors and Outcomes of Recurrent Venous Thromboembolism in Elderly Patients. <i>American Journal of Medicine</i> , 2018, 131, 703.e7-703.e16.	0.6	17

#	ARTICLE	IF	CITATIONS
948	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. <i>Thrombosis Research</i> , 2018, 162, 7-14.	0.8	20
950	Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE-CIRCUIT trial. <i>Journal of Arrhythmia</i> , 2018, 34, 148-157.	0.5	4
951	Anticoagulation Therapy for Venous Thromboembolism in the Real World – From the COMMAND VTE Registry. <i>Circulation Journal</i> , 2018, 82, 1262-1270.	0.7	105
952	Genotype-guided warfarin therapy: current status. <i>Pharmacogenomics</i> , 2018, 19, 667-685.	0.6	38
953	Erythrocyte compression index is impaired in patients with residual vein obstruction. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 31-38.	1.0	7
954	Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naïve patients with atrial fibrillation. <i>American Heart Journal</i> , 2018, 200, 32-36.	1.2	13
956	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. <i>European Heart Journal</i> , 2018, 39, 2942-2955.	1.0	181
957	Real-world antithrombotic therapies and clinical outcomes after second-generation drug-eluting stent implantation in patients with atrial fibrillation: a multi-center cohort study. <i>Heart and Vessels</i> , 2018, 33, 986-996.	0.5	1
958	Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 512-515.	1.0	14
959	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>Data in Brief</i> , 2018, 17, 830-836.	0.5	5
960	Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 536-541.	0.7	1
961	Clinical and Financial Outcomes Evaluation of Multimodal Pharmacist Warfarin Management of a Statewide Urban and Rural Population. <i>Journal of Pharmacy Practice</i> , 2018, 31, 150-156.	0.5	10
962	Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 494-500.	0.5	23
963	Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction. <i>European Heart Journal</i> , 2018, 39, 201-208.	1.0	88
964	Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2018, 34, 415-421.	0.9	18
965	Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 907-915.	2.6	100
966	Enhancing the "real world" prediction of cardiovascular events and major bleeding with the CHA ₂ DS ₂ -VASc and HAS-BLED scores using multiple biomarkers. <i>Annals of Medicine</i> , 2018, 50, 26-34.	1.5	22
968	Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation) Tj ETQq1 1 0.7843147gBT /Overlock 10	1.0	10

#	ARTICLE	IF	CITATIONS
969	Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2018, 252, 96-100.	0.8	10
970	The value of time in therapeutic range in the prediction of outcomes at a populational level in patients treated with vitamin K antagonists. <i>Current Medical Research and Opinion</i> , 2018, 34, 499-500.	0.9	0
971	Validation of knowledge and adherence assessment tools among patients on warfarin therapy in a Saudi hospital anticoagulant clinic. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 56-66.	1.0	21
972	Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 116-124.	1.9	6
973	Multi-dose drug dispensing as a tool to improve medication adherence: A study in patients using vitamin K antagonists. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 46-51.	0.9	9
974	Evaluation of Systemic Heparin Versus Bivalirudin in Adult Patients Supported by Extracorporeal Membrane Oxygenation. <i>ASAIO Journal</i> , 2018, 64, 623-629.	0.9	82
975	Would Less Anticoagulation Be Acceptable in Less-Developed Regions?. , 2018, 13, 245-246.		0
976	Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica. <i>Pharmacy Practice</i> , 2018, 16, 1214.	0.8	2
977	Role of Red Cell Distribution Width in the Relationship between Clinical Outcomes and Anticoagulation Response in Patients with Atrial Fibrillation. <i>Chonnam Medical Journal</i> , 2018, 54, 113.	0.5	9
978	Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	1
979	Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2018, 3, 1174.	3.0	111
980	Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study. <i>Open Heart</i> , 2018, 5, e000837.	0.9	6
981	Triple therapy after PCI â€“ Warfarin treatment quality and bleeding risk. <i>PLoS ONE</i> , 2018, 13, e0209187.	1.1	3
983	Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japanâ€™â€™â€™â€™ Insights From GARFIELD-AF â€™. <i>Circulation Journal</i> , 2018, 83, 67-74.	0.7	12
984	Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study. <i>Drugs in R and D</i> , 2018, 18, 303-308.	1.1	14
985	The agreement between capillary and venous sampling for plasma PT/INR results. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 524-526.	0.6	4
986	Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin. <i>Frontiers in Pharmacology</i> , 2018, 9, 1052.	1.6	16
987	Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. <i>Blood</i> , 2018, 132, 2298-2304.	0.6	42

#	ARTICLE	IF	CITATIONS
988	Factors associated with poor anticoagulation control with vitamin K antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study. <i>Revista Colombiana de Medicina y Salud Pública</i> , 2018, 218, 327-335.	0.3	2
989	Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 178S-181S.	0.7	10
990	Pharmacy Technician Management of Stable, In-Range INRs Within a Clinical Pharmacy Anticoagulation Service. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 1130-1137.	0.5	5
991	Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. <i>PLoS ONE</i> , 2018, 13, e0202803.	1.1	2
992	Portable coagulometer for vitamin K-antagonist monitoring: the patients' point of view. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1521-1526.	0.8	12
993	Improving anticoagulation of patients with an implantable left ventricular assist device. <i>BMJ Open Quality</i> , 2018, 7, e000250.	0.4	11
994	Management of Oral Anti-Coagulation in Patients with Heart Failure—Insights from the ThrombEVAL Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1930-1939.	1.8	1
995	Predictive ability of scores for bleeding risk in heart disease outpatients on warfarin in Brazil. <i>PLoS ONE</i> , 2018, 13, e0205970.	1.1	4
996	Genotype-Guided Warfarin Dosing in Patients With Mechanical Valves: A Randomized Controlled Trial. <i>Annals of Thoracic Surgery</i> , 2018, 106, 1774-1781.	0.7	17
997	Optimum INR intensity and therapeutic INR control in patients with mechanical heart valve prosthesis on warfarin oral anticoagulation at Dr George Mukhari academic hospital: a three-year retrospective study. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2018, 60, 192-196.	0.2	3
998	Influence of Baseline Platelet Count on Outcomes in Patients With Venous Thromboembolism (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	12
999	Long-Term Statin Administration Does Not Affect Warfarin Time in Therapeutic Range in Australia or Singapore. <i>Journal of Clinical Medicine</i> , 2018, 7, 97.	1.0	3
1000	Time spent at blood pressure target and the risk of death and cardiovascular diseases. <i>PLoS ONE</i> , 2018, 13, e0202359.	1.1	27
1001	Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1357-1365.	1.2	18
1002	Should We Switch Patients Who Appear to Be Optimally Anticoagulated on Warfarin to DOACs?. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1366-1368.	1.2	1
1003	Quality of Chronic Anticoagulation Control in Patients with Intracranial Haemorrhage due to Vitamin K Antagonists. <i>Stroke Research and Treatment</i> , 2018, 2018, 1-6.	0.5	1
1004	Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF—TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e008987.	1.6	105
1005	Bivalirudin for left ventricular assist device thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 496-501.	1.0	6

#	ARTICLE	IF	CITATIONS
1006	Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e008755.	1.6	21
1007	Time in Therapeutic Range and Disease Outcomes in Elderly Japanese Patients With Nonvalvular Atrial Fibrillation. <i>Circulation Journal</i> , 2018, 82, 2510-2517.	0.7	6
1008	Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018, 4, 59-68.	1.8	36
1009	Use of D-dimer in oral anticoagulation therapy. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 503-507.	0.7	37
1010	Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <i>International Journal of Cardiology</i> , 2018, 264, 58-63.	0.8	69
1011	Comparing Management and Outcomes in Men and Women With Nonvalvular Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 604-614.	1.3	8
1012	Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD). <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 885-894.	0.8	2
1014	The net clinical benefit of the antithrombotic protection in prosthetic mechanical valves: Changing the paradigm. <i>International Journal of Cardiology</i> , 2018, 267, 77-78.	0.8	0
1015	An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects. <i>Kidney International Reports</i> , 2018, 3, 841-850.	0.4	25
1016	Genetic causes of resistance to vitamin K antagonists in Polish patients. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 429-434.	0.5	3
1018	Sustained atrial fibrillation increases the risk of anticoagulation-related bleeding in heart failure. <i>Clinical Research in Cardiology</i> , 2018, 107, 1170-1179.	1.5	7
1019	Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 316-324.	1.0	11
1020	Individual and monitoring centre influences upon anticoagulation control of AF patients on warfarin: A longitudinal multi-centre UK-based study. <i>European Journal of Haematology</i> , 2018, 101, 486-495.	1.1	0
1021	Outcomes of warfarin therapy managed by pharmacists via hospital anticoagulation clinic versus online anticoagulation clinic. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1072-1077.	1.0	19
1022	Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department. <i>Western Journal of Emergency Medicine</i> , 2018, 19, 346-360.	0.6	11
1023	Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. <i>International Journal of Cardiology</i> , 2018, 267, 68-73.	0.8	36
1024	The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1994-2002.	1.9	32
1025	Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer. <i>Korean Circulation Journal</i> , 2018, 48, 406.	0.7	41

#	ARTICLE	IF	CITATIONS
1026	Three-Year Clinical Outcomes Associated With Warfarin vs. Direct Oral Anticoagulant Use Among Japanese Patients With Atrial Fibrillation—Findings From the SAKURA AF Registry. <i>Circulation Journal</i> , 2018, 82, 2500-2509.	0.7	55
1027	Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial. <i>BMC Medicine</i> , 2018, 16, 104.	2.3	37
1028	Assessment of patients' warfarin knowledge and anticoagulation control at a joint physician- and pharmacist-managed clinic in China. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 783-791.	0.8	17
1029	International normalised ratio monitoring in the community populations of the Auckland and Northland regions of New Zealand: time in therapeutic range and frequency of testing. <i>Internal Medicine Journal</i> , 2018, 48, 1487-1491.	0.5	3
1030	Efficacy and safety of dabigatran versus warfarin from the RE-LY trial. <i>Open Heart</i> , 2018, 5, e000800.	0.9	9
1031	Pharmacist's interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1078-1085.	1.0	20
1032	Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 497-507.	1.0	17
1033	Personalize Warfarin Treatment by Optimizing Protocol Assignment. , 2018, , .		0
1034	Warfarin control in patients transitioning to warfarin after non-vitamin K oral anticoagulant (NOAC) therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 461-465.	1.0	7
1035	Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12458.	1.1	1
1036	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018, 82, 1286-1292.	0.7	4
1037	Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 271-282.	1.2	55
1038	Predictors of International Normalized Ratio Variability in Patients With Atrial Fibrillation Under Warfarin Therapy. <i>Circulation Journal</i> , 2018, 82, 39-45.	0.7	8
1039	Renal Dysfunction Affects Anticoagulation Control With Warfarin and Outcomes in Japanese Elderly Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2018, 82, 2277-2283.	0.7	5
1040	A Standardized Telephone Intervention Algorithm Improves the Survival of Ventricular Assist Device Outpatients. <i>Artificial Organs</i> , 2018, 42, 961-969.	1.0	16
1041	Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. <i>Estudio ALADIN. Revista Clinica Espanola</i> , 2018, 218, 327-335.	0.2	10
1042	Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1144-1152.	2.2	50
1043	Anticoagulation management services in community pharmacy: Feasibility of implementing a quality improvement programme through a practice-based research network. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 877-887.	0.7	1

#	ARTICLE	IF	CITATIONS
1044	Impact of Aspirin on Warfarin Control as Measured by Time in Therapeutic Range. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 504-508.	1.2	4
1045	Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management. <i>BMC Nephrology</i> , 2018, 19, 4.	0.8	8
1046	A multicenter, prospective study evaluating the impact of the clinical pharmacist-physician counselling on warfarin therapy management in Lebanon. <i>BMC Health Services Research</i> , 2018, 18, 80.	0.9	12
1047	Moving anticoagulation initiation and monitoring services into the community: evaluation of the Brighton and hove community pharmacy service. <i>BMC Health Services Research</i> , 2018, 18, 91.	0.9	20
1048	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1121-1201.	0.4	718
1049	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 122, 785-792.	0.7	12
1050	Comparison Between Long-Term Clinical Outcomes of Vitamin K Antagonist and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2018, 82, 2016-2024.	0.7	8
1051	Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients. <i>Drugs and Aging</i> , 2018, 35, 569-574.	1.3	1
1052	Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 749-757.	0.7	11
1053	Evidence-Based Best Practices for Outpatient Management of Warfarin. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1042-1046.	0.9	2
1054	Clinical usefulness of the SAME-TT2R2 score: A systematic review and simulation meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0194208.	1.1	12
1055	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). <i>American Journal of Cardiology</i> , 2018, 122, 821-827.	0.7	3
1056	Relationship between International Normalized Ratio and Outcomes in Modern Trials with Warfarin Controls. <i>Pharmacotherapy</i> , 2018, 38, 899-906.	1.2	9
1057	Assessment of the bleeding risk of anticoagulant treatment in non-severe frail octogenarians with atrial fibrillation. <i>Journal of Cardiology</i> , 2019, 73, 7-13.	0.8	22
1058	Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 176-185.	0.4	18
1059	Secondary stroke prevention and guideline adherent antithrombotic treatment in patients with atrial fibrillation: Insights from the Gulf Survey of atrial fibrillation events (Gulf SAFE). <i>International Journal of Cardiology</i> , 2019, 274, 126-131.	0.8	9
1060	Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 29-36.	1.4	15
1061	Net clinical benefit of anticoagulant treatments in elderly patients with nonvalvular atrial fibrillation: Experience from the real world. <i>Heart Rhythm</i> , 2019, 16, 31-37.	0.3	41

#	ARTICLE	IF	CITATIONS
1062	Comparison of warfarin dosage fluctuation with time in therapeutic range for bleeding or thromboembolism rate in Chinese patients. Journal of the Formosan Medical Association, 2019, 118, 611-618.	0.8	6
1063	A prospective, multi-center cohort study: investigating the ability of warfarin-treated patients to predict their INR. Clinical Research in Cardiology, 2019, 108, 212-217.	1.5	3
1064	Impact of an electronic medium delivery of warfarin education in a low income, minority outpatient population: a pilot intervention study. BMC Public Health, 2019, 19, 1050.	1.2	7
1065	Differences in the quality of oral anticoagulation therapy with vitamin K antagonists in German GP practices – results of the cluster-randomized PICANT trial (Primary Care Management for Optimized) Tj ETQq1 1 0.784314zgBT /Over	1.0	7
1066	<p>Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin</p>. The Application of Clinical Genetics, 2019, Volume 12, 151-159.	1.4	8
1067	The Effect of Flucloxacillin on Warfarin Anticoagulation: A Swedish Register-Based Nationwide Cohort Study. Thrombosis and Haemostasis, 2019, 119, 1617-1623.	1.8	5
1068	Adverse clinical events in Japanese atrial fibrillation patients with and without coronary artery disease—findings from the SAKURA AF Registry. Current Medical Research and Opinion, 2019, 35, 2053-2062.	0.9	7
1069	Long-term effectiveness and safety of self-management of oral anticoagulants in real-world settings. BMC Cardiovascular Disorders, 2019, 19, 186.	0.7	3
1070	<p><p>Reliability and validity of the Maltese version of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q)</p>. Patient Preference and Adherence, 2019, Volume 13, 969-979.	0.8	7
1071	The SAME-TT2R2 Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation. Journal of Clinical Medicine, 2019, 8, 882.	1.0	8
1072	Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. Journal of the American College of Cardiology, 2019, 74, 179-189.	1.2	35
1073	Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists—Data from a Specialized Coagulation Service. Thrombosis and Haemostasis, 2019, 119, 1347-1357.	1.8	8
1074	Cost of Healthcare Associated With Deep Vein Thrombosis in Patients Treated With Warfarin in Turkey: 2010-2013 Database Analysis of a Tertiary Care Center. Value in Health Regional Issues, 2019, 19, 81-86.	0.5	2
1075	An easy-to-use tool to flag patients at risk of poor INR control: A streak of subtherapeutic INRs. Thrombosis Research, 2019, 181, 46-51.	0.8	1
1076	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	3.0	10
1077	Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. International Journal of Clinical Practice, 2019, 73, e13382.	0.8	7
1078	Risk Factors for Major Bleeding during Prolonged Anticoagulation Therapy in Patients with Venous Thromboembolism: From the COMMAND VTE Registry. Thrombosis and Haemostasis, 2019, 119, 1498-1507.	1.8	19
1079	<p>Validation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS)</p>. Psychology Research and Behavior Management, 2019, Volume 12, 741-752.	1.3	7

#	ARTICLE	IF	CITATIONS
1080	Use of simplified HAS-BLED score in patients with atrial fibrillation receiving warfarin. <i>Journal of Arrhythmia</i> , 2019, 35, 711-715.	0.5	3
1081	Evaluation of oral anticoagulants in atrial fibrillation patients over 80 years of age with nonsevere frailty. <i>Journal of Arrhythmia</i> , 2019, 35, 795-803.	0.5	10
1082	Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device. <i>Pharmacotherapy</i> , 2019, 39, 1030-1035.	1.2	14
1083	Clinical outcomes of patients with pulmonary embolism versus deep vein thrombosis: From the COMMAND VTE Registry. <i>Thrombosis Research</i> , 2019, 184, 50-57.	0.8	13
1084	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1850.	1.0	31
1085	Clinical presentation and outcomes in elderly patients with symptomatic isolated subsegmental pulmonary embolism. <i>Thrombosis Research</i> , 2019, 184, 24-30.	0.8	15
1086	Standardized warfarin monitoring decreases adverse drug reactions. <i>BMC Family Practice</i> , 2019, 20, 151.	2.9	7
1087	Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1363-1373.	0.8	24
1088	Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1273-1280.	0.5	3
1089	Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution. <i>European Journal of Internal Medicine</i> , 2019, 69, 64-70.	1.0	34
1090	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 834.	3.8	9
1091	Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. <i>Thrombosis Research</i> , 2019, 183, 28-32.	0.8	13
1092	Cancer-Associated Venous Thromboembolism in the Real World. From the COMMAND VTE Registry. <i>Circulation Journal</i> , 2019, 83, 2271-2281.	0.7	60
1093	First evidence for a pharmacist-led anticoagulant clinic in a medicare part A long term care environment. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 690-693.	1.0	1
1094	Personalised Warfarin Dosing in Children Post-cardiac Surgery. <i>Pediatric Cardiology</i> , 2019, 40, 1735-1744.	0.6	7
1096	Maintenance dose of warfarin beyond time in therapeutic range for preventing vascular events. <i>Journal of the Neurological Sciences</i> , 2019, 398, 69-74.	0.3	0
1097	Comparison of prediction value of four bleeding risk scores for pulmonary embolism with anticoagulation: A real-world study in Chinese patients. <i>Clinical Respiratory Journal</i> , 2019, 13, 139-147.	0.6	8
1098	Poor Quality of Warfarin Treatment Increases the Risk of All Types of Intracranial Hemorrhage in Atrial Fibrillation. <i>Circulation Journal</i> , 2019, 83, 540-547.	0.7	7

#	ARTICLE	IF	CITATIONS
1099	Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation. <i>Journal of Clinical Nursing</i> , 2019, 28, 1839-1846.	1.4	16
1100	Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study. <i>International Journal of Cardiology</i> , 2019, 281, 56-61.	0.8	23
1101	Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007124.	1.4	11
1102	Warfarin loading dose guided by pharmacogenetics is effective and safe in cardioembolic stroke patients – a randomized, prospective study. <i>Pharmacogenomics Journal</i> , 2019, 19, 446-454.	0.9	7
1103	Assessment of anticoagulation management in outpatients attending a warfarin clinic in Windhoek, Namibia. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 341-346.	0.3	9
1104	Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. <i>PLoS ONE</i> , 2019, 14, e0216831.	1.1	19
1105	Intérêt du temps passé dans la zone thérapeutique dans la surveillance des AVK chez les porteurs de prothèses cardiaques mécaniques. <i>Revue Francophone Des Laboratoires</i> , 2019, 2019, 74-80.	0.0	0
1106	Warfarin in nonvalvular atrial fibrillation – Time for a change?. <i>Seminars in Dialysis</i> , 2019, 32, 520-526.	0.7	5
1107	The effect of simvastatin on warfarin anticoagulation: a Swedish register-based nationwide cohort study. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1387-1392.	0.8	7
1109	Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF Registry. <i>Heart and Vessels</i> , 2019, 34, 2021-2030.	0.5	13
1110	Incidence, risk factors, and outcomes of warfarin-associated major bleeding in Thai population. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 942-950.	0.9	6
1111	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. <i>Stroke</i> , 2019, 50, 1372-1379.	1.0	48
1112	Differences between patient-driven adherence to vitamin K antagonists and direct oral anticoagulants. Do few missed doses matter? ACO-MEMS Study. <i>Thrombosis Research</i> , 2019, 179, 20-27.	0.8	12
1113	Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI. <i>Thrombosis Research</i> , 2019, 179, 87-94.	0.8	8
1114	Effect of Warfarin on Ischemic Stroke, Bleeding, and Mortality in Patients with Atrial Fibrillation Receiving Peritoneal Dialysis. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 509-515.	1.0	6
1115	Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation. <i>JAMA Network Open</i> , 2019, 2, e191994.	2.8	43
1116	Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. <i>European Heart Journal</i> , 2019, 40, 3013-3021.	1.0	125
1117	Optimal INR level for warfarin therapy after mechanical mitral valve replacement. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 97.	0.7	4

#	ARTICLE	IF	CITATIONS
1118	Patient compliance with an anticoagulation management system based on a smartphone application. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 263-269.	1.0	10
1119	Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. <i>BMC Medicine</i> , 2019, 17, 76.	2.3	34
1120	International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 27-34.	1.0	11
1121	Anticoagulation Management With Coumarinic Drugs in Chilean Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983434.	0.7	3
1122	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	13.9	833
1123	The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation. <i>PLoS ONE</i> , 2019, 14, e0213517.	1.1	5
1124	Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 331-337.	1.3	2
1125	Anticoagulation: supporting safe and optimal primary care prescribing in a rapidly changing field. <i>British Journal of Haematology</i> , 2019, 186, e17-e20.	1.2	0
1126	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. <i>PLoS ONE</i> , 2019, 14, e0211766.	1.1	26
1127	Deep vein thrombosis in upper extremities: Clinical characteristics, management strategies and long-term outcomes from the COMMAND VTE Registry. <i>Thrombosis Research</i> , 2019, 177, 1-9.	0.8	24
1128	Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983736.	0.7	10
1129	XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. <i>Thrombosis Research</i> , 2019, 176, 125-132.	0.8	17
1130	Implementation of pharmacist-managed anticoagulation in patients with continuous flow left ventricular assist devices. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 623-627.	0.5	1
1131	Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. <i>Clinical Cardiology</i> , 2019, 42, 553-560.	0.7	16
1132	Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention From the TWMU-AF PCI Registry. <i>Circulation Journal</i> , 2019, 83, 1000-1005.	0.7	10
1133	Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study. <i>European Heart Journal</i> , 2019, 40, 3782-3790.	1.0	29
1134	Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: A prospective cohort study. <i>IJC Heart and Vasculature</i> , 2019, 22, 111-116.	0.6	18
1135	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44

#	ARTICLE	IF	CITATIONS
1136	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAME-TT2-R2 Score: An Analysis of Hokusai-VTE. <i>Thrombosis and Haemostasis</i> , 2019, 119, 675-684.	1.8	9
1137	Clinical Outcomes of Off-Label Dosing of Direct Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA AF Registry. <i>Circulation Journal</i> , 2019, 83, 727-735.	0.7	62
1138	Impact of time in therapeutic range after left ventricular assist device placement: a comparison between thrombus and thrombus-free periods. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 361-368.	1.0	13
1139	Anticoagulation quality and clinical outcomes in multimorbid elderly patients with acute venous thromboembolism. <i>Thrombosis Research</i> , 2019, 177, 10-16.	0.8	8
1140	ICUSI questionnaire validation. Quality of anticoagulation in patients with atrial fibrillation treated with vitamin K antagonists. <i>REC: CardioClinics</i> , 2019, 54, 165-172.	0.1	3
1141	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , 2019, 9, e033712.	0.8	3
1142	New warfarin anticoagulation management model after heart valve surgery: rationale and design of a prospective, multicentre, randomised trial to compare an internet-based warfarin anticoagulation management model with the traditional warfarin management model. <i>BMJ Open</i> , 2019, 9, e032949.	0.8	8
1143	Implementation of home-based international normalized ratio testing in adult patients treated with warfarin. <i>Journal of the American Association of Nurse Practitioners</i> , 2021, 33, 563-569.	0.5	0
1144	Protocol of a clinical trial study involving educational intervention in patients treated with warfarin. <i>Medicine (United States)</i> , 2019, 98, e15829.	0.4	5
1145	Assessment of agreement and time in therapeutic range of capillary versus venous international normalised ratio in frail elderly people in a nursing home. <i>Internal Medicine Journal</i> , 2019, 49, 1442-1446.	0.5	1
1146	Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2912.	2.2	16
1147	The effect of vitamin D levels on gastrointestinal bleeding in patients with warfarin therapy. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 331-336.	0.5	3
1148	The Impact of Implementing an Advance Practice Pharmacist-Led Anticoagulation Clinic Within a Correctional Facility. <i>Journal of Pharmacy Practice</i> , 2019, 34, 089719001989212.	0.5	2
1149	One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry. <i>International Journal of Cardiology</i> , 2019, 274, 158-162.	0.8	13
1150	Association between insurance status, anticoagulation quality, and clinical outcomes in patients with acute venous thromboembolism. <i>Thrombosis Research</i> , 2019, 173, 124-130.	0.8	4
1151	Different determinants of vascular and nonvascular deaths in patients with atrial fibrillation: A SAKURA AF Registry substudy. <i>Journal of Cardiology</i> , 2019, 73, 210-217.	0.8	9
1152	Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1261-1267.	1.4	89
1153	Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 225-232.	1.0	14

#	ARTICLE	IF	CITATIONS
1154	Effect of hypertrophic cardiomyopathy on the prediction of thromboembolism in patients with nonvalvular atrial fibrillation. <i>Heart Rhythm</i> , 2019, 16, 829-837.	0.3	18
1155	Predictors for INR-control in a well-managed warfarin treatment setting. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 227-232.	1.0	10
1156	Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 418-426.	1.0	2
1157	Warfarin Absorption in Short Bowel Syndrome. <i>Journal of Pharmacy Technology</i> , 2019, 35, 43-44.	0.5	2
1158	Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial. <i>Haematologica</i> , 2019, 104, 1493-1501.	1.7	26
1159	Cost-effectiveness for prevention of thromboembolism by anticoagulants in non-valvular atrial fibrillation: additional analysis from the Hokuriku-Plus AF Registry. <i>Heart and Vessels</i> , 2019, 34, 1024-1030.	0.5	5
1160	Primary care management for patients receiving long-term antithrombotic treatment: A cluster-randomized controlled trial. <i>PLoS ONE</i> , 2019, 14, e0209366.	1.1	6
1161	Retrospective cohort study for evaluating the INR monitoring patterns in patients with deep vein thrombosis in daily practice: Analysis of 2010-2013 database of a tertiary care center. <i>Phlebology</i> , 2019, 34, 317-323.	0.6	2
1162	Feasibility and safety of a 12-week INR follow-up protocol over 2 years in an anticoagulation clinic: a single-arm prospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 200-208.	1.0	5
1163	Thoracoscopic Left Atrial Appendage Occlusion for Stroke Prevention Compared with Long-Term Warfarin Therapy in Patients With Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 50-56.	0.7	3
1164	The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation. <i>Europace</i> , 2019, 21, 572-580.	0.7	9
1165	Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 463-470.	1.3	13
1166	Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. <i>Circulation</i> , 2019, 139, 604-616.	1.6	117
1167	Risk factors for post-thrombotic syndrome in patients with deep vein thrombosis: from the COMMAND VTE registry. <i>Heart and Vessels</i> , 2019, 34, 669-677.	0.5	18
1169	Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: Assessment of international normalized ratio elevation characteristics and <i>in vitro</i> CYP2C9 activity. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1599-1607.	0.5	9
1170	Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 52-59.	0.5	10
1171	Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 139-148.	1.4	87
1172	D-dimer levels at diagnosis and long-term clinical outcomes in venous thromboembolism: from the COMMAND VTE Registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 551-561.	1.0	9

#	ARTICLE	IF	CITATIONS
1173	Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. <i>Pharmacogenomics Journal</i> , 2020, 20, 104-113.	0.9	13
1174	University hospitals, general hospitals, private clinics: Place-based differences in patient characteristics and outcomes of AF—A SAKURA AF Registry Substudy. <i>Journal of Cardiology</i> , 2020, 75, 74-81.	0.8	3
1175	Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 199-209.	0.8	7
1176	Impact of a pharmacist-led education and follow-up service on anticoagulation control and safety outcomes at a tertiary hospital in China: a randomised controlled trial. <i>International Journal of Pharmacy Practice</i> , 2020, 28, 97-106.	0.3	14
1177	Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin K antagonists: A randomized controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 70-78.	1.9	3
1178	Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1-9.	1.5	13
1179	Optimal oral anticoagulant therapy in Chinese patients with mechanical heart valves. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 144, 105202.	1.9	9
1180	Quality of Warfarin Anticoagulation in Indigenous and Non-Indigenous Australians With Atrial Fibrillation. <i>Heart Lung and Circulation</i> , 2020, 29, 1122-1128.	0.2	4
1181	Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. <i>Clinical Toxicology</i> , 2020, 58, 716-724.	0.8	10
1182	Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. <i>Lupus</i> , 2020, 29, 37-44.	0.8	31
1183	Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin. <i>Kidney International Reports</i> , 2020, 5, 159-164.	0.4	4
1184	Tacrolimus Inpatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies. <i>Transplantation</i> , 2020, 104, 881-887.	0.5	39
1185	New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 301-309.	1.4	29
1186	Impact of hemoglobin concentration and platelet count on outcomes of patients with non-valvular atrial fibrillation: A subanalysis of the J-RHYTHM Registry. <i>International Journal of Cardiology</i> , 2020, 302, 81-87.	0.8	23
1187	Early Detection of Pump Thrombosis in Patients With Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2020, 66, 348-354.	0.9	17
1188	Group-based Trajectory Models to Assess Quality of INR Control and Its Association With Clinical Outcomes. <i>Medical Care</i> , 2020, 58, e23-e30.	1.1	1
1189	Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study. <i>BMJ Open</i> , 2020, 10, e038194.	0.8	10
1190	The relationship between DOAC levels and clinical outcomes: The measures tell the tale. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3163-3168.	1.9	17

#	ARTICLE	IF	CITATIONS
1191	Anticoagulation control with the point-of-care INR: A retrospective pre-/post-analysis. <i>Thrombosis Research</i> , 2020, 196, 21-24.	0.8	0
1192	In-home Compared With In-Clinic Warfarin Therapy Monitoring in Mechanical Heart Valves: A Population-Based Study. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 511-520.	1.2	9
1193	Management of anticoagulant therapy using a portable point-of-care international normalized ratio device and social networking service in a patient with a left ventricular assist device. <i>Journal of Cardiology Cases</i> , 2020, 22, 156-158.	0.2	0
1194	Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 74, 773-780.	0.4	1
1195	Evaluation of the Validity of SAME-TT ₂ R ₂ Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962094503.	0.7	1
1196	The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists: results from the thrombEVAL cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 7, 271-279.	1.4	3
1197	Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study. <i>PLoS ONE</i> , 2020, 15, e0235639.	1.1	4
1198	Safety of low intensity oral anticoagulant therapy in patients with bileaflet mechanical aortic valve prosthesis: A propensity weighted study. <i>International Journal of Cardiology</i> , 2020, 317, 139-143.	0.8	3
1199	Quality of oral anticoagulation control in Chinese patients with non-valvular atrial fibrillation: a prospective controlled study. <i>Current Medical Research and Opinion</i> , 2020, 36, 1433-1439.	0.9	5
1200	LRP1 and APOA1 Polymorphisms: Impact on Warfarin International Normalized Ratio-Related Phenotypes. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 71-76.	0.8	2
1201	Is the time in therapeutic range on coumarins predicted by previous time in therapeutic range?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 604-609.	1.0	3
1202	Health-related quality of life correlates with time in therapeutic range in children on anticoagulants with International Normalised Ratio self-monitoring. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 811-820.	0.7	4
1203	Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 490.	0.7	4
1204	Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. <i>BMJ Open</i> , 2020, 10, e040449.	0.8	11
1205	Improved ability to achieve target trough levels with liquid versus capsule tacrolimus in kidney transplant patients with HIV on protease inhibitor or cobicistat based regimens. <i>Transplant Infectious Disease</i> , 2020, 23, e13517.	0.7	0
1206	Antithrombotic therapy and the risk of new-onset dementia in elderly patients with atrial fibrillation. <i>Postgraduate Medical Journal</i> , 2022, 98, 98-103.	0.9	8
1207	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. <i>New England Journal of Medicine</i> , 2020, 383, 2117-2126.	13.9	161
1208	Evaluation of the Long-Term Impact on Quality After the End of Pharmacist-Driven Warfarin Therapy Management in Patients With Poor Quality of Anticoagulation Therapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 1056.	1.6	1

#	ARTICLE	IF	CITATIONS
1209	The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 398-404.	1.4	69
1210	Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial. <i>Thrombosis Research</i> , 2020, 195, 209-214.	0.8	6
1211	A nurse-led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. <i>International Journal of Clinical Practice</i> , 2020, 74, e13634.	0.8	13
1212	Factors associated with silent cerebral events during atrial fibrillation ablation in patients on uninterrupted oral anticoagulation. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2889-2897.	0.8	8
1213	More precise dosing of acenocoumarol for better control in patients aged above 80 years, a randomised controlled pilot study. <i>Thrombosis Research</i> , 2020, 196, 536-538.	0.8	0
1214	Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3281.	1.0	2
1215	Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation. <i>BMJ Open</i> , 2020, 10, e036220.	0.8	7
1216	Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3280-3288.	1.9	2
1217	Clinical Outcomes of Direct Oral Anticoagulants and Warfarin in Japanese Patients with Atrial Fibrillation Aged ≥85 Years: A Single-Center Observational Study. <i>Drugs - Real World Outcomes</i> , 2020, 7, 325-335.		3
1218	Anticoagulation Control of Warfarin in Pharmacist-Led Clinics Versus Physician-Led Clinics: A Prospective Observational Study. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 1175-1179.	1.2	11
1219	Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 383.	1.0	1
1220	Novel Use of Tamoxifen to Reduce Recurrent Gastrointestinal Bleeding in Patients with Left Ventricular Assist Devices. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 484-491.	1.1	3
1221	Patient experience with an educational mobile health application: A pilot study on usability and feasibility in a Saudi population. <i>Cogent Psychology</i> , 2020, 7, 1843883.	0.6	2
1222	Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 347.	1.0	6
1223	The effect of warfarin knowledge on anticoagulation control among patients with heart valve replacement. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 861-870.	1.0	10
1224	Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. <i>Thrombosis Research</i> , 2020, 192, 12-20.	0.8	12
1225	Predictive ability of modified Ottawa score for recurrence in patients with cancer-associated venous thromboembolism: From the COMMAND VTE Registry. <i>Thrombosis Research</i> , 2020, 191, 66-75.	0.8	2
1226	Evaluation of the clinical and safety outcomes of face-to-face vs a telephonic model of a pharmacist-led outpatient anticoagulation service. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 1444.	0.5	3

#	ARTICLE	IF	CITATIONS
1227	Evaluation of the SAME-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. <i>Thrombosis Research</i> , 2020, 194, 178-182.	0.8	3
1228	Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIA Registry. <i>Annals of Medicine</i> , 2020, 52, 300-309.	1.5	7
1229	Anticoagulation in AF and Elderly Frail Patient: How to Face New Challenges. , 2020, , .		0
1230	Performance of the microlNR Point-of-Care System: A Multicenter Clinical Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 687-691.	1.8	4
1231	Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1698.	1.0	21
1232	Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1457-1464.	0.8	2
1233	Vitamin K Concentration and Cognitive Status in Elderly Patients on Anticoagulant Therapy: A Pilot Study. <i>Journal of Aging Research</i> , 2020, 2020, 1-7.	0.4	3
1234	Understanding risk factors and predictors for stroke subtypes in the ENDURANCE trials. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 639-647.	0.3	14
1235	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1145-1155.	1.2	28
1236	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 1618-1627.	1.6	84
1237	Quality of anticoagulant therapy and the incidence of inâ€stent thrombosis after venous stenting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 594-603.	1.0	4
1238	The anti-clot treatment scale (ACTS): validation of the translated Arabic version among patients undergoing warfarin therapy in Saudi Arabia. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 215.	1.0	2
1239	Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry. <i>IJC Heart and Vasculature</i> , 2020, 29, 100559.	0.6	4
1240	Knowledge, Adherence, and Quality of Life among Warfarin Therapy Users. , 0, , .		0
1241	Effectiveness and Safety of Off-label Dosing of Nonâ€vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients. <i>Scientific Reports</i> , 2020, 10, 1801.	1.6	33
1242	Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting. <i>Frontiers in Pharmacology</i> , 2019, 10, 1527.	1.6	10
1243	Impact of the Fibrosis-4 Index on Risk Stratification of Cardiovascular Events and Mortality in Patients with Atrial Fibrillation: Findings from a Japanese Multicenter Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 584.	1.0	27
1244	The SAMEâ€TT2R2 score as an indicator of warfarin control for patients with deep vein thrombosis in Queensland, Australia. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 614-618.	1.0	2

#	ARTICLE	IF	CITATIONS
1245	Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. <i>British Journal of Haematology</i> , 2020, 190, 588-593.	1.2	14
1246	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <i>PLoS ONE</i> , 2020, 15, e0226259.	1.1	1
1247	Baseline Characteristics of Elderly Japanese Patients Aged ≥75 Years With Non-Valvular Atrial Fibrillation and a History of Stroke—ANAFIE Registry. <i>Circulation Journal</i> , 2020, 84, 516-523.	0.7	1
1248	Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. <i>American Heart Journal</i> , 2020, 223, 3-11.	1.2	38
1249	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. <i>PLoS ONE</i> , 2020, 15, e0227458.	1.1	25
1250	Relationship between the Renal Function and Adverse Clinical Events in Patients with Atrial Fibrillation: A Japanese Multicenter Registry Substudy. <i>Journal of Clinical Medicine</i> , 2020, 9, 167.	1.0	12
1251	Renal dysfunction and long-term clinical outcomes in patients with venous thromboembolism: From the COMMAND VTE Registry. <i>Thrombosis Research</i> , 2020, 187, 39-47.	0.8	2
1252	Risk of Stroke, Bleeding, and Death in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease. <i>Cardiology</i> , 2020, 145, 178-186.	0.6	25
1253	Assessment of patient knowledge on warfarin: An item response theory approach. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 698-706.	0.7	4
1254	Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism. <i>PLoS ONE</i> , 2020, 15, e0232354.	1.1	9
1255	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 740.	1.7	28
1256	Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 166.	0.7	3
1257	Effect of SAME-TT2R2 score and genetic polymorphism on the quality of anticoagulation control in Qatari patients treated with warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 659-666.	1.0	2
1258	Genotype-guided warfarin dosing may benefit patients with mechanical aortic valve replacements: randomized controlled study. <i>Scientific Reports</i> , 2020, 10, 6988.	1.6	6
1259	A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 474-481.	1.0	0
1260	Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962090915.	0.7	5
1261	The use of direct oral anticoagulants in patients with ventricular assist devices: Is there hope for Factor Xa inhibition?. <i>Artificial Organs</i> , 2021, 45, E123-E129.	1.0	6
1262	Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial—The RIWA study. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 363-371.	1.0	20

#	ARTICLE	IF	CITATIONS
1263	GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. <i>Future Cardiology</i> , 2021, 17, 19-38.	0.5	19
1264	Association between Patients' Knowledge and Adherence to Anticoagulants, and Its Effect on Coagulation Control. <i>Pharmacology</i> , 2021, 106, 265-274.	0.9	5
1265	Influence of low body weight on long-term clinical outcomes in patients with venous thromboembolism: From the COMMAND VTE registry. <i>Thrombosis Research</i> , 2021, 198, 26-33.	0.8	5
1266	Evaluation of Warfarin Use in Patients With Mental Health Conditions in a Rural Community Health Center System. <i>Journal of Pharmacy Technology</i> , 2021, 37, 17-22.	0.5	1
1267	Relationship between the nutritional status and safety and efficacy outcomes in atrial fibrillation patients aged 80 years and over receiving oral anticoagulants. <i>Journal of Cardiology</i> , 2021, 77, 147-153.	0.8	5
1268	Real-World Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1282-1292.	2.3	12
1269	Tacrolimus inpatient variability in solid organ transplantation: A multiorgan perspective. <i>Pharmacotherapy</i> , 2021, 41, 103-118.	1.2	33
1270	Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1043-1049.	1.0	3
1271	Tacrolimus monitoring parameters are not associated with acute cellular rejection following lung transplantation. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 63-69.	0.8	5
1272	High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Case Cohort Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 070-075.	1.8	1
1273	Antithrombotic Therapy and Outcomes of Patients With New-Onset Transient Atrial Fibrillation After ST-Segment Elevation Myocardial Infarction. <i>American Journal of Therapeutics</i> , 2021, 28, e30-e40.	0.5	2
1274	Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 20-30.	1.4	4
1275	An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 40-49.	1.4	9
1276	Genetic Polymorphism Effect on Warfarin-Rifampin Interaction: A Case Report and Review of Literature. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 149-156.	0.4	3
1277	Cost saving analysis of specialized, eHealth-based management of patients receiving oral anticoagulation therapy: Results from the thrombEVAL study. <i>Scientific Reports</i> , 2021, 11, 2577.	1.6	4
1278	Comparison of clinical outcomes between multiple antithrombotic therapy versus left atrial appendage occlusion with dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. <i>PLoS ONE</i> , 2021, 16, e0244723.	1.1	2
1280	Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism. <i>Journal of Clinical Medicine</i> , 2021, 10, 141.	1.0	7
1281	The efficacy and safety of Hirudin plus Aspirin versus Warfarin in the secondary prevention of Cardioembolic Stroke due to Nonvalvular Atrial Fibrillation: A multicenter prospective cohort study. <i>International Journal of Medical Sciences</i> , 2021, 18, 1167-1178.	1.1	5

#	ARTICLE	IF	CITATIONS
1282	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. <i>Cardiovascular Research</i> , 2022, 118, 295-304.	1.8	8
1283	Development and Implementation of National Time in Therapeutic Range Reports and Establishing Quality Standards Within Veterans Health Administration. <i>Journal of General Internal Medicine</i> , 2021, 36, 1418-1421.	1.3	2
1284	Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 1275-1283.	1.4	6
1285	Incidence of adverse clinical events during anticoagulant therapy in patients with nonvalvular atrial fibrillation associated with renal dysfunction. <i>Nosotchu</i> , 2021, 43, 313-319.	0.0	0
1286	Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812110460.	0.6	3
1287	Using machine learning to predict anticoagulation control in atrial fibrillation: A UK Clinical Practice Research Datalink study. <i>Informatics in Medicine Unlocked</i> , 2021, 25, 100688.	1.9	7
1288	Which is the best for the warfarin monitoring: following up by fixed or variable physician?. <i>İstanbul Kuzey Klinikleri</i> , 2021, 9, 93-101.	0.1	0
1289	Impact of Blood Pressure Visit-to-Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation: Subanalysis of the RHYTHM Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e018585.	1.6	11
1290	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. <i>International Journal of Clinical Practice</i> , 2021, 75, e14064.	0.8	1
1291	Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 58-67.e4.	0.4	38
1292	Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study). <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2244.	1.2	4
1293	Pharmacist-physician collaborative care for outpatients with left ventricular assist devices using a cloud-based home medical management information-sharing system: a case report. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2021, 7, 5.	0.4	0
1294	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2021, 143, 673-684.	1.6	10
1295	Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007230.	0.9	20
1296	Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 426-438.	1.0	10
1297	Comparison of Edoxaban and Warfarin for the Treatment of Cancer-Associated Venous Thromboembolism: A Retrospective Observational Study. <i>Circulation Journal</i> , 2024, 88, 251-258.	0.7	1
1298	Active management of the target P2Y12 reaction unit range in patients undergoing stent-assisted coil embolization for unruptured cerebral aneurysms. <i>Journal of NeuroInterventional Surgery</i> , 2021, 13, 1017-1021.	2.0	2
1299	Epidemiological characteristics, management, and outcomes of atrial fibrillation in Tunisia: Results from the National Tunisian Registry of Atrial Fibrillation (NATURE-AF). <i>Clinical Cardiology</i> , 2021, 44, 501-510.	0.7	7

#	ARTICLE	IF	CITATIONS
1300	Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study. <i>Molecules</i> , 2021, 26, 1425.	1.7	12
1301	Quality of anticoagulation using intravenous unfractionated heparin for cerebrovascular indications. <i>Thrombosis Research</i> , 2021, 199, 79-81.	0.8	0
1302	Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients: A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland. <i>Clinical Epidemiology</i> , 2021, Volume 13, 183-195.	1.5	9
1303	Evaluating the effects of socioeconomic status on stroke and bleeding risk scores and clinical events in patients on oral anticoagulant for new onset atrial fibrillation. <i>PLoS ONE</i> , 2021, 16, e0248134.	1.1	11
1304	Impact of an oral anticoagulation self-monitoring and self-management program in patients with mechanical heart valve prosthesis. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 307-314.	0.6	0
1305	Warfarin Dose Requirements in Adults Hospitalized With COVID-19 Infection: A Retrospective Case Series. <i>Journal of Pharmacy Practice</i> , 2022, 35, 654-660.	0.5	7
1306	Effectiveness of the Alfalfa App in Warfarin Therapy Management for Patients Undergoing Venous Thrombosis Prevention and Treatment: Cohort Study. <i>JMIR MHealth and UHealth</i> , 2021, 9, e23332.	1.8	12
1307	Comparison of Bleeding Risk Scores in Elderly Patients Receiving Extended Anticoagulation with Vitamin K Antagonists for Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1512-1522.	1.8	8
1308	Tacrolimus timeâ€¦therapeutic range is associated with freedom from acute rejection and graft failure following intestinal transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14291.	0.8	6
1309	Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial. <i>PLoS ONE</i> , 2021, 16, e0248567.	1.1	1
1310	Low Quality of Warfarin Therapy is Associated With Female Gender but Not With Polypharmacy in Patients With Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2021, 12, 651799.	1.6	2
1312	Is there a circannual variation in the anticoagulation control of warfarin?. <i>European Journal of Hospital Pharmacy</i> , 2021, , ejhpharm-2021-002793.	0.5	0
1313	Time to Stable Therapeutic Range on Initiation of Warfarin as an Indicator of Control. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105620.	0.7	0
1314	Driveâ€¦ <sc>INR</sc> testing and phoneâ€¦based consultations service during <sc>COVID</sc>â€¦19 pandemic in a pharmacistâ€¦lead anticoagulation clinic in Qatar: Monitoring, clinical, resource utilization, and patientâ€¦oriented outcomes. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 1117-1125.	0.5	9
1315	Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study. <i>Blood</i> , 2021, 137, 2745-2755.	0.6	6
1316	Clinical Implications of Tacrolimus Time in Therapeutic Range and Inpatient Variability in Urban Renal Transplant Recipients Undergoing Early Corticosteroid Withdrawal. <i>Transplantation Direct</i> , 2021, 7, e698.	0.8	3
1317	Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1110-1116.	1.0	2
1318	Impact of Lower Versus Higher LDL Cholesterol Targets on Cardiovascular Events After Ischemic Stroke in Patients With Diabetes. <i>Diabetes</i> , 2021, 70, 1807-1815.	0.3	0

#	ARTICLE	IF	CITATIONS
1319	Sexâ€™influence on the time in therapeutic range (TTR) during oral anticoagulation with coumarin derivatives: Systematic review and metaâ€™analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4488-4503.	1.1	5
1320	Using a Simple Prescription Gap to Determine Warfarin Discontinuation Can Lead to Substantial Misclassification. <i>Thrombosis and Haemostasis</i> , 2022, 122, 386-393.	1.8	3
1321	Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021, 10, 2866.	1.0	5
1322	Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants. <i>International Journal of Cardiology</i> , 2021, 333, 162-166.	0.8	10
1323	Oral Anticoagulation Use in High-Risk Patients Is Improved by Elimination of False-Positive and Inactive Atrial Fibrillation Cases. <i>American Journal of Medicine</i> , 2021, 134, e366-e373.	0.6	4
1324	Physicianâ€™Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development. <i>Frontiers in Pharmacology</i> , 2021, 12, 673302.	1.6	5
1325	Evaluation of Time in Therapeutic Range in Patients with Cerebrovascular Disease Receiving Treatment with Warfarin. <i>Mustafa Kemal Ãœniversitesi TÃ±p Dergisi</i> , 0, , .	0.1	0
1326	Can clinical pharmacists utilize telehealth to double the safety and efficacy of oral anticoagulation while reducing health care costs and improving patient satisfaction in patients with atrial fibrillation?. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 969-977.	0.5	0
1327	Time in therapeutic range is lower in women than in men and is not explained by differences in age or comorbidity. <i>Thrombosis Research</i> , 2021, 203, 18-21.	0.8	6
1328	Impact of Protocolized Pharmacist Intervention on Critical Activated Partial Thromboplastin Time Values With Heparin Infusions. <i>Journal of Pharmacy Technology</i> , 2021, 37, 225-233.	0.5	0
1329	Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients. <i>Pharmacotherapy</i> , 2021, 41, 649-657.	1.2	4
1330	Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 660-667.	1.4	34
1331	Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis. <i>Current Medical Research and Opinion</i> , 2021, 37, 1493-1500.	0.9	3
1332	Improved Time in Therapeutic Range with International Normalized Ratio Remote Monitoring for Patients with Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2021, Publish Ahead of Print, .	0.9	3
1333	Patient-related factors associated with oral anticoagulation control: a population-based cohort study. <i>International Journal of Pharmacy Practice</i> , 2021, 29, 443-450.	0.3	0
1334	Evaluation of a Pharmacist-Led Remote Warfarin Management Model Using a Smartphone Application (Yixing) in Improving Patientsâ€™ Knowledge and Outcomes of Anticoagulation Therapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 677943.	1.6	9
1335	Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndromeâ€™A retrospective observational study. <i>PLoS ONE</i> , 2021, 16, e0255009.	1.1	4
1336	Relationship between Chronic Kidney Disease, Time-in-Therapeutic Range, and Adverse Outcomes in Atrial Fibrillation: A post hoc Analysis from the AMADEUS Trial. <i>Cerebrovascular Diseases</i> , 2021, , 1-7.	0.8	1

#	ARTICLE	IF	CITATIONS
1337	Risk factors of thrombotic recurrence and major bleeding in patients with intermediate-risk for recurrence of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, , 1.	1.0	2
1338	A retrospective analysis of discordances between international normalized ratio (INR) self-testing and INR laboratory testing in a pediatric patient population. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1575-1584.	0.7	0
1339	The short-term effect of the COVID-19 pandemic on the management of warfarin therapy. <i>Kardiologiya</i> , 2021, 61, 55-59.	0.3	1
1340	Comparison among random forest, logistic regression, and existing clinical risk scores for predicting outcomes in patients with atrial fibrillation: A report from the <sc>J&RHYTHM</sc> registry. <i>Clinical Cardiology</i> , 2021, 44, 1305-1315.	0.7	7
1341	Assessment of Anticoagulation Control Association with Warfarin Knowledge and Demographic Features of Iranian Population. <i>Multidisciplinary Cardiovascular Annals</i> , 2021, 12, .	0.2	0
1342	New Internet-Based Warfarin Anticoagulation Management Approach After Mechanical Heart Valve Replacement: Prospective, Multicenter, Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2021, 23, e29529.	2.1	13
1343	Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 399-409.	1.0	3
1344	Evaluation of a pharmacist vs. Haematologist-managed anticoagulation clinic: A retrospective cohort study. <i>Saudi Pharmaceutical Journal</i> , 2021, 29, 1173-1180.	1.2	2
1345	Evaluation of the "safe multidisciplinary app-assisted remote patient-self-testing (SMART) model" for warfarin home management during the COVID-19 pandemic: study protocol of a multi-center randomized controlled trial. <i>BMC Health Services Research</i> , 2021, 21, 875.	0.9	2
1346	Does Ramadan fasting disrupt international normalised ratio control in warfarin-treated medically stable patients?. <i>International Journal of Clinical Practice</i> , 2021, 75, e14796.	0.8	4
1347	Anticoagulation use and the risk of stroke and major bleeding in patients on hemodialysis: From the VIVALDI, a population-based prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2984-2996.	1.9	10
1348	Tele-pharmacy Anticoagulation Clinic During COVID-19 Pandemic: Patient Outcomes. <i>Frontiers in Pharmacology</i> , 2021, 12, 652482.	1.6	11
1350	Severity of pulmonary embolism at initial diagnosis and long-term clinical outcomes: From the COMMAND VTE Registry. <i>International Journal of Cardiology</i> , 2021, 343, 107-113.	0.8	3
1351	Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil. <i>Thrombosis Research</i> , 2021, 205, 81-83.	0.8	2
1352	Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 153-161.	1.4	6
1353	Time in Therapeutic Range Significantly Impacts Survival and Adverse Events in Destination Therapy Patients. <i>ASAIO Journal</i> , 2022, 68, 14-20.	0.9	3
1354	Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding. <i>Lancet Regional Health - Europe</i> , The, 2021, 10, 100222.	3.0	8
1355	Relationship between multimorbidity and outcomes in atrial fibrillation. <i>Experimental Gerontology</i> , 2021, 153, 111482.	1.2	16

#	ARTICLE	IF	CITATIONS
1356	Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial. <i>Hypertension</i> , 2021, 78, 966-972.	1.3	8
1357	Anticoagulation Quality of Warfarin and the Role of Physician-Pharmacist Collaborative Clinics in the Treatment of Patients Receiving Warfarin: A Retrospective, Observational, Single-Center Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 605353.	1.6	6
1359	Inercia terapéutica en anticoagulación oral en los pacientes con fibrilación auricular no valvular en atención primaria. Estudio ANFAGAL+. <i>REC: CardioClinics</i> , 2021, 56, 22-29.	0.1	3
1360	Evaluation of the algorithm of Anticlot Assistant: an anticoagulant management system based on mobile health technology. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 221-224.	0.5	1
1361	Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. <i>Archives of Internal Medicine</i> , 1993, 153, 1557-1562.	4.3	306
1362	Consensus Needed for Evaluating Safe and Adequate Anticoagulant Control. <i>Archives of Internal Medicine</i> , 2001, 161, 1558-1558.	4.3	3
1364	Measuring Outcomes of Multidimensional Interventions. , 2010, , 1-17.		2
1365	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. <i>American Journal of Medicine</i> , 2020, 133, 1195-1202.e2.	0.6	80
1367	Assessment of Therapeutic Quality Control in a Long-Term Anticoagulant Trial in Post-Myocardial Infarction Patients. <i>Thrombosis and Haemostasis</i> , 1994, 72, 347-351.	1.8	42
1368	International Normalized Ratio Test Frequency in Left Ventricular Assist Device Patients Affects Anticoagulation Quality and Adverse Events. <i>ASAIO Journal</i> , 2021, 67, 157-162.	0.9	10
1369	Influence of sex-based differences on oral anticoagulation control in patients taking coumarin derivatives: a systematic review protocol. <i>JBI Evidence Synthesis</i> , 2021, 19, 477-483.	0.6	4
1370	Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. <i>BMJ: British Medical Journal</i> , 1997, 314, 1252-1252.	2.4	70
1371	Prediction Score for Anticoagulation Control Quality Among Older Adults. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	26
1372	Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. <i>Blood</i> , 2000, 96, 1816-1819.	0.6	2
1373	Major bleeding during anticoagulation after cerebral ischemia. <i>Neurology</i> , 1999, 53, 1319-1319.	1.5	281
1374	Gastrointestinal Bleeding From Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA Atrial Fibrillation Registry. <i>Circulation Journal</i> , 2020, 84, 1475-1482.	0.7	7
1375	Risk Factors for Major Bleeding During Anticoagulation Therapy in Cancer-Associated Venous Thromboembolism From the COMMAND VTE Registry. <i>Circulation Journal</i> , 2020, 84, 2006-2014.	0.7	19
1376	Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry. <i>Medical Science Monitor</i> , 2019, 25, 4691-4698.	0.5	11

#	ARTICLE	IF	CITATIONS
1377	Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease. PLoS ONE, 2014, 9, e94420.	1.1	35
1378	Comorbidities against Quality Control of VKA Therapy in Non-Valvular Atrial Fibrillation: A French National Cross-Sectional Study. PLoS ONE, 2015, 10, e0119043.	1.1	23
1379	The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PLoS ONE, 2015, 10, e0122520.	1.1	69
1380	A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. PLoS ONE, 2015, 10, e0145318.	1.1	27
1381	Use of the SAME-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence. PLoS ONE, 2016, 11, e0150674.	1.1	41
1382	Comparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort Study. PLoS ONE, 2016, 11, e0158130.	1.1	12
1383	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE, 2016, 11, e0164076.	1.1	118
1384	Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. PLoS ONE, 2017, 12, e0181000.	1.1	28
1385	Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study. Cardiology Research, 2014, 5, 12-22.	0.5	4
1386	Translation, validation and psychometric properties of Bahasa Malaysia version of the Perception of Anticoagulant Therapy Questionnaire (PACTQ). Asian Journal of Biomedical and Pharmaceutical Sciences, 2015, 05, 18-22.	0.1	3
1387	Identification of environmental and genetic factors that influence warfarin time in therapeutic range. Genetics and Molecular Biology, 2020, 43, e20190025.	0.6	3
1388	Extended Antithrombotic Therapy in Elderly Patients with Deep Venous Thrombosis. Flebologiya, 2015, 9, 41.	0.2	2
1389	Optimal International Normalized Ratio for Warfarin Therapy in Elderly Korean Patients with Non-Valvular Atrial Fibrillation. International Journal of Arrhythmia, 2016, 17, 167-173.	0.3	4
1390	Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation. Oncotarget, 2016, 7, 54194-54199.	0.8	17
1391	Time in the Therapeutic Range (TTR): An Overly Simplified Conundrum. Journal of Innovations in Cardiac Rhythm Management, 2017, 8, 2643-2646.	0.2	15
1392	Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3428-3434.	0.2	11
1393	TTR: Time in Therapeutic Range or "The Troublesome Report". Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3469-3470.	0.2	1
1394	Economic Evaluation of Point-of-Care Monitoring Devices for Long-Term Oral Anticoagulation Therapy. SSRN Electronic Journal, 0, , .	0.4	6

#	ARTICLE	IF	CITATIONS
1395	Evaluation of a Health Information Technology-Enabled Panel Management Platform to Improve Anticoagulation Control in a Low-Income Patient Population: Protocol for a Quasi-Experimental Design. <i>JMIR Research Protocols</i> , 2020, 9, e13835.	0.5	2
1396	Effective and Safe Management of Oral Anticoagulation Therapy in Patients Who Use the Internet-Accessed Telecontrol Tool SintromacWeb. <i>Interactive Journal of Medical Research</i> , 2015, 4, e10.	0.6	8
1397	Supervised Patient Self-Testing of Warfarin Therapy Using an Online System. <i>Journal of Medical Internet Research</i> , 2013, 15, e138.	2.1	20
1398	Design and Rationale of the National Tunisian Registry of Atrial Fibrillation: Protocol for a Prospective, Multicenter Trial. <i>JMIR Research Protocols</i> , 2018, 7, e181.	0.5	2
1399	Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms. <i>Frontiers in Pharmacology</i> , 2019, 10, 1620.	1.6	3
1400	Impact of a pharmacist-managed anticoagulation clinic on clinical events. <i>Canadian Pharmacists Journal</i> , 2008, 141, 278-284.	0.4	1
1401	Current Management of Pulmonary Thromboembolism. <i>Korean Journal of Medicine</i> , 2013, 84, 659.	0.1	4
1402	Egenkontroll av warfarinbehandling. <i>Tidsskrift for Den Norske Laegeforening</i> , 2015, 135, 849-853.	0.2	5
1403	Impact of Anticoagulation Intensity in Korean Patients with Atrial Fibrillation: Is It Different from Western Population?. <i>Korean Circulation Journal</i> , 2020, 50, 163.	0.7	6
1404	Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience. <i>Journal of Advanced Pharmaceutical Technology and Research</i> , 2017, 8, 14.	0.4	8
1405	The Prevalence and Risks of Inappropriate Combination of Aspirin and Warfarin in Clinical Practice: Results From WARFARIN-TR Study. <i>Balkan Medical Journal</i> , 2019, 36, 17-22.	0.3	12
1406	Title is missing!. <i>Japanese Journal of Electrocardiology</i> , 2011, 31, 225-233.	0.0	9
1407	The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: warfarin -tr. <i>Anatolian Journal of Cardiology</i> , 2015, 16, 595-600.	0.5	18
1408	Evaluating time in therapeutic range for hemodialysis patients taking warfarin. <i>Clinical Nephrology</i> , 2015, 83 (2015), 80-85.	0.4	31
1409	Lack of Association of Clinical Factors (SAME-TT ₂ R ₂) with CYP2C9/VKORC1 Genotype and Anticoagulation Control Quality. <i>Journal of Stroke</i> , 2015, 17, 192.	1.4	13
1410	Managing Excessive Warfarin Anticoagulation. <i>Annals of Internal Medicine</i> , 2001, 135, 460.	2.0	5
1411	Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, FC04-FC06.	0.8	23
1412	Stability of vitamin K antagonist anticoagulation after COVID-19 diagnosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12597.	1.0	3

#	ARTICLE	IF	CITATIONS
1413	Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. <i>Blood Advances</i> , 2022, 6, 1661-1670.	2.5	56
1414	One-year clinical outcome of patients with left ventricular thrombus after acute myocardial infarction discharged on triple or dual antithrombotic therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 410-416.	1.0	3
1415	Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article. <i>Thrombosis Journal</i> , 2021, 19, 72.	0.9	2
1416	Anticoagulant prescribing for atrial fibrillation and risk of incident dementia. <i>Heart</i> , 2021, 107, 1898-1904.	1.2	18
1417	Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 333-343.	1.0	11
1418	Clinical phenotypes of patients with non-valvular atrial fibrillation as defined by a cluster analysis: A report from the J-RHYTHM registry. <i>IJC Heart and Vasculature</i> , 2021, 37, 100885.	0.6	6
1419	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 266-284.	0.9	2
1420	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 266-284.	0.9	0
1421	Oral Warfarin Remains An Effective Treatment Option in the Extended Prophylaxis of VTE for Patients with Cancer: The Effectiveness of the CancerCare Manitoba (CCMB) Anticoagulation Clinic (ACC).. <i>Blood</i> , 2008, 112, 1283-1283.	0.6	1
1422	Clinical Year in Review of Venous Thromboembolism. <i>Tuberculosis and Respiratory Diseases</i> , 2011, 71, 245.	0.7	1
1423	Anticoagulation therapy in non-valvular atrial fibrillation patients with chronic renal dysfunction. <i>Nosotchu</i> , 2011, 33, 559-563.	0.0	0
1424	Status of Bucolome Use and Warfarin Dose in Anticoagulation Therapy in Patients with Atrial Fibrillation--A Report from the J-RHYTHM Registry--. <i>Japanese Journal of Electrocardiology</i> , 2013, 33, 195-208.	0.0	2
1425	Novel Oral Anticoagulants for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation. , 2014, , 55-89.		0
1426	Genomic Analysis for Preventing Complications due to Proton Pump Inhibitor and Warfarin Combination Therapy after Open-Heart Surgery. <i>Japanese Journal of Cardiovascular Surgery</i> , 2014, 43, 163-169.	0.0	0
1427	Elderly Disabled Patients in Oral Anticoagulation Treatment: An Evaluation of a Bioanalyst-Led Management Program Reaching an Average of 72% of Time in Therapeutic Range. <i>World Journal of Cardiovascular Diseases</i> , 2014, 04, 623-630.	0.0	0
1428	Oral Anticoagulant Therapy and Bleeding Events with Vitamin K Antagonists in Patients with Atrial Fibrillation in a Hungarian County Hospital. <i>Medical Science Monitor</i> , 2015, 21, 518-525.	0.5	4
1429	Clinical Outcomes and Anticoagulant Intensity in Japanese Nonvalvular Atrial Fibrillation Patients ≥65 Years of Age with a CHADS₂ Score 0-1 and Taking Warfarin. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 46, 191-197.	0.1	0
1430	Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists. <i>Clinical and Biomedical Research</i> , 2015, 35, 99-103.	0.1	0

#	ARTICLE	IF	CITATIONS
1431	An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among nonvalvular atrial fibrillation patients in Turkey- AFTER-2 Study Design. Turk Kardiyoloji Dernegi Arsivi, 2015, 43, 169-77.	0.6	1
1432	Feasibility of Warfarin Anticoagulation Management with a Patient Self-Testing Model in Korea. Clinical & Experimental Thrombosis and Hemostasis, 2015, 2, 8-10.	0.2	0
1433	Using the software «DAWN AC» for control of dosing warfarin in the special anticoagulation clinics. Uchenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2015, 22, 32-35.	0.0	0
1434	Stroke Management by Anticoagulant Therapy in Atrial Fibrillation. International Journal of Medical Science and Clinical Invention, 0, , .	0.1	0
1435	Thromboprophylaxis in Patients with Atrial Fibrillation: A Real Practice Analysis. Global & Regional Health Technology Assessment, 2016, 3, GRHTA.5000203a.	0.2	0
1436	A yearlong monitoring of the quality of oral anticoagulation therapy in patients with atrial fibrillation and analysis of its influence on the quality of anticoagulation. Timocki Medicinski Glasnik, 2017, 42, 224-235.	0.0	3
1437	Quality of anticoagulation among patients with nonvalvular atrial fibrillation in the Primary health care center 'Novi Beograd'. Opšta Medicina, 2017, 23, 59-66.	0.3	0
1438	Effects of the quality of warfarin therapy on the development of ischemic and hemorrhagic events in elderly Japanese patients with nonvalvular atrial fibrillation. Nosotchu, 2017, 39, 261-267.	0.0	1
1439	Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. Anatolian Journal of Cardiology, 2017, 18, 328-333.	0.5	2
1440	DOES THE SCALE SAME-TT2R2 FUNCTIONS IN REAL CLINICAL PRACTICE?. Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR, 2018, 24, 65-68.	0.1	0
1441	Efficacy and safety of anticoagulation therapy in patients with non-valvular atrial fibrillation in actual clinical setting. Nosotchu, 2019, 41, 85-92.	0.0	1
1442	Compliance Amongst Warfarin Users Diagnosed Non-valvular Atrial Fibrillation are We Aware: Prospective Survey. , 2019, 08, .		0
1443	Impact of Hypertension in Patients with Atrial Fibrillation and Importance of Blood Pressure Management during Anticoagulation Therapy. Nihon Ika Daigaku Igakkai Zasshi, 2019, 15, 12-23.	0.0	0
1444	Comparison of the Efficacy and Safety of Warfarin and Antiplatelet Therapy in Patients with Atrial Fibrillation and End-Stage Renal Disease. Korean Journal of Medicine, 2019, 94, 191-199.	0.1	0
1445	Quality Assessment of Oral Anticoagulation by Time in Therapeutic Range in Patients with Venous Thromboembolism in Korea. Clinical & Experimental Thrombosis and Hemostasis, 2019, 5, 8-10.	0.2	0
1447	Anticoagulation with Warfarin: Roles of Adherence, Social Support and Illness Perception. Innovations in Pharmacy, 2019, 10, 5.	0.2	1
1448	Use of SAME-TT ₂ R ₂ Score to Predict the Quality of Anticoagulation Control in Patients with Atrial Fibrillation Receiving Warfarin in Thailand. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2020, 103, 548-552.	0.4	3
1449	Time in Therapeutic Range for Bivalirudin Among Pediatric Ventricular Assist Device Recipients. ASAIO Journal, 2021, 67, 588-593.	0.9	3

#	ARTICLE	IF	CITATIONS
1451	Real-Life International Normalized Ratio Profile in Patients with Non-Valvular Atrial Fibrillation Prescribed Vitamin K Antagonist. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 522-527.	0.3	1
1452	Association between transportation barriers and anticoagulation control among an inner-city, low-income population: A prospective observational cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12605.	1.0	2
1453	Benefit of Self-Managed Anticoagulation in Patients with Left Ventricular Assist Device. <i>Thoracic and Cardiovascular Surgeon</i> , 2021, 69, 518-525.	0.4	3
1454	Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 136, 71-75.	0.7	0
1455	SAME-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. <i>Singapore Medical Journal</i> , 2020, 61, 641-646.	0.3	5
1457	Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2021, 20, 103-107.	0.2	1
1458	Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies. <i>Drugs in Context</i> , 2019, 8, 1-11.	1.0	2
1459	Surgical Management of Atrial Fibrillation. , 2020, , 727-733.		0
1460	The impact of a pharmacist-led warfarin educational video in a Saudi setting. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2020, 12, 413.	0.2	2
1461	Serum Digoxin Concentrations and Outcomes in Patients with Heart Failure and Atrial Fibrillation: A Single-Center Observational Study. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2020, 51, 57-64.	0.1	1
1462	Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110497.	0.7	2
1463	Pharmacists'™ interventions improve health-related quality of life of rural older person on warfarin: a randomized controlled trial. <i>Scientific Reports</i> , 2021, 11, 21897.	1.6	7
1464	Comparison of Long-Term Outcomes Between Combination Antiplatelet and Anticoagulant Therapy and Anticoagulant Monotherapy in Patients With Atrial Fibrillation and Left Atrial Thrombi. <i>Circulation Reports</i> , 2020, 2, 457-465.	0.4	0
1465	A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation" A Single-centre Retrospective Cohort Study in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2020, 49, 838-847.	0.2	1
1466	Adherence to rivaroxaban for the treatment of venous thromboembolism"Results from the FIRST registry. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12614.	1.0	3
1467	Differences in Secure Messaging, Self-management, and Glycemic Control Between Rural and Urban Patients: Secondary Data Analysis. <i>JMIR Diabetes</i> , 2021, 6, e32320.	0.9	4
1468	Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation. <i>Cardiology Research and Practice</i> , 2021, 2021, 1-8.	0.5	0
1469	Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 339-352.	1.9	7

#	ARTICLE	IF	CITATIONS
1470	Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin. <i>Journal of the American Heart Association</i> , 2021, 10, e020904.	1.6	9
1471	Association of tacrolimus time-to therapeutic range on renal dysfunction and acute cellular rejection after orthotopic heart transplantation in a high use basiliximab population. <i>Clinical Transplantation</i> , 2021, , e14542.	0.8	0
1472	Early Monitoring and Subsequent Gain of Tacrolimus Time-In-Therapeutic Range May Improve Clinical Outcomes After Living Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 728-735.	1.0	2
1473	Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study. <i>Thrombosis Research</i> , 2021, 208, 162-169.	0.8	5
1474	Different Kinetics of Activated Clotting Time Among Uninterrupted Oral Anticoagulants During Catheter Ablation Procedure. <i>Journal of Clinical Pharmacology</i> , 2021, , .	1.0	0
1475	Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Thrombosis Research</i> , 2022, 209, 69-74.	0.8	8
1476	Efficacy and safety of genotype-guided warfarin dosing versus non-genotype-guided warfarin dosing strategies: A systematic review and meta-analysis of 27 randomized controlled trials. <i>Thrombosis Research</i> , 2022, 210, 42-52.	0.8	2
1477	Determinants of Anticoagulation Control in Patients Receiving Warfarin Therapy. <i>The Egyptian Journal of Hospital Medicine</i> , 2020, 81, 2389-2394.	0.0	0
1479	Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 20-28.	1.0	7
1480	Electronic health record-embedded decision support to reduce stroke risk in patients with atrial fibrillation â€“ Study protocol. <i>American Heart Journal</i> , 2022, 247, 42-54.	1.2	1
1481	Therapeutic-Dose Warfarin (International Normalized Ratio >1.6) Plus Aspirin Improved Long-Term Patency of Saphenous Vein Graft without Bleeding Complication. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2022, 28, .	0.3	1
1482	Virtual Education for Patient Self-Testing for Warfarin Therapy Is Effective During the COVID-19 Pandemic. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2022, 48, 214-214.	0.4	1
1483	Effect of Shared Decision-Making for Stroke Prevention on Treatment Adherence and Safety Outcomes in Patients With Atrial Fibrillation: A Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e023048.	1.6	13
1484	Management Strategies Following Slightly Out of Range INRs: Watchful Waiting vs. Dose Changes. <i>Blood Advances</i> , 2022, , .	2.5	0
1486	Controlled Level and Variability of Systolic Blood Pressure on the Risk of Thromboembolic Events in Atrial Fibrillation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1487	Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3â€“G5D. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1169-1178.	1.4	6
1488	Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study. <i>Medicina Clínica</i> , 2022, , .	0.3	0
1489	Vitamin K-dependent anticoagulant use and level of anticoagulation control in sub-Saharan Africa: protocol for a retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e057166.	0.8	1

#	ARTICLE	IF	CITATIONS
1490	Time within therapeutic range: A comparison of three tacrolimus formulations in renal transplant recipients. <i>Journal of Clinical Nephrology</i> , 2022, 6, 019-025.	0.1	0
1491	Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-8.	0.8	1
1492	Keeping warfarin patients safe during the COVID-19 pandemic: review of an INR self-testing programme. <i>British Journal of Nursing</i> , 2022, 31, 142-146.	0.3	1
1493	The Role of Intra-Patient Variability of Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas. <i>Pharmaceutics</i> , 2022, 14, 379.	2.0	11
1494	Fixed-Dose Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Pulmonary Embolism Associated with COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1495	The Rate of Clinical Outcomes in Atrial Fibrillation according to Antithrombotic Strategy: The COOL-AF Registry. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-10.	1.1	1
1496	Real-life contemporary vitamin K antagonist is still associated with very low time in therapeutic range despite strict international normalized ratio monitoring: Results of big data analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, , .	0.7	0
1497	Rivaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial. <i>International Journal of Cardiology</i> , 2022, 356, 83-86.	0.8	6
1498	<sc>JCS</sc>/<sc>JHRS</sc> 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. <i>Journal of Arrhythmia</i> , 2022, 38, 833-973.	0.5	8
1499	The Impact of Pharmacist-Managed Service on Warfarin Therapy in Patients after Mechanical Valve Replacement. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-6.	0.8	2
1500	The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists. <i>Thrombosis and Haemostasis</i> , 2022, 122, 377-385.	1.8	5
1501	Development of an interview-based warfarin nomogram predicting the time spent in the therapeutic INR range: A cost-effective, and non-invasive strategy building from a cross sectional study in a low resource setting. <i>Indian Heart Journal</i> , 2022, , .	0.2	2
1502	Relation of the "Atrial Fibrillation Better Care (ABC) Pathway"™ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. <i>Journal of Personalized Medicine</i> , 2022, 12, 487.	1.1	4
1503	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. <i>Circulation Journal</i> , 2022, 86, 1790-1924.	0.7	49
1504	Revised <sc>HAS-BLED</sc> score for bleeding prediction in atrial fibrillation patients with oral anticoagulants. <i>Journal of Arrhythmia</i> , 0, , .	0.5	0
1505	Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 369-379.	1.9	8
1506	Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism. <i>Blood Advances</i> , 2023, 7, 205-213.	2.5	2
1507	Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study. <i>American Heart Journal</i> , 2022, 248, 42-52.	1.2	6

#	ARTICLE	IF	CITATIONS
1508	Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients. <i>Pharmacotherapy</i> , 2022, 42, 106-111.	1.2	4
1509	The effectiveness of split tablet dosing versus alternate-day dosing of warfarin: a randomized control trial. <i>Scientific Reports</i> , 2021, 11, 24060.	1.6	0
1510	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 695-706.	1.4	5
1512	Protocol-based anticoagulation management for mechanical circulatory support patients can be safe and efficient. <i>International Journal of Artificial Organs</i> , 2022, , 039139882210930.	0.7	0
1513	Feasibility study of the Fearon Algorithm in anticoagulation service guided warfarin management. <i>Thrombosis Update</i> , 2022, 7, 100105.	0.4	0
1518	Sex Differences in the Management of Oral Anticoagulation and Outcomes for Emergency Department Presentation of Incident Atrial Fibrillation. <i>Annals of Emergency Medicine</i> , 2022, 80, 97-107.	0.3	8
1521	Safety and efficacy of treatment with vitamin K antagonists in patients managed in a network of anticoagulation services or as routine general care. , 2022, 1, .		1
1522	Online KidClot education for patients and families initiating warfarin therapy: The eKITE study. <i>Thrombosis Research</i> , 2022, , .	0.8	0
1523	Over-anticoagulation by vitamin K antagonists and gender differences. <i>International Journal of Cardiology</i> , 2022, , .	0.8	0
1524	DOACs in Mechanical and Bioprosthetic Heart Valves: A Narrative Review of Emerging Data and Future Directions. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211035.	0.7	14
1525	Clinical Characteristics, Outcomes, and Risk Factors for Adverse Events in Elderly and Non-Elderly Japanese Patients With Non-Valvular Atrial Fibrillation—Competing Risk Analysis From the Hokuriku-Plus AF Registry —. <i>Circulation Reports</i> , 2022, 4, 298-307.	0.4	2
1526	Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 524-534.	1.0	1
1527	Evaluation of a Standardized Tacrolimus Therapeutic Drug Monitoring Protocol in Stable Kidney Transplant Recipients. <i>Progress in Transplantation</i> , 0, , 152692482211070.	0.4	0
1528	Qualidade da Anticoagulação Oral em Pacientes com Fibrilação Atrial em um Hospital Terciário no Brasil. <i>Arquivos Brasileiros De Cardiologia</i> , 2022, , .	0.3	2
1530	Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism. <i>Blood Advances</i> , 2022, 6, 4605-4616.	2.5	7
1531	Cost-Utility and Budget Impact Analysis of Implementing Anticoagulation Clinics and Point-of-Care Monitoring Devices in Anticoagulated Patients in Argentina. <i>PharmacoEconomics - Open</i> , 0, , .	0.9	0
1532	Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations. <i>JAMA Network Open</i> , 2022, 5, e2222089.	2.8	3
1533	Assessing impact of an interdisciplinary erythropoiesis-stimulating agent dosing protocol at an outpatient community hospital hemodialysis unit. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	0.5	0

#	ARTICLE	IF	CITATIONS
1534	Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study. , 2022, 26, 567-576.		7
1535	Impact of direct oral anticoagulant use on mortality in very old patients with non-valvular atrial fibrillation. Age and Ageing, 2022, 51, .	0.7	4
1536	Cost-Effectiveness of the Pharmacist-Managed Warfarin Therapy vs. Standard Care for Patients With Mechanical Mitral Valve Prostheses: An Egyptian Healthcare Perspective. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
1538	Optimal quality of vitamin K antagonist therapy in Japanese patients with venous thromboembolism. Journal of Cardiology, 2022, , .	0.8	0
1539	Trends in Uptake and Adherence to Oral Anticoagulation for Patients With Incident Atrial Fibrillation at High Stroke Risk Across Health Care Settings. Journal of the American Heart Association, 2022, 11, .	1.6	5
1540	Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial - KABUKI trial. BMJ Open, 2022, 12, e061225.	0.8	4
1541	Oral Anticoagulant Management in Sub-Saharan African Patients with Mechanical Heart Valves: Observations on Quality of Anticoagulation and Thrombotic Risk. SSRN Electronic Journal, 0, , .	0.4	0
1542	Oral milrinone for management of refractory right ventricular failure in patients with left ventricular assist devices. ESC Heart Failure, 0, , .	1.4	1
1543	Impact of Systolic Blood Pressure Time in Target Range on Adverse Events in Patients With Nonvalvular Atrial Fibrillation (from the J-RHYTHM Registry). American Journal of Cardiology, 2022, 180, 52-58.	0.7	6
1544	Fixed-Dose Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Pulmonary Embolism Associated with COVID-19. Viruses, 2022, 14, 1606.	1.5	2
1545	Major bleedings in mechanical prosthetic heart valves patients on Vitamin K antagonist treatment. Data from the PLECTRUM Study. , 2022, 1, .		0
1546	Controlled Level and Variability of Systolic Blood Pressure on the Risk of Thromboembolic Events in Atrial Fibrillation and Hypertension. American Journal of Cardiology, 2022, 180, 37-43.	0.7	0
1547	Veno-arterial extracorporeal membrane oxygenation without allogeneic blood transfusion: An observational cohort study. Perfusion (United Kingdom), 0, , 026765912211190.	0.5	0
1548	Predictive value of the adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: a longitudinal study. Rheumatology, 2023, 62, 1576-1585.	0.9	3
1549	Time in Therapeutic Range With Vitamin K Antagonists in Congenital Heart Disease: A Multicentre Study. Canadian Journal of Cardiology, 2022, 38, 1751-1758.	0.8	2
1550	Long-term clinical outcomes in older patients with acute venous thromboembolism who have renal impairment. Thrombosis Research, 2022, 218, 64-71.	0.8	1
1551	Rate and risk factors for thromboembolism and major bleeding in adults with congenital heart disease taking vitamin K antagonist therapy. Thrombosis Update, 2022, 9, 100122.	0.4	1
1552	Safety and efficacy of non- vitamin K antagonist oral anticoagulants compared with well-controlled warfarin in Thai patients with atrial fibrillation. Asian Biomedicine, 2022, 16, 131-136.	0.2	0

#	ARTICLE	IF	CITATIONS
1553	Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease. <i>Open Heart</i> , 2022, 9, e002043.	0.9	6
1554	Warfarin anticoagulation management during the COVID-19 pandemic: The role of internet clinic and machine learning. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1555	Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial. <i>Stroke</i> , 2022, 53, 3260-3267.	1.0	9
1556	GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. <i>Clinical Research in Cardiology</i> , 2023, 112, 759-771.	1.5	3
1557	Determination of Factors Affecting Time in Therapeutic Range in Patients on Warfarin Therapy. <i>Biological Research for Nursing</i> , 0, , 109980042211279.	1.0	0
1558	Dual Anticoagulation With Warfarin and Apixaban: A Case Report. <i>Cureus</i> , 2022, , .	0.2	0
1559	Screening for Atrial Fibrillation by Village Doctors in Rural Areas of China: The Jiangsu Province Rural Community AF Project. <i>Vascular Health and Risk Management</i> , 0, Volume 18, 757-766.	1.0	1
1560	Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients with Diabetes. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1147-1155.	1.2	14
1561	Evaluation of a pharmacist-led drive-up anticoagulation clinic during the coronavirus 2019 pandemic. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, , .	0.7	0
1562	Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2022, 8, .	0.4	6
1563	Development and validation of a bleeding risk prediction score for patients with mitral valve stenosis and atrial fibrillation or mechanical heart valves receiving long-term warfarin therapy. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	0
1564	Efficacy and Safety of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus After Acute Anterior Myocardial Infarction in Patients Who Underwent Percutaneous Coronary Intervention. <i>Current Vascular Pharmacology</i> , 2022, 20, 517-526.	0.8	2
1565	Oral anticoagulant management of patients with mechanical heart valves at the Salam Centre of Khartoum: Observations on quality of anticoagulation and thrombotic risk. <i>Thrombosis Research</i> , 2022, 219, 155-161.	0.8	4
1566	Time in therapeutic range for virtual anticoagulation clinic versus in-person clinic during the COVID-19 pandemic: a crossover study. <i>Annals of Saudi Medicine</i> , 2022, 42, 305-308.	0.5	4
1567	Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences. <i>Systematic Reviews</i> , 2022, 11, .	2.5	2
1568	Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial. <i>BMC Medicine</i> , 2022, 20, .	2.3	9
1569	Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study. <i>Medicina Clínica (English Edition)</i> , 2022, 159, 366-371.	0.1	0
1570	Lower Time in Therapeutic Range Relates to a Worse Kidney Graft Outcome. <i>Transplantation Proceedings</i> , 2022, , .	0.3	0

#	ARTICLE	IF	CITATIONS
1571	Early anticoagulation after aortic valve replacement with porcine bioprosthesis randomized control trial(ANTIPRO). European Journal of Cardio-thoracic Surgery, 0, .	0.6	1
1572	Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation, 2022, 146, 1735-1745.	1.6	71
1573	Men who live alone have worse anticoagulation control: A Danish registry study. American Heart Journal, 2023, 257, 30-32.	1.2	0
1574	Use of SAME-TT2R2 in a racially diverse anticoagulation clinic: prediction of optimal anticoagulation. Journal of Thrombosis and Thrombolysis, 2023, 55, 175-180.	1.0	3
1575	A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation, 2023, 147, 296-309.	1.6	49
1576	Optimizing warfarin dosing using deep reinforcement learning. Journal of Biomedical Informatics, 2023, 137, 104267.	2.5	6
1577	Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?. Biomedicine and Pharmacotherapy, 2023, 158, 114064.	2.5	3
1578	Atrial fibrillation and anticoagulation are associated with hospitalisations in patients with end-stage kidney disease on haemodialysis: a prospective population-based cohort study. Thrombosis Journal, 2022, 20, .	0.9	1
1579	Apixaban in Patients With Post-Myocardial Infarction Left Ventricular Thrombus: A Randomized Clinical Trial. CJC Open, 2023, 5, 191-199.	0.7	2
1580	Safety and efficacy of using portable coagulation monitor for INR examination after left-sided mechanical prosthetic valve replacement. Journal of Cardiothoracic Surgery, 2022, 17, .	0.4	1
1581	Social App to Improve Warfarin Therapy in Post-MHVR Chinese Patients: A Randomized Controlled Trial. Cardiovascular Therapeutics, 2023, 2023, 1-10.	1.1	0
1582	Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Trial. Annals of Thoracic Surgery, 2023, 115, 929-938.	0.7	7
1583	Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3â€“G5D. CKJ: Clinical Kidney Journal, 2023, 16, 835-844.	1.4	2
1584	Warfarin Time in Therapeutic INR Range and Direct Oral Anticoagulant Adherence for Venous Thromboembolism Across the Spectrum of Weight and Body Mass Index: Findings from Veterans Health Administration. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, 107602962311524.	0.7	1
1585	A case of pulmonary embolism with bad warfarin anticoagulant effects caused by <i>E. coli</i> infection. Open Life Sciences, 2023, 18, .	0.6	1
1587	Impact of Achieving Blood Pressure Targets and High Time in Therapeutic Range on Clinical Outcomes in Patients With Atrial Fibrillation Adherent to the Atrial Fibrillation Better Care Pathway: A Report From the COOLâ€“AF Registry. Journal of the American Heart Association, 2023, 12, .	1.6	0
1588	Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists. Journal of Clinical Medicine, 2023, 12, 1141.	1.0	1
1589	Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country. American Journal of Cardiovascular Drugs, 2023, 23, 173-183.	1.0	0

#	ARTICLE	IF	CITATIONS
1590	Anticoagulation Management in Patients Receiving Warfarin at Private Cardiac Centers in Addis Ababa, Ethiopia. <i>Journal of Blood Medicine</i> , 0, Volume 14, 107-117.	0.7	0
1591	Effect of dronedarone vs. placebo on atrial fibrillation progression: a <i>post hoc</i> analysis from ATHENA trial. <i>Europace</i> , 2023, 25, 845-854.	0.7	1
1592	<sc>Warfarinâ€Rifampinâ€Gene</sc> (WARIFâ€G) Interaction: AÂRetrospective, Genetic, <sc>Caseâ€Control</sc> Study. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 1150-1159.	2.3	1
1593	Relation between laxative use and risk of major bleeding in patients with atrial fibrillation and heart failure. <i>Heart and Vessels</i> , 2023, 38, 938-948.	0.5	1
1594	Evaluating the influence of sleep quality and quantity on glycemic control in adults with type 1 diabetes. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
1595	Quality of Anticoagulation With Phenprocoumon and Warfarin in Left Ventricular Assist Device Patients: A Multicenter Study. <i>ASAIO Journal</i> , 0, Publish Ahead of Print, .	0.9	0
1596	Longer time in blood pressure target range improves cardiovascular outcomes among patients with Type 2 diabetes: A secondary analysis of a randomized clinical trial. <i>Diabetes Research and Clinical Practice</i> , 2023, 198, 110600.	1.1	2
1597	Systolic blood pressure time in target range and long-term outcomes in patients with ischemic cardiomyopathy. <i>American Heart Journal</i> , 2023, 258, 177-185.	1.2	2
1598	The Value of Anticoagulation Management Combining Telemedicine and Self-Testing in Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 19, 279-290.	0.9	1
1599	Secure Messaging for Diabetes Management: Content Analysis. <i>JMIR Diabetes</i> , 0, 8, e40272.	0.9	1
1600	Telemedicine-Based Management of Oral Anticoagulation Therapy: Systematic Review and Meta-analysis. <i>Journal of Medical Internet Research</i> , 0, 25, e45922.	2.1	2
1601	<u>S</u>AIL <u>S</u>tudy of <u>S</u>troke, <u>S</u>ystemic Embolism and <u>B</u>leeding, <u>O</u>utcomes with <u>W</u>arfarin Anticoagulation in <u>N</u>on-<u>V</u>alvular <u>A</u>trial <u>F</u>ibrillation (S4-BOW-AF). <i>European Heart Journal Open</i> , 0, , .	0.9	0
1602	Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study. <i>PLoS ONE</i> , 2023, 18, e0284425.	1.1	0
1603	Standard-Intensity Versus Low-Intensity Anticoagulation with Warfarin in Asian Patients with Atrial Fibrillation: A Multi-Center, Randomized Controlled Trial. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962311710.	0.7	2
1649	SAMe-TT2R2 Score to Predict Time in Therapeutic Range of Vitamin K Antagonists in Asian and Non-Asian patients: A Systematic Review and Meta-analysis. <i>American Journal of Cardiovascular Drugs</i> , 2024, 24, 211-240.	1.0	0